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Abstract 
 
Tuberculosis (TB) and Cancer are among the most devastating and therapeutically 
challenging diseases that need to be addressed in South Africa today. The development of 
muti-drug resistance in TB causing bacteria, Mycobacterium tuberculosis and cancerous cells 
has prompted the search for effective novel compounds. The present study focuses on the 
synthesis and the evaluation of different analogues of diospyrin, a proven anti-TB and anti-
cancer agent. Two binaphthoquinone compounds viz., 2,2´-bis(7-methyl-1,4-naphthoquinone) 
and 2,2´-bis(5-methoxy-7-methyl-1,4-naphthoquinone) were synthesized by using Suzuki 
methodology. Two naphthoquinone-benzoquinone compounds viz., 2-(1´,4´-benzoquinon-2´-
yl)-7-methyl-1,4-naphthoquinone and 2-(1´,4´-benzoquinon-2´-yl)-5-hydroxy-7-methyl-1,4-
naphthoquinone,  which differ only in the hydroxyl group at C-5 position were synthesized in 
fairly good yields by using the same methodology. Several other naphthoquinone-naphthalene 
biaryl compounds were also synthesized by using commercially available boronic acids. 
 
Initially 7 analogues were evaluated for their biological activity against fast growing bacteria 
viz., M. smegmatis and M. aurum using the broth microdilution method. These compounds 
were found to be very potent against these strains. Since different strains of mycobacteria 
behave differently to the same compounds so these analogues were evaluated against a 
clinical strain of M. tuberculosis using the BACTEC method, where 2-(6´-
hydroxynaphthalen-2´-yl)-5-hydroxy-7-methyl-1,4-naphthoquinone   and 2-(5´,10´-
dioxydithianthren-1´-yl)-7-methyl-1,4-naphthoquinone demonstrated promising results and 
need further investigation to check their potential to be considered for drug trials. 
 
Four different analogues 2-(1´,4´-benzoquinon-2´-yl)-5-hydroxy-7-methyl-1,4-
naphthoquinone, 2-(5´,10´-dioxydithianthren-1´-yl)-7-methyl-1,4-naphthoquinone,                
2-(1´,4´,5´-trimethoxy-7´-methylnaphthalen-2´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 
and 2-(1´,4´-benzoquinon-2´-yl)-7-methyl-1,4-naphthoquinone were evaluated for their ability 
to induce apoptosis in three cancer cell lines viz., HeLa, MCF7, MG63 and one non-
transformed cell line i.e. CHO. The various methods employed to assess the apoptotic 
potential of the compounds were the APOpercentage, DNA fragmentation and Cell cycle. 
APOpercentage revealed that the compounds 2-(1´,4´-benzoquinon-2´-yl)-5-hydroxy-7-
methyl-1,4-naphthoquinone and 2-(5´,10´-dioxydithianthren-1´-yl)-7-methyl-1,4-
naphthoquinone were active apoptosis inducers. Since 2-(1´,4´-benzoquinon-2´-yl)-5-
hydroxy-7-methyl-1,4-naphthoquinone was the most active inducer in three cell lines under 
investigation, it was further tested for its ability to induce apoptosis via  the DNA 
fragmentation, which confirmed the induction of apoptosis in the malignant cells in response 
to 2-(1´,4´-benzoquinon-2´-yl)-5-hydroxy-7-methyl-1,4-naphthoquinone, after 24 hours and at 
a concentration of 10 μM.  
 
Thus several analogues of diospyrin were successfully synthesized in fairly good yield and 
were identified to have anti-mycobacterial and anti-cancer activities. This preliminary 
investigation has created an interest to synthesize more structurally modified quinonoids in 
order to develop and establish them as potent drugs against mycobacterium and cancer. 
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Chapter 1: Introduction 
 
Tuberculosis (TB) is as old as mankind.1 Archaeologists have identified skeletal tuberculosis 
of the spine in prehistoric populations from Egypt, Peru, Canada, Germany, Denmark and in 
Britain. A German doctor, Robert Koch (1881) first identified, the organism that causes TB in 
humans. He named the organism Mycobacterium tuberculosis, which means 'fungus-
bacterium' because of the fungus-like membrane that the bacteria produce when grown on 
liquid media. Mycobacteria are aerobic, non-endospore-forming, non-motile, slightly curved 
or straight rods. These bacteria are relatively resistant to normal staining procedures. Once 
stained, however, mycobacteria are not easily decolourised, even with acid-alcohol and are 
therefore classified as acid-fast.2 This characteristic reflects on the unusual composition of the 
cell wall, which contains mycolic acids together with free lipids. There are approximately 70 
other species in the genus Mycobacterium, many of which are opportunistic pathogens in 
animals and humans. 
Fig 1.1 Scanning electron micrograph of Mycobacterium tuberculosis 
  
                                         
 
Mycobacterium tuberculosis is an intracellular pathogen, which has a predilection for lung 
tissue, which has a rich oxygen supply. TB is spread through the air from one person to 
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another.  When infectious people cough, sneeze, talk or spit, they propel TB germs, known as 
bacilli, into the air. The tubercle bacilli enter the body via the respiratory route. The bacilli 
spread from the site of initial infection in the lung through the lymphatics or blood to other 
parts of the body with the apex of the lung and the regional lymph node being favoured sites. 
Extrapulmonary TB of the pleura, lymphatics, bone, genito-urinary system, meninges, 
peritoneum, or skin occurs in about 15% of TB patients.3 
A person needs only to inhale a small number of bacilli to be infected. Left untreated, each 
person with the active TB disease will infect on average between 10 and 15 people every year. 
However, people infected with TB bacilli will not necessarily become sick with the disease. 
The immune system “walls off” the TB bacilli, which, protected by a thick waxy coat, can lie 
dormant for years. When someone’s immune system is weakened, the chances of becoming 
sick are greater. Most people who become infected with TB are able to fight the bacteria and 
stop them from multiplying.  The bacteria become inactive, but they remain alive in the body 
and can become active later.  This is called latent TB infection. The diagnosis of TB includes 
medical history, a chest X-ray, physical examination and a microbiological test of a person's 
mucus coughed up from the lungs.  
According to the World Health Organization, TB infection is currently spreading at the rate of 
one person per second. The disease kills more young people and adults than any other 
infectious disease and is the world's biggest killer of women. Each year, an estimated 8 to 10 
million people contract the disease and about two million people die from it. About one-third 
of the world's population or approximately two billion people carry the TB bacteria but most 
never develop the active disease. Around 10% of people infected with TB actually develop 
the disease at some point during their lives, but this proportion is changing because of HIV.  
HIV severely weakens the human immune system and makes people much more vulnerable to 
TB infection. It is estimated that between now and 2020, nearly 1 billion more people will be 
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newly infected, 200 million will become sick and 70 million will die from TB if control is not 
strengthened.4  
Table1.1 Estimated incidence, prevalence and TB mortality, 20044  
 Incidence* Prevalence* Mortality 
 All forms Smear-
positive* 
 
WHO region 
 (% of 
global 
total) 
per 100000 
population 
per 100000 
population 
per 100000 
population 
per 100000 
population 
Africa 29 356 152 518 81 
The Americas 4 41 18 53 5.9 
Eastern 
Mediterranean 
7 122 55 206 27 
Europe 5 50 23 65 7.8 
South-East Asia 33 182 81 304 33 
Western Pacific 22 111 50 216 18 
Global 100 140 62 229 27 
 
*Incidence - new cases arising in given period; *prevalence - the number of cases, which exist 
in the population at a given point in time. *Smear-positive cases are those confirmed by smear 
microscopy, and are the most infectious cases.  
The TB epidemic in South Africa has been documented as one of the worst in the world, with 
disease rates more than double those observed in other developing countries and up to 60 
times higher than those currently seen in the USA or Western Europe. It is the fifth largest 
cause of death among the black population (South African Tuberculosis Association, 1998). 
At the current pace of the epidemic, nearly one out of every twelve South Africans will 
become sick with TB in the next ten years. About ten thousand people die of TB every year. 
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The 11 countries of the Southern Africa sub region contribute approximately 275,000 cases 
every year to the total caseload in Africa. Almost half of these come from South Africa. The 
MRC (Medical Research Council, South Africa, 1998) estimated that the country had an 
estimated 180,507 cases (55% reported) in 1997, or 419 per 100,000 of the total population.5 
Of these, 32.8% (73,679 cases) were probably infected with HIV. Estimates by the MRC 
National Tuberculosis Programme indicate that current trends in the epidemic will continue 
unless effective control is achieved, resulting in 3,5 million new cases of tuberculosis over the 
next decade and at least 90,000 patients dying. The financial implications are staggering: 
Given that more than US$100 million is spent annually on tuberculosis in South Africa, in 
excess of US$3 billion would be required over the next 10 years if current increases in 
tuberculosis rates are allowed to continue unabated.  
Multi-drug Resistance Tuberculosis (MDR-TB) is caused by Mycobacterium tuberculosis 
which is resistant to both isoniazid 1.1 and rifampicin 1.2 with or without resistance to other 
drugs.4 MDR-TB is among the most worrisome elements of the pandemic of antibiotic 
resistance because TB patients that fail treatment have a high risk of death.6 While host 
genetic factors may contribute, drug resistance can occur when, a) TB patients do not adhere 
to their prescribed drug regimens, b) health professionals prescribe an incorrect treatment 
regimen, c) an unreliable drug supply interrupts patient's treatment. This means that the drug 
can no longer kill the bacteria. Only 3% of all the new tuberculosis cases that arise worldwide 
every year are estimated to be multi-drug resistant.6 There are several hotspots around the 
world where MDR-TB prevalence is high. These Include Estonia, Latvia and two Russian 
oblasts (territories) in Europe; Henan and Zhejiang province in China; Argentina and the 
Dominican Republic in the Americas; and Cote d’Ivoire in Africa. People with MDR-TB 
disease must be treated with specific drugs that often are much more expensive (>US$250 
000 per case) than conventional therapy.  
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Extensively Drug Resistant TB (XDR-TB) is a form of MDR-TB that is resistant to any 
fluoroquinolone, and at least one of the three injectable second-line drugs (capreomycin, 
kanamycin, and amikacin).4 XDR-TB can develop when these second-line drugs are also 
misused or mismanaged and therefore also become ineffective. Because XDR-TB is resistant 
to first- and second-line drugs, treatment options are seriously limited. Recent findings from a 
survey conducted by WHO and US centres for Disease Control and Prevention, on data from 
2000-2004 found that XDR-TB has been identified in all regions of the world but is most 
frequent in the countries of the former Soviet Union and in Asia. In the United States, 4% and 
in Latvia, a country with one of the highest rates of MDR-TB, 19% of MDR-TB cases met the 
criteria of XDR-TB. Separate data on a recent outbreak of XDR-TB in an HIV-positive 
population in Kwazulu-Natal in South Africa was characterized by alarmingly high mortality 
rates.7   
HIV/AIDS and TB are so closely connected that the term  "co-epidemic" or "dual epidemic" 
is often used to describe their interrelationship. TB and HIV infections are both intracellular 
and known to have a profound influence on the progression of each other. HIV infection 
brings about the reduction in CD4+ T cells, which play a major role in immunity to TB. HIV 
also can facilitate both the progression of latent TB infection to active disease status and 
relapse of the disease in previously treated patients.  
TB kills up to half of all AIDS patients worldwide. People who are co-infected with HIV and 
TB are up to 50 times more likely to develop active TB in a given year compared to people 
who are HIV-negative. An estimated 33% of the 40 million people living with HIV/AIDS 
worldwide are co-infected with TB. Furthermore, without proper treatment, approximately 
90% of people living with HIV/AIDS die within months of contracting TB. The majority of 
people who are co-infected with both diseases live in sub-Saharan Africa, where up to 70% of 
TB patients are co-infected with HIV in some countries. 
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Drug treatment for TB has been available since streptomycin was produced in 1944. This was 
followed by isoniazid (INH) 1.1 in 1952, and rifampicin (RIF) 1.2 in1966. Pyrazinamide 
(PZA) 1.3 was added later, and is of value especially in the initial phase of treatment. The 
most common medicines used to treat TB patients are: isoniazid 1.1, rifampicin 1.2, 
pyrazinamide 1.3, ethambutol (EMB) 1.4, and streptomycin (SM) 1.5. 
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Treatment of TB depends on whether a person has either the active TB or latent TB form of 
the infection.  A person who has become infected with TB but who does not have active TB 
might be given preventive therapy; the usual prescription is a daily dose of INH.  The person 
takes INH for six to nine months, possibly for up to a year for some patients. However, when 
a patient has active TB, several different medicines are needed. Patients commonly receive a 
combination of several drugs, most frequently INH plus two to three others, usually for at 
least six months.8  
Table 1.2 Current regimens for treatment of drug susceptible tuberculosis 
Regimen Initial Phase Continuation Phase 
Daily 2 months of isoniazid, rifampicin, 
pyrazinamide with or without ethambutol 
4 months of isoniazid 
and rifampicin 
Intermittent 2 weeks of daily isoniazid, rifampicin, 
pyrazinamide and streptomycin or 
ethambutol  
24 weeks of twice 
weekly isoniazid and 
rifampicin 
8 weeks of thrice weekly isoniazid, 
rifampicin, pyrazinamide and 
streptomycin or ethambutol 
18 weeks of thrice 
weekly isoniazid and 
rifampicin 
 
When MDR-TB is suspected on the basis of history or epidemiological information, the 
patient’s sputum must be subjected to culture and anti-tuberculosis drug sensitivity testing. If 
there is resistance to isoniazid and rifampicin (with or without resistance to streptomycin), or 
there is resistance to isoniazid, rifampicin and ethambutol (with or without resistance to 
streptomycin), the following are the suggested treatments (Table 3).9  
Baseline liver function tests and periodic and regular monitoring are advocated in view of the 
potential hepatotoxicity of isoniazid 1.1, rifampicin 1.2, and pyrazinamide 1.3. The risk of 
liver damage is less than 1%, but mild asymptomatic increase in transaminase blood 
concentrations are seen in up to 20% of the patients. Doses of ethambutol 1.4 should be 
carefully adjusted in patients with renal impairment.10 Regimens containing thiacetazone also 
have a greater risk causing potentially lethal cutaneous drug reactions in people with AIDS.11 
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Table 1.3 Suggested treatments for MDR-TB 
Resistance pattern Initial Phase 
 
Continuation Phase 
 Drugs Minimum 
duration 
(months) 
Drugs Minimum 
duration 
(months) 
Resistance to isoniazid 
and rifampicin with or 
without resistance to 
streptomycin 
Aminoglycoside 
3 
Ofloxacin or 
Levofloxacin 
18-24 
Ofloxacin or 
Levofloxacin 
Ethambutol 
Ethionamide 
Pyrazinamide 
Ethambutol 
Ethionamide 
Resistance to isoniazid, 
rifampicin and 
ethambutol with or 
without resistance to 
streptomycin 
Aminoglycoside 
3 
Ofloxacin or 
Levofloxacin 
18-24 
Ofloxacin or 
Levofloxacin 
Ethionamide 
Cycloserine 
Pyrazinamide 
Ethionamide 
Cycloserine 
 
New quinolones are being recommended for use as second-line drugs in the treatment of 
MDR-TB, since they have potent anti-Mycobacterium tuberculosis activity and good 
pharmacokinetics, in terms of tissue and cellular distribution, and have few adverse effects.12, 
13 Ofloxacin 1.6 (OFLX), sparfloxacin (SPFX), and levofloxacin 1.7 (LVFX), ciprofloxacin 
1.8 (CPFX) have good therapeutic efficacies against experimental M. tuberculosis infection in 
mice14 and are efficacious in the clinical control of tuberculosis, including MDR-TB, when 
given in combination with other antituberculous drugs.12 A new fluoroquinolone HSR-903 
1.9, (S)-(-)-5-Amino-7-(7-amino-5-azaspiro[2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-
dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid, has a broad spectrum of action against 
both gram-positive and gram-negative bacteria.15 The in vitro antimicrobial activity of HSR-
903 1.9 against M. tuberculosis was compared with those of several other fluoroquinolones, 
including LVFX 1.7, sitafloxacin (STFX) 1.10 and gatifloxacin (GTFX) 1.11, which possess 
potent in vitro and in vivo antimycobacterial activities.14, 16   The MIC50 and MIC90 of test 
quinolones were distributed over a range from 0.1 to 0.78 mg/ml and 0.39 to 25 mg/ml for 
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non-MDR M. tuberculosis and MDR M. tuberculosis strains, respectively. Their MICs were 
in the order STFX 1.10 ≈ GTFX < LVFX 7 ≤ HSR-903 1.9.17 The minimal inhibitory 
concentration (MIC) is defined as the lowest concentration of the compound that inhibits 
more than 99% of the bacterial population. The MICs of RMP 1.2 and INH 1.1 were lowest 
among test drugs for non-MDR M. tuberculosis strains, but markedly increased in the case of 
MDR-M. tuberculosis strains. Notably, the MICs of test quinolones for MDR-M. tuberculosis 
isolates were 4 to 32 times higher than their MICs for non-MDR-M. tuberculosis strains.  
 
  
 1.6     1.7  
   
1.8     1.9  
   
   1.10     1.11  
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The fluoroquinolones are by far the most promising new agents for treatment of tuberculosis. 
The most potent of the currently available drugs in descending order of in vitro activity are 
moxifloxacin (MXFX) 1.12, gatifloxacin 1.11, levofloxacin 1.7, ofloxacin 1.6 and 
ciprofloxacin 1.8.18 While recent studies suggested that moxifloxacin 1.12 is particularly 
active, the long term tolerability and safety of third generation fluoroquinolones like 
moxifloxacin 1.12 or gatifloxacin 1.11 have not been established as they have for ofloxacin 
1.6 and levofloxacin 1.7.19 The oxazolidinones are also a novel group of antimicrobials.20 One 
member of the family, linezolid 1.13, has been used in the management of extensive drug 
resistance TB and it has shown some apparent efficacy (unreported data).21 However, its 
utility is compromised by its toxicity and high cost. Nitroimidazopyrans have also been 
shown to be active compared to static M. tuberculosis populations, and replicate bacilli.22 
After activation by a mechanism dependent on the M. tuberculosis F420 cofactor, 
nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid. Bacille Calmette-
Guerin vaccine is currently the only vaccine available for treatment against TB. Although it 
does appear to lessen disease, particularly extrapulmonary TB in young people following 
primary infection, it has had very meagre effects upon adult pulmonary disease. Efforts to 
develop a more effective TB vaccine are underway, and researchers hope to make such a 
vaccine available within a decade. 
 
  
                  
1.12                                                      1.13    
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Currently available second-line drugs used to treat MDR-TB are four to ten times more likely 
to fail than standard therapy for drug-susceptible tuberculosis.23 After the initial introduction 
of rifampicin 1.2 almost 30 years ago, no worthwhile anti-tuberculosis drug with a new 
mechanism of action has been developed. Moreover, no new drugs that might be effective in 
the treatment of MDR-TB are currently undergoing clinical trials. It appears that effective 
new drugs for tuberculosis are at least a decade away.24                              
The resurgence of tuberculosis as a major disease in many parts of the world is prompting the 
search for novel compounds, active against the causative organism, Mycobacterium 
tuberculosis. Over the past decade, there has been a proliferation in the literature on the 
antimycobacterial properties of plant extracts. The quinones exhibiting inhibitory activity 
against M. tuberculosis were found to be multiortho-quinone and 12-
demethylmultiorthoquinone isolated from Salvia multicaulis.25 The compounds such as allicin 
isolated from garlic oil,26 Hypargenin F, from the roots of Salvia hypargeia,27 triterpenes from 
Borrichia frutescens,28 ambroxol, a semi-synthetic derivative of vasicine from the Indian 
shrub Adhatoda vasica,29 alkaloids isolated from Galipea officinalis30 were found to have 
good activity against M. tuberculosis. These compounds act bactericidally by denying access 
of essential metabolites through the membrane into the interior of the cell.31  
A naphthoquinone, kigelinone 1.14, isolated from Kigelia pinnata synonymous with             
K. africana has been shown to be active against Gram-positive bacteria at concentrations 
ranging from 0.05 to 0.2 mg/ml. This activity has been attributed to the position of the 
hydroxyl group on the aromatic ring of the naphthoquinone nucleus. The position of the 
hydroxyl group relative to the quinone carbonyl as in kigelinone 1.14 advances its ability of 
chelation with an active site.32 The compound known as pinnatin 1.15 (4-Methoxy-7-phenyl-
6,7-dihydrofuro[3,2-g]-chromen-5-one), was isolated from Derris indica, a mangrove plant 
belonging to the Leguminosae family, showed moderate antimycobacterial activity against 
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Mycobacterium tuberculosis H37Ra with a minimum inhibition concentration of 12.5 
mg/ml.33   
O
OHO
O
CH3
OH
                
OO
OOCH3  
   1.14      1.15 
 
Twenty South African medicinal plants used to treat pulmonary diseases were screened for 
activity against drug-resistant and a drug-sensitive strain of M. tuberculosis.34 A preliminary 
screening of acetone and water plant extracts, against a drug-sensitive strain of M. 
tuberculosis; H37Rv was done by the agar plate method. Acetone as well as water extracts of 
Cryptocarya latifolia, Euclea natalensis, Helichrysum melanaome, Nidorella anomala and 
Thymus valgaris inhibited the growth of M. tuberculosis. These active acetone extracts were 
screened using rapid radiometric method, against the H37Rv strain as well as a strain resistant 
to the drugs, isoniazid 1.1 and rifampin 1.2. The minimal inhibitory concentration of Croton 
pseudopulchellus, Ekebergia capensis, Euclea natalensis, Nidorella anomala and Polygala 
myrtifolia was 0.1 mg/ml against the H37Rv strain.34 Out of 20 medicinal plants investigated, 
Euclea natalensis exhibited the best activity against drug-sensitive and drug-resistant strains 
of M. tuberculosis. E. natalensis, a tree of the Ebenaceae family is used extensively  in oral 
health care, for chest complains, bronchitis, pleurisy, chronic asthma, urinary tract infections, 
venereal diseases etc. by the indigenous people of South Africa. It was found that the MIC of 
a crude extract of E. natalensis against M. tuberculosis was 100 μg/ml.35  
The large subtropical genus Euclea is well known as a source for naphthoquinones; 
monomers, complex dimers and trimers such as 7-methyljuglone 1.16, diospyrin 1.22 and 
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mamegakinone. Lall and Meyer, 34 first reported the inhibitory effect of the crude extract of E. 
natalensis against the drug-sensitive and two drug-resistant strains of M. tuberculosis. They 
also reported the isolation and identification of the active principle from E.natalensis, viz., a 
binaphthoquinone, diospyrin 1.22. Diospyrin 1.22 and methyljuglone 1.16 have been found to 
inhibit several antibiotic resistant as well as antibiotic susceptible strains of M. tuberculosis. 
The traditional use of E. natalensis extract against sores, purulent lesions and skin infections 
and cough could possibly be attributed to the activity of diospyrin against S. aureus and M. 
tuberculosis. This might explain the plant’s use in traditional remedies against TB. The 
antimycobacterial properties of the root extract, probably, provide the reason for its use in 
folk medicines also, to treat leprosy, which is caused by another mycobacterial species.  
Twenty-eight compounds were screened for activity against Mycobacteria.36 The 1,4-diketone 
quinone motif has strong inhibitory activity, while the 1,2-naphthoquinone motif was 8-fold 
less active than 1,4-naphthoquinone 1.17. Compounds without this quinone structure had 
much lower activity. Activity fell, when the 1,4-diketone moiety itself was retained but not 
part of the aromatic ring as with benzil (1,2-diphenylethanedione).36 Thus the ketone group 
themselves are not toxic. While adding a second conjugated ring mildly improved activity (M. 
smegmatis MIC of benzoquinone 463 μM, while that of 1.17 316 μM), adding a third ring 
strongly decreased activity (anthraquinone MIC of 30,700 μM). Plumbagin 1.18 was reported 
to be one of the most potent synthesized compounds against RGM (rapidly growing 
Mycobacteria) and MAC (M. avium complex), with an MIC of 66 μM, while juglone 1.19 had 
an MIC against MAC of 72 μM. For comparison, kanamycin 1.20 has an MIC against M. 
smegmatis of 4 μM, and against M. avium of 26 μM. Not only are compounds 1.18 and 1.19 
the most toxic examined, their mechanism of killing may be novel.36  
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Six compounds were isolated from D. piscatorial and identified as isodiospyrin 1.21, 
diospyrin 1.22, bisisodiospyrin, an unidentified tetrameric form of plumbagin 1.18, betulinic 
acid and an unidentified oily compound.37 It was observed that activity of diospyrin 1.22 and 
isodiospyrin 1.21 were significant especially on M. chelonae, which is a pathogenic organism. 
The MICs of isodiospyrin 1.21 for the eight Gram-positive organisms ranged between 0.78 to 
50 μg/ml, while those against the four Gram-negative organisms ranged between 50 μg/ml 
and 100 μg/ml.37 On the other hand, the MICs of diospyrin 1.22 for the eight Gram-positive 
bacteria ranged between 1.56 to above 100 μg/ml. It is however, interesting to note that the 
two compounds were effective against M. chelonae, with isodiospyrin 1.21 being more potent 
(MICs of 6.26 to 25 μg/ml) than diospyrin 1.22 (MICs of 25 to 100 μg/ml).37 Diospyrin 1.22 
has also been isolated from other species of Euclea such as E. pseudebenus, E. crispa,          
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E. divinorum, and E. schimper, and from Diospyros species, D. mannii, D. montana and D. 
chamaethamus. 
 
O
O
CH3
OH
O
OOH
CH3
 
1.21  
      
Diospyrin 1.22 was first isolated in 1961 by Kapil and Dhar as an orange-red constituent of 
Diospyros Montana, a small or medium-sized tree found throughout India.38 Its structure was 
proposed by Ganguly and Govindachari in 1966 as a dimer of 7-methyljuglone 1.16 linked 
between C-2 and C-3´.39 Subsequent studies by Sidhu and Pardhasaradhi led to the correct 
structure of diospyrin 1.22 with a linkage between C-2 and C-6´.40 Diospyrin 1.22 is optically 
inactive and thus there is no restricted rotation around the connecting bond between C-2 and 
C-6´.  
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Arguments based on NMR spectra40 indicated that diospyrin 1.22 has the structure with a    2-
6´ linkage present between the naphthoquinonyl units, and its synthesis41 has provided 
support for this hypothesis. It is now established crystallographically that diospyrin 1.22 does 
indeed have the 2-6´ structure.42 In the crystal, the two ring systems are not coplanar, the 
angle between their least-squares planes being 59.74˚. The length of the inter-ring C9-C12 
bond (1.494 A˚) suggests that it is essentially a single bond. A somewhat surprising feature is 
that the bulky C11 methyl group lies close to atom O4 rather than, as might be expected, close 
to the much smaller H atom attached to atom C13. As a result, atom O4 is significantly 
displaced (by 0.387 A˚) from the least-squares plane of its naphthoquinonyl unit (C12-
C22/O5-O6). Conversely, atom C11 shows no significant deviation (displacement = 0.018 A˚) 
from the C1-C11/O1-O3 least-squares plane.  
Fig 1.2 Crystal structure of diospyrin showing intra-molecular H-bonding  
 
 
 
Both OH groups participate in bifurcated intra/intermolecular hydrogen bonds to C=O 
acceptors. The intra-molecular OH---O bonds are much shorter and stronger than the 
intermolecular links. This difference results in an `unbalanced' hydrogen-bonding network, in 
which atoms O2 and O5 accept two hydrogen bonds each (one intra-molecular and one 
intermolecular), and atoms O1 and O4 do not accept any conventional hydrogen bonds. 
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Together the OH---O bonds generate infinite stacks of molecules of 1.22, The structure shown 
is dissymmetric, but crystal symmetry generates a racemic mixture that is consistent with the 
lack of optical activity shown by 1.22 in solution.43 The inter-conversion of the two 
enantiomeric forms would be expected to occur readily in solution by analogy with the 
behaviour of trisubstituted biphenyls, which undergo rapid racemization in solution. 44  
Fig 1.3 Crystal structure of diospyrin showing intra-molecular and intermolecular H-
bonding  
 
Three derivatives and one structural analogue of diospyrin 1.22 were synthesized and 
investigated for their inhibitory activity against M. tuberculosis.45 A novel aminoacatate 
derivative 1.23 (of diospyrin dimethyl ether) was found to be more active than the diospyrin 
1.22, the MIC’s being 10-50 and 100 mg/L, respectively, for a drug-susceptible strain, 
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H37Rv, of M. tuberculosis.45 This derivative also exhibited an MIC of 50 mg/L, for a few 
multidrug-resistant strains of M. tuberculosis. The other three analogues i.e. diospyrin 
dimethyl ether hydroquinone 1.24, diospyrin diethyl ether 1.25 and the dimer of lawsone 1.26 
did not show any activity against any strain at the highest concentration tested. However, the 
reported tuberculostatic activity of Lawsonia inermis would indicate the probable 
involvement of lawsone, i. e. 2-hydroxynaphthoquinone, which is known to be the major 
bioactive contituent of this herb.46 This observation is consistent with the enormous influence 
of structural modification on the biological activity of the bisnaphthoquinonoid, diospyrin.  
 
O
O
OMe
CH3
OOMe
CH3
O
NHCOCH3
  
OH
OH
OMe
CH3
OHOMe
CH3
OH   
1.23       1.24 
 
 
 
O
O
OC2H5
CH3
OOC2H5
CH3
O       
O
O
OH
O
O
OH
     
  1.25       1.26 
               
 
 
 
 
 19
   
O
O
OMe
CH3
OOMe
CH3
O      
1.27  
The broad spectrum of action of diospyrin 1.22 invoked research into various other 
disciplines. A limited number of studies highlighting anti-tumour activity of diospyrin 1.22 
are available. The stem bark of Diospyros montana was first reported to be useful in the 
treatment of tumours.47 It has been shown that crude ethanolic extract of the bark produces 
significant regression in the growth of Ehrlich Ascites Carcinoma (EAC) in Swiss Albino 
mice and the haematological parameters of tumour bearing mice could be significantly 
restored towards the normal range.48 Later, diospyrin 1.22 has been identified as a 
biologically active principle present in the bark extract of Diospyros montana.49   The in vitro 
studies indicated marked effects of small doses of diospyrin 1.22 on EAC cell surfaces, 
leading to agglutination and exocytosis. Higher doses caused disruption of the whole cell 
resulting in the expulsion of intracellular material leading to total lysis. Several experiments 
showing the significant inhibition of in vivo growth of EAC and increase in the life span of 
the tumour bearing mice confirmed the effect of diospyrin 1.22 against EAC. 
Diospyrin 1.22 and its two derivatives viz., 1.24 and 1.27 were tested for their inhibitory 
activities towards EAC in vivo.50 The growth of EAC in vivo was significantly inhibited by all 
three compounds. However, the derivatives 1.24 and 1.27 were far more effective than 
diospyrin 1.22. One other tetraacetate derivative 1.28 and 1.24 were also checked for their 
activity against EAC and Sarcoma 180 and it was noted that the activity of 1.28 was less than 
that of 1.24.51 
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Diospyrin 1.22 and its three synthetic derivatives i.e. diospyrin dimethyl ether 1.27, diospyrin 
dimethyl ether hydroquinone 1.24 and diospyrin diethyl ether 1.25 have been tested for their 
activity on four human cancer cell lines viz., acute myeloblastic leukemia (HL-60), chronic 
myelogenic leukemia (K-562), breast adenocarcinoma (MCF-7) and cervical epithelial 
carcinoma (HeLa).52 Diethyl ether derivative 1.25 was most effective in this regard while the 
parent compound diospyrin 1.22 was least active. A concentration-dependent response in 
leukemic cell lines showed maximum growth inhibition with 1.25. Thus, IC50 (50% inhibitory 
concentration) values in HL- 60 cells were >100 µM for 1.22, 64 µM for 1.27, 54 µM for 1.24 
and 30 µM for 1.25, and the corresponding values in K-562 cells were >100 µM, >100 µM, 
65 µM and 40 µM, respectively. Compound 1.25 was not cytotoxic toward normal human 
lymphocytes, suggesting its action is specific for tumor cells. On microscopic examination, 
1.25 treated cells exhibited characteristic morphological features of apoptosis, such as cell 
shrinkage and formation of apoptotic bodies. In earlier studies, diospyrin 1.22, was found to 
show significant tumor-inhibitory effects against Ehrlich ascites carcinoma in vivo.53 
Subsequently, synthesis of some derivatives of diospyrin 1.22 led to the isolation of more 
potent inhibitors against murine tumors.54  
A series of aminonaphthoquinones was synthesized for the first time in fairly good yield, 
starting with diospyrin 1.22, isolated from Diospyros montana. The aminoacetate derivative 
1.29 showed the maximum (~93%) increase in life-span with respect to the untreated control 
in Swiss A. mice bearing Ehrlich Ascites Carcinoma (EAC) and exhibited the lowest 
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inhibitory concentrations (IC50 of 1.29 = 0.06 µM, of 1.30 = 0.07 µM and of 1.31 = 0.09 µM) 
in vitro.55 (Please refer to chapter 5 for detailed introduction to apoptosis). 
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Diospyrin 1.22 and three other compounds i.e. Atovaquone 1.32, Diospyrin dimethyl ether 
1.27 and Diospyrin dimethyl ether hydroquinone 1.24 were also tested for their effect on 
cellular ATP of P. carinii.56 Of the napthoquinone drugs tested in this study, atovaquone 1.32 
was the most effective in reducing ATP (Adenosine triphosphate) levels after 24 h, but this 
inhibitory effect then remained stable through the duration of the 3-day study. The average 
50% inhibitory concentration (IC50) after 24 to 72 hours of exposure was 1.5 µg/ml (4.2 µM). 
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In contrast, the diospyrin-based quinoid drugs were ineffective in reducing cellular ATP 
levels after 24 h of exposure. These compounds were able to reduce ATP pools in P. carinii 
only after 48 h of exposure, and this effect dramatically increased after 72 h of exposure. All 
of the diospyrin 1.22 type compounds had greater activity, expressed as the IC50, than 
atovaquone 1.32 at the 72 h time point. When considered individually, the diospyrin dimethyl 
ether 1.27 analog exhibited greater activity against P. carinii than the other quinoid 
compounds at 48 and 72 h of exposure with IC50 of 1.67 µg/ml (6.71 µM) and 0.31 µg/ml 
(1.25 µM) respectively. 
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Exposure of P. carinii to the diospyrin analogues caused a continual decrease in ATP levels 
over time. In contrast, the decrease in ATP levels at all concentrations of atovaquone 1.32 
remained the same from 24 to 72 h. Since all the compounds targeted the electron transport 
chain, as evidenced by the decrease in ATP, these differences in the kinetics likely involve 
effects on other cellular processes. Diospyrins have been reported to inhibit protistan 
topoisomerase activity.57 Topoisomerases are enzymes involved in many cellular processes 
and are classified into two groups by virtue of the nicks made in single stranded (type I) or 
double stranded (type II) DNA. These breaks relax the DNA strands during replication and 
chromosomal separation. Since P. carinii replicates very slowly in the in vitro setting, 
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deleterious effects from the inhibition of topoisomerases may require longer exposure to 
manifest.  
Diospyrin 1.22 and its two synthetic derivatives viz., 1.24 and 1.27 were tested in vitro 
against intracellular amastigotes of Leishmania donovani and Trypanosoma cruzi in 
macrophages and extracellular Trypansoma brucei brucei bloodstream form 
trypomastigotes.58 Diospyrin 1.22 was inactive against L. donovani but had ED50 (50% 
effective doses) values of 27 and 50 µM, respectively, against T. cruzi and T.b. brucei. The 
dimethyl ether 1.27 derivative was more active than the parent compound 1.22 against T. 
cruzi and T.b. brucei, but the hydroquinonoid 1.24 form was the most active antiparasitic 
agent with ED50 values of 2.2 and 0.7 µM, respectively, against L. donovani and T.b. brucei. 
Studies suggested that diospyrin 1.22 exerts its action by interacting with type I DNA 
topoisomerase of leishmania and stabilizing the “cleavable complex”. The inhibition by 
diospyrin 1.22 is relatively specific as the compound requires 10-fold higher concentrations to 
inhibit DNA topoisomerase I from calf thymus and it does not inhibit DNA topoisomerase II 
of L. donovani at this concentration. Results suggested that diospyrin 1.22 is a novel inhibitor 
of type I DNA topoisomerase of L. donovani. Like camptothecin 6.3, a class I inhibitor, it also 
stabilizes the cleavable complex. However it differs from camptothecin 6.3 with respect to its 
mode of action. Camptothecin 6.3 does not bind with the enzyme alone, but diospyrin 1.22 
does; this interaction is reversible.57  
Diospyrin 1.22 and its derivatives, viz., alkyl ethers 1.25, 1.27, hydroquinonoid 1.24 and 
amino 1.33 were tested for their activity against Leishmania major.59 Diospyrin 1.22 was only 
slightly active at a dose of 5 µg/ml, causing only 22% inhibition of the parasite growth, while 
all of its derivatives produced more than 98% inhibition under comparable conditions. Thus, 
modifications in the structure of diospyrin 1.22 could produce marked enhancement of its 
antileishmanial activity whereas 1.34, the dimeric naphthoquinonoid analogue (dimer of 
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lawsone), did not show any inhibitory activity up to 5µg/ml concentration. Among the 
derivatives, the dimethyl ether 1.27 and its hydroquinonoid analogue 1.24 were the most 
active compounds, causing nearly 98% inhibition at a dose of 2.5  µg/ml. The lower activity 
of the compounds 1.22 and 1.33 may be explained on the basis of H-bonding between the 
phenolic –OH and their adjacent quinonoid moieties. However studies on some more 
analogues are needed in order to elucidate the specific role of these structural features. 
The insolubility of naphthoquinonoid compounds, including diospyrin 1.22 and its 
derivatives, in aqueous medium poses a major problem in the evaluation of their activities in 
biological systems. The polyethylene glycol (PEG) conjugated technique used in this study59 
could effectively solubilise the compound 1.24 in aqueous medium, which might have a 
significant impact on the pharmacological profile and future applications. In preliminary 
experiments, this conjugate showed significantly higher (~10 fold) inhibitory activity on the 
growth of the leishmanial parasite as compared to the ‘free’ drug, when tested at a dose of 1.2  
µg/ml, thereby indicating a potential advantage of this modification. PEG as a carrier polymer 
is known to be non-toxic, non-antigenic and biocompatible. Conjugation to PEG is expected 
to increase the water-solubility and therapeutic effect of hydrophobic compounds like 
naphthoquinonoids with concomitant reduction in the toxicity. 
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Plumbagin 1.18, a naphthoquinone isolated from many species of the genus Plumbago, has 
been reported to have an activity (IC50) of 0.42 and 1.1 µg/ml against amastigotes of L. 
donovani and L. amazonensis, respectively.60 Plumbagin 1.18, and the dimeric products    3,3-
 
 
 
 
 25
biplumbagin 1.35 and 8,8-biplumbagin 1.36, have been isolated from the bark of Pera 
benensis, a plant used in Bolivia for the treatment of cutaneous leishmaniasis. While 1.18 and 
1.36 show activity against promastigotes of L. braziliensis, L. amazonensis, and L. donovani 
at a concentration (IC90 = 90% Inhibitory concentration) of 5 µg/ml, 1.35 shows a lower 
activity (IC90 =50 µg/ml) against the same Leishmania species. 
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Two novel hydroquinoid analogues derived from diospyrin 1.22 also show enhanced 
inhibitory effects against Plasmodium falciparum, in vitro, and may be a useful model for the 
development of novel antimalarial drugs.61 
The evidences accumulated to date suggest that diospyrin 1.22 is a potent inhibitor against a 
variety of organisms’ viz., Mycobacterium tuberculosis, Leishmania donovani, Leishmania 
major, P. carinii, Trypanosoma brucei, Trypanosoma cruzi, Plasmodium falciparum as well 
as various cancer cell lines. Tuberculosis and cancer are among the most devastating diseases 
with few therapeutic options available. Both diseases develop resistance against the drugs 
being administered, thus demanding a continuous and exhaustive search for potential new 
drugs.  
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AIMS and OBJECTIVES 
 
Diospyrin, a naturally occurring bisnaphthoquinone compound, has been shown to exhibit 
significant antimycobacterial and anti-tumour activity. By considering diospyrin as a lead 
compound, the present study is aimed at the synthesis of similar types of biaryl systems and 
the evaluation of their biological activity against different strains of Mycobacterium 
tuberculosis and certain cancer cell lines. The initial target was the synthesis of quinone-
quinone biaryl systems, which one may think of as bisnaphthoquinone compounds or 
naphthoquinone-benzoquinone compounds having different substituent groups. The envisaged 
route towards the synthesis of these compounds would involve Suzuki methodology for C-C 
bond formation between two quinone moieties. Following on from this it was then further 
planned to synthesize several other naphthoquinone-naphthalene biaryl compounds from 
precursors available as it was envisaged that from the results of the evaluations of the 
activities of these compounds it would help in deducing their structure and activity 
relationship. 
It was proposed that the evaluation of the different analogues against fast growing bacteria 
viz., Mycobacterium smegmatis and Mycobacterium aurum will be done by using the broth 
microdilution method at the facility available at the University of the Cape Town. Further 
evaluation against a clinical strain 1432 (sensitive to all front line drugs i.e. Isoniazid, 
Rifampicin, Ethambutol, Streptomycin) of M. tuberculosis using the BACTEC method at the 
Stellenbosch Medical School facility was also proposed. These were considered to be the 
preliminary studies. Depending on the results the possibility for further investigation to check 
their potential to be considered for drug trials was a strong possibility. 
Further investigation of the potential of these compounds to induce apoptosis in three cancer 
cell lines viz., HeLa, MCF7, MG63 and one normal cell line i.e. CHO was also envisaged. 
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The various methods, which will be employed to assess the apoptotic potential of the 
compounds, are APOpercentage, DNA fragmentation and Cell cycle. The APOpercentage 
assay will help to identify the apoptosis inducing potential of the compounds. This is 
considered to be one of the basic and preliminary tests. DNA fragmentation will also be 
measured since this is a confirmatory test for detecting cell death mediated by apoptosis. Cell 
cycle analysis will help us to identify the phase during which cell growth arrests in response 
to the induced compound. 
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Chapter 2 
 
Section 2.1: An investigation into the synthesis of diospyrin 1.22 
In 2000, Masao Yoshida and Kenji Mori first reported the synthesis of diospyrin 1.22 as 
illustrated in Scheme 2.1, 2.2 and 2.3.41 The two-naphthoquinone moieties 2.1 and 2.2 were 
synthesized separately and then coupled by using Suzuki coupling via an organoboronic acid 
intermediate. The first stage of the synthesis was to prepare the naphthalene building blocks 
2.1 and 2.2 obtained in the retrosynthetic analysis of Scheme 2.1.  
 
1
2
4
1´
4´
6´
Br
O
O
OMe OMe
OMe
OMe
(HO)2B
O
O
OH
CH3
O
O
OH
CH3 +
 
  1.22          2.1       2.2 
 
Scheme 2.1 
 
A Diels-Alder reaction between the known 1-methoxy-3-methyl-1-trimethylsilyloxy-1,3-
butadiene 2.3 and 2,5-dibromo-1,4-benzoquinone 2.4 afforded 2-bromo-5-hydroxy-7-methyl-
1,4-naphthoquinone 2.5. This was further methylated with methyl iodide and silver oxide to 
give 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 2.1 and is illustrated in Scheme 2.2. 
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Scheme 2.2 
 
For the synthesis of boronic acid 2.2, another Diels-Alder reaction was executed. For that 
purpose, 2-bromo-1-methoxy-3-methyl-1-trimethylsilyloxy-1,3-butadiene 2.7 was prepared 
from the known methyl 2-bromosenecioate 2.6. A Diels-Alder reaction between 2.7 and 1,4-
benzoquinone 2.8 proceeded in dichloromethane, and the resulting mixture was treated with 
dilute hydrochloric acid to remove the partly remaining trimethylsilyl group, giving a mixture 
of 6-bromo-5-hydroxy-7-methyl-1,4-naphthoquinone 2.9 and 6-bromo-5-methoxy-7-methyl-
1,4-naphthoquinone 2.10. This mixture was subsequently fully methylated with methyl iodide 
and silver oxide to afford pure 2.10. Reduction of 2.10 with tin(II) chloride furnished 
naphthalenediol 2.11, which was then methylated to give 6-bromo-1,4,5-trimethoxy-7-
methylnaphthalene 2.12.  The conversion of 2.12 to the corresponding tributyltin derivative 
by lithiation followed by stannylation was first attempted. These attempts, however, were 
unsuccessful, and the use of Stille methodology for coupling of the two naphthalene units was 
abandoned. The alternative approach was to employ Suzuki coupling. The desired boronic 
acid 2.2 was prepared by lithiation of 2.12 and subsequent reaction with trimethyl borate.  
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Scheme 2.3 
 
The coupling of 2.1 and 2.2 was successfully done under the standard conditions, employing 
tetrakis(triphenylphosphine)palladium(0) as the catalyst in the presence of aqueous sodium 
carbonate to give the coupling product 2.13 as oranges red needles in 53% yield. Oxidative 
demethylation of 2.13 with ceric ammonium nitrate furnished diospyrin dimethyl ether 2.14 
as yellow needles. Further demethylation of 2.14 with aluminium chloride in dichloromethane 
at room temperature yielded diospyrin 1.22 in 19% yield based on 2.13. 
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Scheme 2.4 
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Section 2.2: The Suzuki coupling between a Boronic acid and an Aryl halide 
The Suzuki reaction, which was discovered by Akira Suzuki in 1979, is one of the most 
common cross-coupling methods in organic synthesis and allows C-C bonds to be formed 
between aryl or alkenyl halides and aryl, alkenyl or alkyl borates in the presence of a 
palladium(0) catalyst. Suzuki chemistry provides an efficient, cost effective, mild and 
environmentally safe methodology for the selective formation of C-C bonds. As opposed to 
the Stille coupling,62 Suzuki reagents do not involve highly toxic (tin) reagents.  
This transformation utilizes palladium catalyzed coupling between two reactants: an 
organohalide and an organoborane as shown in Scheme 2.5. The organohalide is normally 
aryl or alkenyl, but the organoborane can be practically anything, as long as it can be prepared 
and is relatively stable. 
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Scheme 2.5 
 
Aryl halides are treated with butyl lithium to form the corresponding lithiated reagents, which 
are then reacted with trimethylborate B(OMe)3 to form the boronic acid esters and these are 
hydrolyzed with either aqueous HCl or aqueous NH4Cl to form the corresponding boronic 
acids as shown in Scheme 2.6.  
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+
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Scheme 2.6 
Aryl halides function as electrophiles whose reactivity order is Ar-I > Ar-Br >> Ar-Cl. Aryl 
chlorides are usually not reactive enough, with the exception of those having heteroaromatic 
rings and electron-withdrawing groups. This is because the oxidative addition of aryl 
chlorides to palladium complexes is too slow to develop the catalytic cycle. A recent paper 
showed that the use of nickel catalysts for the cross-coupling reaction with aryl chlorides 
produced favourable results.63 
Arylboronic acids are stable and easy to handle. They are normally stable in air and to a 
limited amount of heat, and can be recrystallised from water and alcohol. Various arylboronic 
acids are prepared relatively easily by functionilization reactions of the parent arylboronic 
acid since the boronic acid group is inert to many chemical reactions. 
In 1981, Suzuki and Miyaura et al. reported that the cross-coupling reaction of phenylboronic 
acid with any aryl bromide in the presence of palladium catalysts and an aqueous base 
provides the corresponding biaryl molecules in good yields as shown in Scheme 2.7.64 The 
Suzuki reaction is tolerant to a wide variety of functional groups so that variously substituted 
aromatic rings can be used. By-products from homocoupling are limited because of the 
selective reaction involved. 
B(OH)2 Br+
Pd(PPh3)4
aq. Na2CO3
benzene, reflux
.
Z
.
Z  
Scheme 2.7 
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The mechanism of the Suzuki process essentially involves three steps. The first step is the 
oxidative addition of the alkyl or aryl halide to the palladium(0) atom of a two-coordinate 
complex. This species is generated by a series of equilibria in which triphenylphosphine 
ligands dissociate from the metal. The oxidation state of the palladium does not change until 
reaction with either the alkyl or aryl halide occurs. Alkyl or aryl halides react very slowly in 
the oxidative addition step as shown in Scheme 2.8. 
 
 
Pd
PPh3
PPh3
Ph3P
Ph3P
Pd
PPh3
Ph3P PPh3
Pd PPh3Ph3P
Pd
R
X
Ph3P
Ph3P
-PPh3 -PPh3
R - X
  
 
Scheme 2.8 
 
The coupling reaction of organic boron compounds proceeds only in the presence of base. 
This is due to the fact that the organic group on boron is not nucleophilic enough for the 
transfer from boron to the palladium in the transmetallation step because of the strong 
covalent character of the B-C bond in boron compounds. Therefore, it is necessary to increase 
the carbanion character of organic groups by the formation of an organoborate having a 
tetravalent boron atom upon treatment with base (Scheme 2.9). 
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R´ B
Na
+
 OH
-
B
R´
OH
-
Na
+
  
 
Scheme 2.9 
 
In the next step, a substitution reaction occurs at the metal ion. The organic group attached to 
boron is transferred to palladium(II) ion, replacing the halide ion. The intermediate five-
coordinate Pd(II) ion is sterically crowded, which facilitates the dissociation of the halide ion 
to produce the four-coordinate (diorgano) palladium(II) species. 
Pd
R
X
Ph3P
Ph3P
Pd
R
X
Ph3P
Ph3P
R´B
R´
OH
+ BOH
-
Pd
R
R´
Ph3P
Ph3P
+ X-
Na
+
-
 
 
Scheme 2.10 
 
This complex then immediately undergoes reductive elimination, yielding the coupled organic 
product and regenerating the two-coordinated palladium complex as shown in Scheme 2.11. 
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Pd
R
R´
Ph3P
Ph3P
Pd PPh3Ph3P + R - R´Reductive elimination
 
 
Scheme 2.11 
 
Although the catalyst most often used in the Suzuki reaction is Pd(PPh3)4, various other 
palladium catalysts have been employed, viz., Pd(dppb)Cl2, PdCl2(PPh3)2, Pd(OAc)2 and 
PdCl2. 
Bases are always required in the Suzuki reaction as opposed to the coupling reaction using 
organotin or organozinc reagents. The best results are achieved with the use of relatively weak 
bases of which Na2CO3 is most frequently used. However, other bases, such as Et3N, 
NaHCO3 and K3PO4, have also successfully been employed. In the case of sterically hindered 
boronic acids, strong bases for example aqueous Ba(OH)2 or NaOH, accelerate the coupling 
reaction, while weak bases are more favorable in the case of sterically unhindered boronic 
acids since hydrolytic deboronation is suppressed. In some cases, anhydrous K3PO4 or CsF in 
aprotic solvents, such as dimethoxyethane (DME), have been used.65  
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Chapter 3: Results and Discussion  
Section 3.1: Synthesis of 2,2´-bis(7-methyl-1,4-naphthoquinone) 3.1 
In deciding on analogues of diospyrin 1.22, we considered the most convenient one from the 
point of view of easily accessible starting materials and synthetic procedures. Thus the first 
analogue that we decided to synthesize was the binaphthoquinone 3.1 in which the two 
retrosynthons were quinone 3.2 and boronic acid 3.3, shown in the retro Scheme 3.1. It was 
thus clear that the two naphthalene moieties were to be synthesized separately and then 
coupled together by using Suzuki methodology via the organoboronic acid 3.3 and 
naphthoquinone 3.2. 
O
O
CH3
O
O
CH3
O
O
CH3 Br
OMe
OMe
CH3(HO)2B
+
 
  3.1        3.2         3.3 
Scheme 3.1 
Section 3.1.1: Synthesis of 2-Bromo-7-methyl-1,4-naphthoquinone 3.2 
The proposed synthetic protocol of the target naphthoquinone 3.2 is illustrated in Scheme 3.2 
below. 
O
O
Br
Br
O
O
CH3 Br
O
O
CH3 Br
+
CH2
CH2
CH3
 
 3.4     3.5    3.6           3.2 
Scheme 3.2 
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The first step was to synthesize the one starting material viz., dibromobenzoquinone 3.5 by 
using the method reported by Lopez-Alvarado et al.,66 depicted in Scheme 3.3 below. 
 
OMe
OMe
OMe
OMe
Br
Br
O
O
Br
Br
 
     3.7    3.8          3.5 
Scheme 3.3 
A solution of 1,4-dimethoxybenzene 3.7 in acetic acid was treated with 2 mole equivalents of 
bromine in acetic acid to afford the corresponding 2,5-dibromo-1,4-dimethoxybenzene 3.8 
which on oxidation with cerium ammonium nitrate (CAN) afforded the corresponding 
dibromobenzoquinone 3.5 with 82% yield. The resulting material was assigned the structure 
3.5 based on a singlet at 7.48ppm, which is due to the two symmetrical quinone hydrogens in 
the 1H nmr spectrum and a m.p. of 159-160˚C (Lit.66 m.p. is 160-161˚C). 
Diels-Alder reaction between dibromobenzoquinone 3.5 and 2-methyl-1,3-butadiene 
(isoprene) 3.4, commercially available from Acros Organics, afforded the expected adduct 3.6 
(64%) in refluxing THF as shown in Scheme 3.4 below as reported by Ho et al.67  
O
O
Br
Br
O
O
CH3 Br
+
CH2
CH2
CH3
 
   3.4        3.5         3.6 
 
Scheme 3.4 
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The assigned structure for 3.6 is based on the following spectral evidence. The HRMS of 
251.9787 demonstrated a molecular formula of C11H9BrO2 (79Br) (required 251.9785). In the 
1H nmr spectrum, a 4-proton multiplet at 3.05ppm is due to H-5 and H-8 and a 1-proton 
multiplet at 5.48ppm is due to the H-6. In the 13C nmr spectrum, signals at 179.3ppm and 
184.5ppm are due to the two quinone carbonyls.   
Bromonaphthoquinone 3.6 was then oxidized with chloranil in benzene under reflux for 30h 
to afford 75% yield of the 2-bromo-7-methyl-1,4-naphthoquinone 3.2 as shown in Scheme 3.5 
below.67 
 
O
O
Br
O
O
Br
 
       3.6           3.2 
Scheme 3.5 
 
The disappearance of the 4-proton multiplet at 3.05ppm and replaced by only signals in the 
aromatic region in the 1H nmr spectrum supported aromatisation. A HRMS of 251.9631 
supported the molecular formula C11H7BrO2 (81Br) (required 251.9629). 
It was noted that even after the 30h reflux period some starting material was still present in 
the reaction mixture but by careful chromatographic separation using EtOAc: hexane (5: 95) 
as eluent the fully aromatised product 3.2 was obtained in pure form. 
The proposed general mechanism for oxidation of unsaturated alicyclic rings with chloranil is 
shown in scheme 3.6 below. 
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Scheme 3.6 
Section 3.1.2: Synthesis of 1,4-dimethoxy-7-methylnaphthalene-2-boronic acid 3.3 
The next step was the synthesis of boronic acid 3.3, which was to be coupled to 3.2 by Suzuki 
coupling methodology. The envisaged route to 3.3 was expected to proceed according to 
Scheme 3.7 as shown below. 
O
O
Br
OH
OH
Br
OMe
OMe
Br
 
  3.2    3.9    3.10 
OMe
OMe
B(OH)2
 
   3.3 
 
Scheme 3.7 
 
 
 
 
 41
The first step was the reduction of quinone 3.2 to 2-bromo-7-methyl-1,4-naphthalenediol 3.9 
as reported by Kesteleyn et al.,68 as shown in Scheme 3.8 below. 
 
O
O
Br
OH
OH
Br
 
         3.2    3.9 
 
Scheme 3.8 
 
A suspension of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 in ethanol was treated with a 
solution of tin(II) chloride in concentrated HCl, poured into cold water and then filtered to 
afford 77% of the product 3.9. The resulting material was assigned the structure 3.9 based on 
the following spectral evidence. The infrared spectrum showed the –OH stretching frequency 
at 3297 cm-1. In the 1H nmr spectrum a 2-proton broad singlet at 5.56ppm is assigned to the 
two hydroxyl protons. However in the 1H nmr spectrum (d6-acetone), the two peaks for the 
hydroxyl groups appeared at 7.77 and 8.83ppm for the 4-OH and 1-OH groups respectively. 
In the 13C spectrum, C-4 and C-1 appeared at 133.8 and 138.9ppm respectively. The naphthol 
is immediately used in further reactions since it undergoes aerial oxidation to afford a blue 
residue.  
The next step was the methylation of 3.9 to afford 2-bromo-1,4-dimethoxy-7-
methylnaphthalene 3.10 as reported by Jung et al.,69 and is shown in Scheme 3.9. 
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OH
OH
Br
OMe
OMe
Br
 
        3.9          3.10 
 
Scheme 3.9 
A solution of naphthalenediol 3.9 in acetone was treated with anhydrous potassium carbonate 
and dimethyl sulphate and heated under reflux for 20h and filtered. The residue obtained by 
removal of solvent then dissolved in ether and treated with triethylamine to afford 77% of the 
product 3.10. The spectral evidence for the structure 3.10 of the product includes the 
disappearance of hydroxyl peak in the infrared spectrum. In the 1H nmr spectrum, two 
methoxy signals appeared at 3.94 and 3.96ppm respectively. In the 13C nmr spectrum, C-1 and 
C-4 appeared at 150.6 and 152.4ppm. 
Great difficulty was experienced in transforming bromonaphthalene 3.10 into boronic acid 3.3 
following the method of Yoshida et al.41 Eventually it was found that addition of HCl to 
hydrolyse the initial borate has to be very carefully performed and thus the method of Alo et 
al.,70 was subsequently followed as illustrated in Scheme 3.10. 
 
OMe
OMe
Br
OMe
OMe
B(OH)2
 
3.10      3.3 
 
Scheme 3.10 
 
 
 
 
 43
A solution of 2-bromo-1,4-dimethoxy-7-methylnaphthalene 3.10 in THF was treated with n-
butyllithium and trimethyl borate at -78˚C and then stirred for 20h at room temperature. The 
reaction mixture was then cooled to 0˚C and aqueous HCl (5% v/v) was added until the pH 
was approximately 6 to afford a 70% yield of 3.3. The spectral evidence includes two 
methoxy peaks at 3.55 and 3.81ppm and a 2-proton singlet at 5.58ppm assigned to B(OH)2 in 
the 1H nmr spectrum. The boronic was not characterized further by spectroscopy and was 
used immediately in the next biaryl-coupling reaction.   
Section 3.1.3: Coupled product 
In the next step, naphthoquinone 3.2 and boronic acid 3.3 were coupled together to provide 2-
(1´,4´-dimethoxy-7´-methylnaphthalen-2´-yl)-7-methyl-1,4-naphthoquinone 3.11 by using 
Suzuki coupling as reported by Miyaura et al.,64, 65 and is shown in Scheme 3.11 below. 
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CH3
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 3.2    3.3    3.11 
 
Scheme 3.11 
 
A mixture of naphthoquinone 3.2 and Pd(PPh3)4 (catalytic amount) in benzene was treated 
with an aqueous solution of sodium carbonate and boronic acid 3.3 in benzene at 24˚C and 
then heated under reflux for 16h to afford a 41% yield of product 3.11. The resulting material 
was assigned the structure 3.11 based on the following spectral evidence. In the infrared 
spectrum, two peaks at 1664 and 1657 cm-1 shows carbonyl stretching frequencies for the 
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quinone moiety. In the 1H nmr spectrum, signals for the two methyl groups appeared at 2.53 
and 2.55ppm. A 1-proton singlet at 6.56ppm is assigned to H-3´ because of the electron 
donating resonance effect of the methoxy groups attached to the same ring. A 1-proton dd at 
7.38ppm with J 8.4 and 1.4 Hz was assigned to H-6´ and a 1-proton dd at 7.59ppm with J 7.6 
and 1.0 Hz was assigned to H-6. In the 13C spectrum, C-1´ and C-4´ appeared at 145.0 and 
151.7ppm while the two quinone carbonyl peaks, C-1 and C-4 appeared at 184.4 and 
185.1ppm. A HRMS of 372.1299 supported the molecular formula C24H20O4 (required 
372.1361). 
The last step in the synthesis of 2,2´-bis(7-methyl-1,4-naphthoquinone) 3.1, required 
oxidative demethylation of the 3.11 and the method reported by Syper et al.,71 was chosen as 
shown in Scheme 3.12 below. 
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3.11      3.1 
 
Scheme 3.12 
A suspension of naphthoquinone 3.11 in a mixture of acetonitrile and water at 0˚C was treated 
with cerium(IV) ammonium nitrate in a mixture of acetonitrile and water and stirred for 30 
min at 24˚C to afford a 15% yield of product 3.1 with m.p. 179-181°C (from ethanol), (lit.72 
240°C). Spectral evidence for the structure 3.1 includes two aryl methyl peaks at 2.52 and 
2.54ppm and the absence of methoxy peaks in the 1H nmr spectrum. In the 13C nmr spectrum, 
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the peaks for the quinone carbonyls, (C-1´, C-4´, C-1 and C-4)a appeared at (177.3, 180.0, 
182.0 and 183.8ppm)a. A HRMS of 342.0627 supported the molecular formula C22H14O4 
(required 342.0892). 
Laatsch72 as illustrated in Schemes 3.13 and 3.14 below also reported a synthesis of 3.1.  
O
O
H2, Pd, C
MeOH
OH
OMe  
 
Scheme 3.13 
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        3.1 
 
Scheme 3.14 
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Section 3.2: Synthesis of 2,2´-bis(5-methoxy-7-methyl-1,4-naphthoquinone) 3.12 
The second molecule that we decided to synthesize was the bisnaphthoquinone with two 
methoxy groups 3.12. It was reported that the dimethyl ether derivative of diospyrin 1.27 is 
more biologically active than diospyrin 1.22, against Ehrlich Ascites Carcinoma (EAC) in 
Swiss Albino mice50 and human cancer cell lines.52 Based on the previous references in the 
thesis, molecule 3.12 could also act as an effective anti-cancer agent.  Two possible 
retrosynthons of this target molecule were quinone 3.13 and boronic acid 3.14, as shown in 
Scheme 3.15. 
O
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OMe
CH3
OMe
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CH3 Br
OMe OMe
OMe
CH3(HO)2B
OMe
+
 
   3.12    3.13   3.14 
Scheme 3.15 
Section 3.2.1: Synthesis of 2-Bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 
The synthetic protocol of the target naphthoquinone 3.13 is illustrated in Scheme 3.16. 
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Scheme 3.16 
The synthesis of butadiene 3.15 was successfully carried out using the method reported by 
Casey et al.,73 depicted in Scheme 3.17. 
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3.17      3.15 
Scheme 3.17 
Methyl-3-methyl-2-butenoate 3.17 in THF was treated with a solution of 
lithiumdiisopropylamide at –78˚C followed by addition of trimethylsilyl chloride and 
triethylamine. The temperature was allowed to rise to 24˚C to afford an 80% yield of the 
diene 3.15, which was immediately allowed to react with dibromobenzoquinone 3.5, and 
afforded the hydroxynaphthoquinone 3.16 in a 57% yield as illustrated in Scheme 3.18 
below.41  
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  3.15   3.5    3.16 
Scheme 3.18 
Spectral evidence for the structure of the adduct 3.16 includes a 1-proton singlet at 11.70ppm 
for the 5-OH group in the 1H nmr spectrum. In the 13C nmr spectrum, signals at 177.5 and 
186.9ppm are assigned to the two quinone carbonyls. The proposed mechanism for the 
reaction is illustrated in Scheme 3.19. 
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Scheme 3.19 
The next step was the methylation of 3.16 to get 2-Bromo-5-methoxy-7-methyl-1,4-
naphthoquinone 3.13 as reported by Jung et al.,69 depicted in Scheme 3.20. 
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  3.16     3.13 
 
Scheme 3.20 
A solution of hydroxynaphthoquinone 3.16 in benzene was treated with powdered Ag2O and 
methyl iodide to afford 56% yield of the methoxynaphthoquinone 3.13. Spectral evidence for 
the structure of product 3.13 includes a 3-proton singlet at 3.99ppm assigned to the methoxy 
group in the 1H nmr spectrum. In the 13C nmr spectrum, signals for the two quinone carbonyls 
viz., C-1 and C-4 appeared at 178.6 and 181.3ppm. 
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Section 3.2.2: Synthesis of 1,4,5-trimethoxy-7-methylnaphthalene-2-boronic acid 3.14 
The next step was the synthesis of trimethoxyboronic acid 3.14, which was to be coupled to 
quinone 3.13. The synthetic protocol of the target boronic acid 3.14 is illustrated in Scheme 
3.21.  
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 3.13   3.18   3.19    3.14 
 
Scheme 3.21 
The first step in this route was the reduction of 3.13 to naphthalenediol 3.18 as reported by 
Kesteleyn et al.,68 shown in Scheme 3.22. 
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O
CH3 Br
OMe OH
OH
CH3 Br
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    3.13    3.18 
Scheme 3.22 
A suspension of methoxynaphthoquinone 3.13 in dichloromethane was shaken in a separatory 
funnel with a freshly prepared solution of sodium dithionate in water to afford a 78% yield of 
naphthalenediol 3.18. The resulting material was assigned the structure 3.18 based on the 
following spectral evidence. In the 1H nmr spectrum, two peaks for 1-OH and 4-OH appeared 
at 5.43 and 8.91ppm. In the 13C spectrum, signals for C-1 and C-4 appeared at 147.9 and 
155.5ppm. 
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Subsequently methylation of 3.18 as reported by Jung et al.,69  was effected as depicted in 
Scheme 3.23. 
OH
OH
CH3 Br
OMe OMe
OMe
CH3 Br
OMe
 
   3.18     3.19 
Scheme 3.23 
A solution of naphthalenediol 3.18 in acetone was treated with anhydrous potassium 
carbonate and dimethyl sulphate and heated under reflux for 20h to afford an 82% yield of 
trimethoxynaphthalene 3.19. Spectral evidence for the structure of compound 3.19 includes 
three methoxy signals at 3.91, 3.93 and 3.95ppm in the 1H nmr spectrum while in the 13C nmr 
spectrum, signals at 146.2, 153.8 and 157.3ppm were assigned to C-5, C-1 and C-4. 
The method of Alo et al.,70 was employed in the transformation of trimethoxynaphthalene 
3.19 into the corresponding boronic acid 3.14 as shown in Scheme 3.24. 
OMe
OMe
CH3 Br
OMe OMe
OMe
CH3 B(OH)2
OMe
 
   3.19     3.14 
 
Scheme 3.24 
A solution of trimethoxynaphthalene 3.19 in THF was treated with n-butyllithium and 
trimethyl borate at -78˚C and then stirred for 20h at room temperature after which the mixture 
was then cooled to 0˚C and treated with aqueous HCl (5% v/v) until the pH was 
approximately 6 to afford 75% yield of the boronic acid 3.14. The boronic was not 
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characterized further by spectroscopy, but was used immediately in the next biaryl-coupling 
reaction.   
 
Section 3.2.3: Coupled product 
Next the two naphthalene subunits 3.13 and 3.14 were coupled together by using Suzuki 
methodology as reported by Miyaura et al.,64, 65 to afford the biaxial binaphthalene unit 3.20 
as illustrated in scheme 3.25. 
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 3.13    3.14    3.20 
 
Scheme 3.25 
Thus a mixture of bromonaphthoquinone 3.13 and Pd(PPh3)4 in benzene was treated with an 
aqueous solution of sodium carbonate and trimethoxyboronic acid 3.14  in benzene at 24˚C 
and then heated under reflux for 16h to afford a 41% yield of the product 3.20. The resulting 
material was assigned the structure 3.20 based on the following spectral evidence. In the 1H 
nmr spectrum, a 6-proton singlet at 2.50ppm was assigned to both of the methyl groups and 
signals for the four methoxy groups appeared at 3.68, 3.94, 3.97 and 4.03ppm. In the 13C 
spectrum, signals at 147.8, 153.4, 157.4, 159.8, 184.3 and 184.5ppm were assigned to C-5´, 
C-1´, C-4´, C-5, C-1 and C-4. A HRMS of 432.1546 supported the molecular formula 
C26H24O6 (required 432.1572). 
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The final step in the synthesis of 2,2´-bis(5-methoxy-7-methyl-1,4-naphthoquinone) 3.12, 
involved the oxidative demethylation of 3.20 as reported by Syper et al.,71 as illustrated in 
Scheme 3.26. 
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Scheme 3.26 
A suspension of 2-(1′,4′,5′-trimethoxy-7′-methylnaphthalen-2′-yl)-5-methoxy-7-methyl-1,4-
naphthoquinone 3.20 in a mixture of acetonitrile and water at 0˚C was treated with cerium(IV) 
ammonium nitrate in a mixture of acetonitrile and water and stirred for 30 min at 24˚C to 
afford a 34% yield of the product 3.12. The resulting material was assigned the structure 3.12 
based on the following spectral evidence. In the 1H nmr spectrum, a 6-proton singlet at 
2.49ppm was assigned to both CH3-7´ and CH3-7 and a 6-proton singlet at 4.02ppm was 
assigned to two methoxy groups. A singlet at 6.94ppm was assigned to H-6´ and H-6. In the 
13C spectrum, a signal at 22.5ppm was assigned to CH3-7´ and CH3-7 and a signal at 56.6ppm 
was assigned to two methoxy groups. A signal at 183.2ppm was assigned to (C-1´ and C-1) 
and a signal at 183.5ppm was assigned to (C-4´ and C-4). A HRMS of 402.1247 supported 
the molecular formula C24H18O6 (required 402.1103). 
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Section 3.3: Synthesis of 2-(1´,4´-benzoquinon-2´-yl)-7-methyl-1,4-naphthoquinone 3.21 
The next molecule that we decided to synthesize was benzoquinonenaphthoquinone 3.21. This 
molecule differs from the previously synthesized molecule 3.1 with regard to it having a 
benzoquinone and not a naphthoquinone on the right hand ring as depicted in scheme 3.27. 
These factors may affect its biological activity as an anti-TB and anti-cancer agent in 
comparison to the other analogues. The two retrosynthons for the molecule were quinone 3.2 
and boronic acid 3.22, shown in retro Scheme 3.27 below. 
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  3.21      3.2      3.22 
Scheme 3.27 
The proposed synthetic protocol of the target naphthoquinone 3.2 is already illustrated in 
Scheme 3.2. 
Section 3.3.1: Synthesis of 1,4-dimethoxybenzene-2-boronic acid 3.22 
The envisaged route to boronic acid70 3.22 was expected to proceed according to Scheme 
3.28. 
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       3.23    3.22 
Scheme 3.28 
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A solution of 2-bromo-1,4-dimethoxybenzene 3.23 in THF was treated with n-butyllithium 
and trimethyl borate at -78˚C and then stirred for 20h at room temperature after which the 
cooled (0˚C) mixture was treated with an aqueous HCl (5% v/v) until the pH was 
approximately 6 to afford an 80% of yield of the boronic acid 3.22. The resulting material was 
assigned the structure 3.22 based on the following spectral evidence. In the 1H nmr spectrum, 
two methoxy signals appeared at 3.81 and 3.88ppm and a 2-proton broad singlet at 6.38ppm 
was assigned to the B(OH)2 group. In the 13C nmr spectrum, signals at 153.9 and 158.9ppm 
were assigned to C-1 and C-4. A HRMS of 182.0755 supported the molecular formula 
C8H11BO4 (required 182.0752). The boronic was used immediately in the next biaryl-coupling 
reaction.   
 
Section 3.3.2: Coupled product: Next the two aryl units 3.2 and 3.22 were coupled together 
to form naphthoquinone 3.24 by using Suzuki methodology as reported by Miyaura et al.,64, 65 
illustrated in Scheme 3.29. 
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        3.2  3.22     3.24 
Scheme 3.29 
A mixture of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 and Pd(PPh3)4 in benzene was 
treated with an aqueous solution of sodium carbonate and dimethoxyboronic acid 3.22  in 
benzene at 24˚C and heated under reflux for 16h to afford a 76% yield of the coupled product 
3.24. The resulting material was assigned the structure 3.24 based on the following spectral 
evidence. In the 1H nmr spectrum, a 3-proton singlet at 2.51ppm was assigned to the C-7 
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methyl group and peaks at 3.74 and 3.79ppm were assigned to the two methoxy groups. In the 
13C spectrum, signals at 151.5, 153.5, 183.7 and 185.1ppm were assigned to C-1´, C-4´, C-1 
and C-4. A HRMS of 308.1049 supported the molecular formula C19H16O4 (required 
308.1048). 
The final step involved the oxidative demethylation of dimethyl ether 3.24 using a protocol 
reported by Syper et al.,71, 68 depicted in Scheme 3.30. 
O
O
CH3
OMe
OMe
O
O
O
O
CH3
 
3.24      3.21 
Scheme 3.30 
A suspension of 2-(1´,4´-dimethoxybenzen-2´-yl)-7-methyl-1,4-naphthoquinone 3.24 in a 
mixture of acetonitrile and water at 0˚C was treated with cerium(IV) ammonium nitrate in a 
mixture of acetonitrile and water and stirred for 30 min at 24˚C to afford a 71% yield of the 
product 3.21. Spectral evidence for the structure of biquinone 3.21 includes the disappearance 
of the two methoxy signals in the 1H nmr spectrum. In the 13C nmr spectrum, signals at 182.9, 
183.8, 184.6 and 186.4ppm were assigned to C-1´, C-4´, C-1 and C-4 respectively. A HRMS 
of 278.0570 supported the molecular formula C17H10O4 (required 278.0579). 
 
Section 3.4: Synthesis of 2-(1´,4´-benzoquinon-2´-yl)-5-hydroxy-7-methyl-1,4-
naphthoquinone 3.25 
The next molecule that we decided to synthesize was binaphthoquinone 3.25. This molecule 
differs from the previous molecule 3.21 with regard to it having the hydroxyl group at C-5. 
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Any difference in the biological activity of the compound in comparison to the previous 
molecule 3.21 would be due to the hydroxyl group. This should provide evidence as to 
whether the hydroxyl group is responsible for any enhanced biological activity of the 
compound. The two retrosynthons were quinone 3.13 and boronic acid 3.22 shown in retro 
Scheme 3.31.  
 
OCH3
OCH3
B(OH)2
O
O
CH3 Br
OMe
+
O
O
CH3
O
O
OH
 
  3.25      3.13      3.22 
 
Scheme 3.31 
 
The proposed synthetic protocol of the target naphthoquinone 3.13 and boronic acid 3.22 are 
already illustrated in Scheme 3.16 and 3.28 respectively. In the first step, two aryl units were 
coupled together by using Suzuki methodology64, 65 as shown in Scheme 3.32. 
OMe
OMe
B(OH)2
O
O
CH3 Br
OMe
+
O
O
CH3
OMe
OMe
OMe
 
       3.13         3.22     3.26 
     Scheme 3.32 
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A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 and Pd(PPh3)4 in 
benzene was treated with an aqueous solution of sodium carbonate and dimethoxyboronic 
acid 3.22 in benzene at 24˚C and heated under reflux for 16h to afford a 32% yield of the 
product 3.26. The resulting material was assigned the structure 3.26 based on the following 
spectral evidence. In the 1H nmr spectrum, a 3-proton singlet at 2.46ppm was assigned to the 
C-7 methyl group and peaks at 3.71, 3.77 and 3.98ppm were assigned to three methoxy 
groups. In the 13C spectrum, signals at 151.4, 153.4, 159.5, 183.8 and 184.2ppm were 
assigned to C-1´, C-4´, C-5, C-1 and C-4. A HRMS of 338.1143 supported the molecular 
formula C20H18O5 (required 338.1154). 
The next step was the oxidative demethylation of the dimethyl ether 3.26 by using a protocol 
reported by Syper et al.,71, 68 and is illustrated in Scheme 3.33. 
O
O
CH3
OMe
OMe
OMe O
O
O
O
CH3
OMe
 
  3.26            3.27 
Scheme 3.33 
A suspension of trimethoxyquinone 3.26 in a mixture of acetonitrile and water at 0˚C was 
treated with cerium(IV) ammonium nitrate in a mixture of acetonitrile and water and stirred 
for 30 min at 24˚C to afford a 72% yield of the product 3.27. The resulting material was 
assigned the structure 3.27 based on the following spectral evidence. In the 1H nmr (d6-
DMSO) spectrum a 1-proton doublet at 7.39ppm with J 2.6 was assigned to H-3´ and a 1-
proton singlet at 7.48ppm was assigned to H-3. In the 13C nmr (d6-DMSO) spectrum, signals 
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at 154.7, 155.8, 160.5, 173.4 and 180.8ppm were assigned to C-5, C-1´, C-4´, C-1 and C-4. A 
HRMS of 308.0611 supported the molecular formula C18H12O5 (required 308.0684). 
Last step in the synthetic protocol involved the demethylation of the C-5 methoxy group and 
the method of Syper et al.,71, 68 was adopted as depicted in Scheme 3.34. 
 
O
O
O
O
CH3
OHO
O
O
O
CH3
OMe
 
3.27      3.25 
 
Scheme 3.34 
A solution of methoxyquinone 3.27 in dry CH2Cl2 at 25˚C was treated with aluminium 
trichloride. The mixture was stirred at 25˚C for 24h, poured into water, and then acidified 
with dilute HCl to afford a 55% yield of the hydroxyquinone 3.25. The resulting material was 
assigned the structure 3.25 based on the following spectral evidence. In the 1H nmr (d6-
DMSO) spectrum, a skewed 2-proton doublet at 7.43ppm with J 2.4 was assigned to H-3´, 
which is overlaid by H-3, and a 1-proton singlet at 11.77ppm, which was assigned to the 5-
OH. In order to clarify this signal unambiguously, the spectrum was also run in d6-acetone. 
Thus in the 1H nmr (d6-acetone) spectrum, a 1-proton singlet at 7.16ppm was assigned to H-3, 
a 1-proton doublet at 7.62ppm with J 2.4 was assigned to H-3´ and a 1-proton singlet at 
11.99ppm was assigned to 5-OH. In the 13C nmr (d6-DMSO) spectrum, signals at 153.5, 
156.0, 161.4, 178.9 and 180.3ppm were assigned to C-5, C-1´, C-4´, C-1 and C-4. A HRMS 
of 294.0571 supported the molecular formula C17H10O5 (required 294.0528). 
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Synthesis of naphthoquinone-naphthalene biaryl systems 
 
The availability of commercially pure boronic acids allowed for the synthesis of 
naphthoquinone-naphthalene biaryl systems with a fair variety of groups attached to either of 
the naphthalenic nuclei. An evaluation of their biological activity against M. tuberculosis and 
certain cancer cell lines was consequently made possible which would provide guidelines in 
deducing the structure-activity relationship.  
 
Section 3.5: Synthesis of 2-(6′-hydroxynaphthalen-2′-yl)-5-hydroxy-7-methyl-1,4-
naphthoquinone 3.28 
The first compound to be synthesized was 3.28, which has two hydroxyl groups, the one on 
the naphthoquinone half and the other on the naphthalene moiety. In this synthesis, the first 
major step was the formation of 2-(6′-methoxynaphthalen-2′-yl)-5-methoxy-7-methyl-1,4-
naphthoquinone 3.29, which involved the Suzuki coupling64, 65 between the naphthoquinone 
3.13 and boronic acid 3.30 to afford a 90% yield of the quinone 3.29 as shown in Scheme 
3.35. 
 
O
O
Br
OMe
CH3 OMe
(HO)2B
O
O
OMe
OMe
CH3+
 
     3.13   3.30    3.29 
 
Scheme 3.35 
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The resulting material was assigned the structure 3.29 based on the following spectral 
evidence. In the 1H nmr spectrum, a signal at 2.51ppm was assigned to the 7- CH3 and peaks 
at 3.95 and 4.03ppm were assigned to the two methoxy groups. In the 13C nmr spectrum, 
signals at 158.9, 159.7, 184.4 and 185.3ppm were assigned to C-6´, C-5, C-1 and C-4. A 
HRMS of 358.1049 supported the molecular formula of C23H18O4 (required 358.1204). 
The next involved the demethylation of the C-5 OCH3 group as reported by Kesteleyn et al.74 
as shown in Scheme 3.36. 
 
O
O
OMe
OMe
CH3
O
O
OMe
OH
CH3
 
  3.29       3.31 
Scheme 3.36 
 
Thus a solution of 3.29 in dry DCM was treated with boron tribromide to afford a 51% yield 
of the 5-hydroxyquinone 3.31. The resulting material was assigned the structure 3.31 based on 
the following spectral evidence. In the 1H nmr spectrum, there was only one signal for a 
methoxy group at 4.03ppm and the 1-proton singlet at 12.00ppm was assigned to 5-OH. In the 
13C nmr spectrum, signals at 155.1, 161.4, 184.2 and 189.5ppm were assigned to C-6´, C-5, 
C-1 and C-4. A HRMS of 343.0867 supported the molecular formula of C22H16O4 (required 
344.1048). 
The final step involved the further demethylation of the C-6´ OCH3 and in this instance the 
method of Kesteleyn et al.74  was used to afford a 46% yield of the quinone 3.28 as illustrated 
in Scheme 3.37. 
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O
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CH3
O
O
OH
OH
CH3
 
 
  3.31       3.28 
Scheme 3.37 
The resulting material was assigned the structure 3.28 based on the following spectral 
evidence. In the 1H nmr spectrum, the signals at 6.05 and 12.00ppm were assigned to 6´-OH 
and 5-OH. In the 13C nmr spectrum, signals at 152.1, 161.4, 184.1 and 189.5ppm were 
assigned to C-6´, C-5, C-1 and C-4. A HRMS of 330.0872 supported the molecular formula 
of C21H14O4 (required 330.0892). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62
Section 3.6: Synthesis of 2-(5´,10´-dioxydithianthren-1´-yl)-7-methyl-1,4-
naphthoquinone 3.32 
The second compound synthesized by using the commercially available boronic acid 3.33 was 
sulphone 3.32. Suzuki coupling was employed in coupling bromoquinone 3.2 to boronic acid 
3.33 in the first step as shown in Scheme 3.38. 
O
O
CH3 Br
SS
(HO)2B
+
O
O
CH3
S S
 
3.2            3.33    3.34 
     Scheme 3.38 
A mixture of 3.2 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and thiantherene-1-boronic acid 3.33  in benzene at 24˚C and heated under reflux 
for 16h to afford  an 82% yield of the quinone 3.34. The resulting material was assigned the 
structure 3.34 based on the following spectral evidence. In the 1H nmr spectrum, a 5-proton 
multiplet at 7.27ppm was assigned to H-2´, H-3´, H-4´, H-7´ and H-8´. A M+ in the HRMS of 
386.0487 supported the molecular formula of C23H14O2S2 (required 386.0435). 
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The final step was the oxidation of the 3.34 by following the method reported by Nakayama et 
al.75 as shown in Scheme 3.39. 
O
O
CH3
SS OOO
O
CH3
S S
 
 
   3.34       3.32 
Scheme 3.39 
A solution of 3.34 in DCM was treated with m-chloroperbenzoic acid to afford a 58% yield of 
the sulphone 3.32. The resulting material was assigned the structure 3.32 based on the 
following spectral evidence. In the ir spectrum, peaks at 1164 and 1328 cm-1 were assigned to 
two S=O groups.  A M+ in the HRMS of 418.1630 supported the molecular formula of 
C23H14O4S2 (required 418.0334). 
 
Section 3.7: Synthesis of 2-(5´,10´-dioxydithianthren-1´-yl)-5-methoxy-7-methyl-1,4-
naphthoquinone 3.35 
The other sulphone synthesized was 3.35 having an additional methoxy group at C-5 position. 
The initial step was the synthesis of 5-methoxy-7-methyl-2-(thianthren-1´-yl)-1,4-
naphthoquinone 3.36 by using the Suzuki methodology64, 65 as shown in Scheme 3.40. 
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O
O
CH3 Br
OMe
+
O
O
CH3
SS
MeOS S
(HO)2B
 
  3.13      3.33     3.36 
Scheme 3.40 
 
A mixture of 3.13 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and thianthrene-1-boronic acid 3.33  in benzene at 24˚C and heated under reflux for 
16h to afford  a 86% yield of the quinone 3.36. The resulting material was assigned the 
structure 3.36 based on the following spectral evidence. In the 1H nmr spectrum, a signal at 
4.04ppm was assigned to the 5-OMe. A 5-proton multiplet at 7.27ppm was assigned to H-2´, 
H-3´, H-4´, H-7´ and H-8´. In the 13C nmr spectrum, signals at 159.8, 183.8 and 183.9ppm 
were assigned to C-5, C-1 and C-4. A HRMS of 416.0498 supported the molecular formula of 
C24H16O3S2 (required 416.0541). 
 
 
 
The next step involved the oxidation of 3.36 by following the method reported by Nakayama 
et al.75 as shown in Scheme 3.41. 
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  3.36       3.35 
Scheme 3.41 
 
A solution of 3.36 in DCM was treated with m-chloroperbenzoic acid to afford 64% yield of 
the sulphone 3.35. The resulting material was assigned the structure 3.35 based on the 
following spectral evidence. In the ir spectrum, peaks at 1168 and 1326 cm-1 were assigned to 
two S=O groups.  In the 1H nmr spectrum, a signal at 4.04ppm was assigned to the 5-OMe. A 
7-proton multiplet at 7.61ppm was assigned to H-3, H-8, H-2´, H-3´, H-7´, H-8´ and H-9´. In 
the 13C nmr spectrum, signals at 160.0, 182.9 and 185.0ppm were assigned to C-5, C-1 and C-
4. A HRMS of 448.1156 supported the molecular formula of C24H16O5S2 (required 448.0439). 
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Section 3.8: Synthesis of 5-hydroxy-7-methyl-2-(4′-methylnaphthalen-1′-yl)-1,4-
naphthoquinone 3.37 
The first step is the synthesis of 5-methoxy-7-methyl-2-(4′-methylnaphthalen-1′-yl)-1,4-
naphthoquinone 3.39, which involved Suzuki coupling64, 65 as illustrated in Scheme 3.42. 
 
O
O
CH3 Br
OMe
+
O
O
CH3
MeO
CH3CH3
B(OH)2
 
  3.13        3.38     3.39 
Scheme 3.42 
 
A mixture of 3.13 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and 4-methylnaphthalene-1-boronic acid 3.38  in benzene at 24˚C and heated under 
reflux for 16h to afford  a 90% yield of the quinone 3.39. The resulting material was assigned 
the structure 3.39 based on the following spectral evidence. In the 1H nmr spectrum, singlets 
at 2.51 and 2.74ppm were assigned to 7-CH3 and 4´-CH3 while the 5-OMe signal appeared at 
4.04ppm. In the 13C nmr spectrum, signals at 159.8, 184.3 and 185.0ppm were assigned to C-
5, C-1 and C-4. A HRMS of 342.1272 supported the molecular formula of C23H18O3 (required 
342.1255).  
Demethylation of the 3.39 by the method reported by Kesteleyn et al.,74 was then effected to 
produce the naphthol 3.37 as shown in Scheme 3.43. 
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CH3
O
O
CH3
OH
CH3 
    3.39       3.37 
Scheme 3.43 
A solution of 3.39 in dry DCM was treated with borontribromide to afford a 45% yield of the 
quinone 3.37. The resulting material was assigned the structure 3.37 based on the following 
spectral evidence. In the ir spectrum, a broad signal at 3433 cm-1 was assigned to the 5-OH 
group. In the 1H nmr spectrum, the peaks for the two aryl methyl groups appeared at 2.58 and 
2.76ppm and a 1-proton singlet at 12.01ppm was assigned to 5-OH. A HRMS of 328.0170 
supported the molecular formula of C22H16O3 (required 328.1099). 
 
Section 3.9: Synthesis of 2-(2´-naphthyl)- 5-hydroxy-7-methyl-1,4-naphthoquinone 3.40 
The next compound synthesized was quinone 3.40, which had only one hydroxyl group on the 
naphthoquinone half of the molecule. Again Suzuki coupling64, 65 was employed for this 
purpose as shown in Scheme 3.44.  
O
O
CH3 Br
OMe
+
O
O
OMe
CH3
(HO)2B
 
 
 3.13    3.41    3.42 
 
Scheme 3.44 
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A mixture of 3.13 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and 2-naphthaleneboronic acid 3.41  in benzene at 24˚C and heated under reflux for 
16h to afford  an 88% yield of the quinone 3.42. The resulting material was assigned the 
structure 3.42 based on the following spectral evidence. In the 1H nmr spectrum, a signal at 
4.03ppm was assigned to the C-5 methoxy group while a 1-proton singlet at 7.09ppm was 
assigned to H-3. A 2-proton multiplet at 7.54ppm was assigned to H-6´ and H-7´. A HRMS of 
328.1181 supported the molecular formula of C22H16O3 (required 328.1099). 
 
O
O
OMe
CH3
O
O
OH
CH3
 
  3.42       3.40 
 
Scheme 3.45 
 
Demethylation74 was effected by treatment of a solution of 3.42 in dry DCM with 
borontribromide to afford a 37% yield of the quinone 3.40 (Scheme 3.45). The resulting 
material was assigned the structure 3.40 based on the following spectral evidence. In the ir 
spectrum, a signal at 3340 cm-1 was assigned to the 5-OH group. In the 1H nmr spectrum, the 
peak for the methoxy group was absent while a 1-proton singlet at 7.15ppm was assigned to 
H-3. A HRMS of 314.0898 supported the molecular formula of C21H14O3 (required 
314.0943). 
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Section 3.10: Synthesis of 2-(naphthalen-2′-yl)-7-methyl-1,4-naphthoquinone 3.43 
O
O
CH3
O
O
CH3 Br
(HO)2B
+
 
  3.2   3.41     3.43 
 
Scheme 3.46 
A mixture of 3.2 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and 2-naphthaleneboronic acid 3.41  in benzene at 24˚C and heated under reflux for 
16h to afford  an 86% yield of the quinone 3.43 (Scheme 3.46). The resulting material was 
assigned the structure 3.43 based on the following spectral evidence. In the 1H nmr spectrum, 
a signal at 2.53ppm was assigned to the C-7 methyl group and a 1-proton singlet at 7.16ppm 
was assigned to H-3. A HRMS of 298.1030 supported the molecular formula of C21H14O2 
(required 298.0993). 
 
Section 3.11: Synthesis of 2-(4-methylnaphthalen-1′-yl)-7-methyl-1,4-naphthoquinone 
3.44 
O
O
CH3 Br
B(OH)2
CH3
+
O
O
CH3
CH3
 
  3.2   3.38    3.44 
Scheme 3.47 
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A mixture of 3.2 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and 4-methyl-1-naphthaleneboronic acid 3.38  in benzene at 24˚C and heated under 
reflux for 16h to afford  a 90% yield of the quinone 3.44 as shown in Scheme 3.47. The 
resulting material was assigned the structure 3.44 based on the following spectral evidence. In 
the 1H nmr spectrum, the signals at 2.53ppm and 2.76ppm were assigned to CH3-7 and CH3-
4´ and a 1-proton singlet at 7.07ppm was assigned to H-3. A HRMS of 312.1139 supported 
the molecular formula of C22H16O2 (required 312.1150). 
 
Section 3.12: Synthesis of 2-(naphthalen-2′-yl)-5-acetoxy-1,4-naphthoquinone 3.45 
The two retrosynthons in Scheme 3.48 for the target quinone 3.45 are bromoquinone 3.46 and 
boronic acid 3.41, which is commercially available.  
O
O
AcO
O
OOAc
Br (HO)2B
+
 
  3.45     3.46    3.41 
Scheme 3.48 
Section 3.12.1: Synthesis of 5-acetoxy-2-bromo-1,4-naphthoquinone 3.46 
The proposed synthetic protocol of the target naphthoquinone 3.46 is illustrated in Scheme 
3.49 below. 
1
5
OAc
OAc
1
5
OH
OH
O
O
Br
OAc
1
45
 
  3.47    3.48    3.46 
Scheme 3.49 
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The first step was the synthesis of 1,5-diacetoxynaphthalene 3.48 as shown in Scheme 3.50. 
1
5
OAc
OAc
1
5
OH
OH  
   3.47      3.48 
Scheme 3.50 
1,5-Naphthalenediol 3.47 was treated with pyridine and acetic anhydride to afford 97% yield 
of the diacetate product 3.48 with m.p. 158-160˚C (from benzene). (Lit. m.p. 161˚C)69. In the 
1H nmr spectrum, a 6-proton singlet at 2.47ppm was assigned to the –CO2CH3 groups and the 
a 2-proton dd at 7.29ppm with J 7.2 and 1.2 was assigned to H-2 and H-6. In the 13C nmr 
spectrum, the signal at 21.0ppm was assigned to the acetate -CH3 groups. The signals at 146.7 
and 169.2ppm were assigned to (C-1 and C-5) and (2 x C=O). 
Next step was the oxidative bromination of the 3.48 by the method reported by Jung et al.69 as 
shown in Scheme 3.51. 
1
5
OAc
OAc
O
O
Br
OAc
1
45
 
3.48     3.46 
Scheme 3.51 
A solution of 1,5-diacetoxynaphthalene 3.48 in warm acetic acid was treated with a solution 
of N-bromosuccinimide in acetic acid and water to afford 92% yield of the 5-acetoxy-2-
bromo-1,4-naphthoquinone 3.46 with m.p. 156-157°C (Lit. m.p. 158˚C).69 In the 1H nmr 
spectrum, the signals at 2.44 and 7.39ppm were assigned to the –CO2CH3 group and H-3. In 
 
 
 
 
 72
the 13C nmr spectrum, the signals at 169.2, 177.4 and 180.9ppm were assigned to [C=O 
(ester)], C-1 and C-4. 
Section 3.12.2: Coupled product 3.45 
 
O
O
AcO
O
OOAc
Br (HO)2B
+
 
 3.46    3.41     3.45 
Scheme 3.52 
A mixture of 3.46 and Pd(PPh3)4 in benzene was treated with an aqueous solution of sodium 
carbonate and 2-naphthaleneboronic acid 3.41  in benzene at 24˚C and heated under reflux for 
16h to afford  79% yield of the quinone 3.45 as shown in Scheme 3.52. The resulting material 
was assigned the structure 3.45 based on the following spectral evidence. In the 1H nmr 
spectrum, a 3-proton singlet at 2.49ppm was assigned to –OCOCH3 group and a 3-proton 
multiplet at 7.58ppm was assigned to H-3´, H-6´ and H-7´. In the 13C nmr spectrum, the 
signals at 169.4, 183.7 and 183.8 were assigned to (ester, C=O), C-1 and C-4.  A HRMS of 
342.0890 supported the molecular formula of C22H14O4 (required 342.0892). 
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Section 3.13: Synthesis of 2-(4-methylnaphthalen-1′-yl)-5-acetoxy-1,4-naphthoquinone 
3.49 
Synthesis of quinone 3.49 involved the coupling64, 65 of bromoquinone 3.46 and boronic acid 
3.38 via the Suzuki protocol to afford the biaryl quinone 3.49 in 77% yield as shown in 
Scheme 3.53. 
 
O
O
AcO
CH3
1
4
5
1
4
O
OOAc
Br
CH3(HO)2B
+
1´ 4´
 
 3.46    3.38    3.49 
 
Scheme 3.53 
In the 1H nmr spectrum of 3.49, 3-proton signals at 2.49 and 2.75ppm were assigned to the 
ester-CH3 and 4´-CH3. A 2-proton multiplet at 7.35ppm was assigned to H-2´ and H-3´ and a 
2-proton multiplet at 7.54ppm was assigned to H-6´ and H-7´. In the 13C nmr spectrum, the 
signals at 19.6 and 21.1ppm were assigned to 4´- CH3 and the ester-CH3. The signals at 169.5, 
183.7 were assigned to (ester, C=O) and (C-1 and C-4).  A HRMS of 356.1049 supported the 
molecular formula of C23H16O4 (required 356.1048). 
 
Conclusion: The synthesis of two binaphthoquinone compounds viz., 3.1 and 3.12 has been 
achieved. The latter molecule has been synthesized by keeping in mind that the dimethyl ether 
derivative 1.27 of diospyrin was biologically more active than diospyrin 1.22 itself.59 The 
synthesis of two further naphthoquinone-benzoquinone biaryl compounds viz., 3.21 and 3.25 
has also been achieved. These quinones viz., 3.21 and 3.25 differ only by the C-5 hydroxyl 
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group and any enhanced biological activity of 3.25 as compared to 3.21 will thus be attributed 
to the hydroxyl group at C-5 position.  
The synthesis of several naphthoquinone-naphthalene biaryl systems with different 
substituent groups has also been achieved. Evaluations of these molecules as 
antimycobacterial and anticancer agents would certainly assist in deducing the structure-
activity relationship and thus determine future target molecules for synthesis.    
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Chapter 4:  Experimental 
 
Section 4.1: General 
Nuclear magnetic resonance spectra were recorded using a Varian 200 MHz spectrometer. All 
spectra were recorded at 20°C in deuterocholoroform (CDCl3) and J values are given in Hz. 
In the 1H and 13C spectra, assignments of signals with the same superscript are 
interchangeable. Mass spectra were recorded on a Finnigan-Matt Ion Trap Detector 
spectrometer at 70 eV with automatic gain control. High-resolution mass spectra were 
recorded on a modified AEI-902 High Resolution Mass Spectrometer at the University of the 
Witwatersrand, Johannesburg. Infrared spectra were recorded as Nujol mulls on a Perkin 
Elmer 1000PC Fourier Transform spectrometer. Melting points are uncorrected and were 
recorded on Fisher-Johns Melting Point Apparatus.  
 
Column chromatography was carried out using Merck Kieselgel 60 (70-230 mesh) as dry 
columns. Preadsorption was carried out on Merck kieselgel 60 (35-70 mesh). Preparative 
layer chromatography was performed on glass plate coated with silica gel with UV254 as a 
1.0 mm thick layer, while thin layer chromatography was carried out on aluminium plates 
coated with Merck Kieselgel 60 F254. The residue obtained upon workup refers to material 
obtained from the dried (magnesium sulphate) organic extract after filtration and solvent 
removal. Hexane refers to the fraction of boiling point 68°C -72°C. All solvents were purified 
by distillation and, if necessary, were dried according to standard methods.  
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2-Bromo-7-methyl-5,5,8,8-tetrahydro-1,4-naphthoquinone  3.6 
 
O
O
Br
 
3.6 
 
To a solution of 2,5-dibromo-1,4-benzoquinone 3.5 (2.68 g, 10.0 mmol) in 20 ml of THF at 
24°C under nitrogen was added a solution of isoprene 3.4 (0.68 g, 10.0 mmol) in 10 ml of 
THF drop-wise over 15 minutes. The resulting solution was heated under reflux for 8h and 
then cooled down to 24°C. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:19) to afford quinone 3.6 (1.64 g, 64%) as bluish black needles, m.p. 73-
75°C (from ethanol). υmax 1660 (m, C=O), 1651 (m, C=O), 1601 (w, Ar) and 1585 cm-1 (w, 
Ar); δH 1.77 (3H, s, CH3-7), 3.05 (4H, m, H-5 and H-8), 5.48 (1H, m, H-6) and 7.24 (1H, s, 
H-3). δC  22.9 (CH3), 25.3 (C-5)a, 29.5 (C-8)a, 116.6 (C-6), 130.2 (C-2)b, 137.2 (C-7)b, 137.9 
(C-3), 139.4 (C-4a)c, 140.2 (C-8a)c, 179.3 (C-1)d, 184.5 (C-4)d. (HRMS: Found M+ 251.9787; 
C, 52.4 ; H, 3.5. Calc. for C11H9BrO2: M 251.9785; C, 52.2; H, 3.6%). 
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2-Bromo-7-methyl-1,4-naphthoquinone  3.2 
 
                
O
O
Br
 
                  3.2 
 
A mixture of 2-bromo-7-methyl-5,5,8,8-tetrahydro-1,4-naphthoquinone 3.6 (1.82 g, 7.1 
mmol), chloranil (1.74 g, 7.1 mmol) and 30 ml of benzene was heated under reflux for 30h. 
The residue obtained upon workup was chromatographed using EtOAc:hexane (1:19) to 
afford quinone 3.2 (1.35 g, 75%) as yellow needles, m.p. 124 - 126°C (from ethanol). υmax 
1674 (s, C=O), 1650 (s, C=O), 1597 (m, Ar) and 1587 cm-1 (m, Ar); δH 2.51 (3H, s, CH3-7), 
7.49 (1H, s, H-3), 7.57 (1H, dd, J 8.0 and 1.2, H-6), 7.96 (1H, d, J 1.2, H-8) and 7.98 (1H, d, J 
8.0, H-5). δC 21.9 (CH3), 127.2 (C-3)a, 128.3 (C-6)a, 129.7 (C-2)b, 131.0 (C-7)b, 135.2 (C-5)c, 
139.9 (C-4a)d, 140.5 (C-8)c, 145.6 (C-8a)d, 179.0 (C-1)e and 182.4 (C-4)e. (HRMS: Found M+ 
251.9631; C, 52.7; H, 2.6. Calc. for C11H7BrO2: M 251.9629; C, 52.6; H, 2.8%). 
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2-Bromo-7-methyl-1,4-naphthalenediol 3.9 
 
OH
OH
Br
 
3.9 
 
To a stirred suspension of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 (1 g, 3.98 mmol) in 40 
ml of ethanol at 50°C was added a solution of tin(II) chloride (3.1 g, 13.9 mmol) in 
concentrated HCl (5 ml). After stirring for 45 min at the same temperature, the reaction 
mixture was poured into cold water (150 ml), and the solid material was filtered and washed 
with water to afford the product 3.9 (0.77g, 77%) as white needles, m.p. ~115°C (decomp, 
from benzene). υmax 3297 (m, -OH) and 1595 cm-1 (m, Ar); δH 2.54 (3H, s, CH3-7), 5.56 (1H, 
s, -OH), 6.81 (1H, s, H-3), 7.36 (1H, dd, J 8.5 and 1.6, H-6), 7.95 (1H, d, J 1.6, H-8) and 7.97 
(1H, d, J 8.5, H-5). δH [d6-acetone] 2.50 (3H, s, CH3-7), 6.92 (1H, s, H-3), 7.36 (1H, dd, J 8.4 
and 1.6, H-6), 7.77 (1H, s, 1-OH)a, 7.98 (1H, d, J 1.6, H-8), 8.07 (1H, d, J 8.4, H-5) and 8.83 
(1H, s, 4-OH)a. δC  [d6-acetone] 12.9 (CH3), 95.4 (C-2), 101.8 (C-3)a, 113.0 (C-6)a, 114.2 (C-
5)a, 115.4 (C-4a)b, 118.4 (C-8a)b, 119.3 (C-8)a, 128.0 (C-7)b, 133.8 (C-1)c and 138.9 (C-4)c. 
(HRMS: Found M+ 251.9782; C, 52.4 ; H, 3.3. Calc. for C11H9BrO2: M 251.9785; C, 52.2; H, 
3.6%). 
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2-Bromo-1,4-dimethoxy-7-methylnaphthalene 3.10 
 
OMe
OMe
Br
 
3.10 
 
To a solution of 2-bromo-7-methyl-1,4-naphthalenediol 3.9 (0.73 g, 2.89 mmol) in dry 
acetone (20 ml) was added anhydrous potassium carbonate (4.79 g, 34.68 mmol). 
Dimethylsulphate (1.82 g, 1.36 ml, 14.40 mmol) was then added in one portion and the 
mixture was heated and vigorously stirred under reflux for 20h. It was then cooled down to 
25°C, filtered and the filtrate was concentrated under reduced pressure. The residue was 
dissolved in 50 ml of ether, and triethylamine (1.46 g, 2.0 ml, 14.40 mmol) was added. After 
being stirred for 20 min at 25°C, the solution was washed with 1M HCl (2 X 20 ml) and water 
(1 X 25 ml). The residue obtained upon workup was chromatographed using EtOAc:hexane 
(1:5) to afford the product 3.10 (0.62g, 77 %) as colourless needles, m.p. 73-74°C (form 
ethanol). υmax 1626 (w, Ar) and 1587 cm-1 (m, Ar); δH 2.54 (3H, s, CH3-7), 3.94 (3H, s, OMe), 
3.96 (3H, s, OMe), 6.81 (1H, s, H-3), 7.33 (1H, dd, J 8.4 and 1.6, H-6), 7.81 (1H, d, J 1.6, H-
8) and 8.09 (1H, d, J 8.4, H-5). δC 22.0 (CH3), 55.9 (OMe), 61.4 (OMe), 107.3 (C-3), 112.1 
(C-2)a, 121.0 (C-6)b, 122.6 (C-5)b, 124.1 (C- 4a)a, 128.0 (C- 8)b, 129.3 (C-8a)a, 137.4 (C- 7)a, 
150.6 (C-1)c and 152.4 (C-4)c. (HRMS: Found M+ 280.0099; C, 55.7 ; H, 4.6. Calc. for 
C13H13BrO2: M 280.0098; C, 55.5; H, 4.7%). 
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1,4-dimethoxy-7-methylnaphthalene-2-boronic acid 3.3 
 
OMe
OMe
B(OH)2
 
3.3 
 
n-Butyllithium (1.67 ml, 1.28M, 2.14 mmol, 1.2 mol equiv) was added drop-wise to a stirring 
solution of 2-bromo-1,4-dimethoxy-7-methylnaphthalene 3.10 (500 mg, 1.78 mmol) in dry 
THF (10 ml) at -78˚C. The reaction was stirred at this temperature under N2 for 15 min, 
during which time the mixture colour went from colourless to lime green. Trimethyl borate 
(1.0 ml, 0.92 g, 8.90 mmol, 5.0 mol equiv) was then added drop-wise causing the reaction 
mixture to become clear again. The reaction mixture was stirred at -78˚C for a further 30 min 
and then allowed to warm to 24˚C over 20h. The reaction mixture was then cooled to 0˚C and 
aqueous HCl (5% v/v) was added until the pH was approximately 6. The aqueous phase was 
extracted with DCM (3×30 ml) to afford the product 3.3 (308 mg, 70%) that was used 
immediately in the further reaction. δH 2.52 (3H, s, CH3-7), 3.55 (3H, s, OMe), 3.81 (3H, s, 
OMe), 5.58 (2H, s, B(OH)2), 6.57 (1H, s, H-3), 7.57 (1H, dd, J 8.0 and 1.2, H-6), 7.97 (1H, d, 
J 1.2, H-8) and 8.02 (1H, d, J 8.0, H-5). 
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Palladium-tetrakis(triphenylphosphine) 3.50 
 
Into a dry 200 ml Schlenk tube containing argon was placed DMSO (120-130 ml) and the 
solvent was degassed at least five times by a sequence of vacuum – argon replenishment. To 
the solvent was added PdCl2 (1.77 g, 9.98 mmol) followed by triphenylphosphine (13.1 g, 
49.9 mmol). The solution was once again degassed several times and the stopper on the 
Schlenk tube was replaced by a new septum. The slurry was then heated and at about 150°C 
the PdCl2 was completely solubilised however some PPh3 remained undissolved. Dissolution 
of all components occurred at about 170°C thus producing a homogenous orange solution. 
The solution was removed from the oil bath and without delay hydrazine hydrate (2.0 g, 40 
mmol) was added by means of a syringe via the septum. Vigorous effervescence of the 
reaction mixture occurred during the addition and the solution immediately darkened in 
colour. 
Whilst stirring, the solution was allowed to cool without external cooling and eventually 
Pd(PPh3)4 precipitated as bright yellow crystals. The solution was allowed to cool to room 
temperature and then rapidly filtered (under argon). The filtrate was washed twice with cold 
ethanol (2 x 20 ml, degassed), then washed twice with cold ether (2 x 20 ml, degassed) and 
dried overnight in a sintered glass funnel by passing a stream of dry nitrogen gas through the 
solid to afford the product 3.50 (10.40 g, 90%) as bright yellow solid. 
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2-(1´,4´-Dimethoxy-7-methylnaphthalen-2´-yl)-7-methyl-1,4-naphthoquinone 3.11 
O
O
OCH3
OCH3
CH3
CH3 1
4
1´
2´
 
3.11 
A mixture of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 (314 mg, 1.25 mmol) and Pd(PPh3)4 
(150 mg, 0.13 mmol) in benzene (20 ml) was stirred for 0.5h at 24˚C under nitrogen. An aqueous 
solution of sodium carbonate (2M, 1.0 ml) and boronic acid 3.3 (307 mg, 1.25 mmol) in benzene 
(20 ml) were added successively. The mixture was heated under reflux for 16h with vigorous 
stirring. The resulting mixture was extracted with DCM. The residue obtained upon workup was 
chromatographed using EtOAc:hexane (3:7) to afford quinone 3.11 (190mg, 41%) as red crystals. 
m.p. 141-143°C (from EtOAc/Hexane). υmax 1664 (s, C=O), 1657 (m, C=O) and 1597 cm-1 (m, 
Ar); δH 2.53 (3H, s, CH3-7´), 2.55 (3H, s, CH3-7), 3.74 (3H, s, OMe), 3.97 (3H, s, OMe), 6.56 
(1H, s, H-3´), 7.17 (1H, s, H-3), 7.38 (1H, dd, J 8.4 and 1.4, H-6´), 7.59 (1H, dd, J 7.6 and 1.0, H-
6), 7.87 (1H, d, J 1.4, H-8´) 8.00 (1H, d, J 1.0, H-8), 8.05 (1H, d, J 7.6, H-5) and 8.16 (1H, d, J 
8.4, H-5´). δC 21.9 (CH3), 22.0 (CH3), 55.7 (OMe), 62.4 (OMe), 104.0 (C-3´),  108.8 (C-2´), 
118.0 (C-2), 121.5 (C-6)a, 122.4 (C-6´)a, 126.3 (C-5´)b, 127.4 (C-8´)b, 128.7 (C-3)b, 130.0 (C-7´)c, 
130.3 (C-4a´)c,132.5 (C-8a´)c, 134.5 (C-5)d, 136.8 (C-7)d, 137.5 (C-8)d, 145.0 (C-1´)e, 147.7 (C-
4a)e, 147.9 (C-8a)e, 151.7 (C-4´)e, 184.4 (C-1)f and 185.1 (C-4)f. (HRMS: Found M+ 372.1299; 
C, 77.7; H, 5.2. Calc. for C24H20O4: M 372.1361; C, 77.4; H, 5.4%). 
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2,2´-Bis(7-methyl-1,4-naphthoquinone) 3.1 
 
O
O
O
O
CH3
CH3
1´
2´1
4
 
    3.1 
 
A suspension of 2-(1´,4´-dimethoxy-7-methylnaphthalen-2´-yl)-7-methyl-1,4-naphthoquinone 
3.11 (200 mg, 0.54 mmol) in a mixture of acetonitrile (18 ml) and water (8 ml) was cooled to 
0˚C. Over the course of 10 min a cooled solution of cerium(IV) ammonium nitrate (1.10 g, 2.0 
mmol) in a mixture of acetonitrile (12 ml) and water (12 ml) was added to the suspension. The 
reaction mixture was stirred for 20 min and allowed to warm to 24˚C over 30 min. The mixture 
was diluted with water and extracted with DCM. The residue obtained upon workup was 
chromatographed using EtOAc:hexane (2:3) to afford quinone 3.1 (30mg, 15%) as yellow 
crystals. m.p. 179-181°C (from ethanol). υmax 1668 (s, C=O), 1657 (s, C=O) and 1599 (m, Ar) 
and 1587 cm-1 (m, Ar); δH 2.52 (3H, s, CH3-7´)a, 2.54 (3H, s, CH3-7)a, 6.93(1H, s, H-3´)b, 7.26 
(1H, s, H-3)b, 7.60 (2H, dd, J 8.2 and 2.0, H-6´ and H-6), 7.93 (1H, d, J 2.0, H-8/8´), 8.01 (1H, d, 
J 8.2, H-5´/5) 8.03 (1H, d, J 2.0, H-8/8´) and 8.05 (1H, d, J 8.2, H-5/5´). δC 21.9 (CH3), 29.7 
(CH3), 126.7 (C-3´)a,  127.4 (C-3)a, 127.6 (C-6´)a, 128.2 (C-6)a, 129.2 (C-2´)b, 129.8 (C-2)b, 
131.0 (C-7´)c, 131.7 (C-7)c, 135.0 (C-5´)d, 135.4 (C-5)d,137.8 (C-4a´)e, 138.1 (C-8a´)e, 140.0 (C-
4a)e, 144.3 (C-8a)e, 145.5 (C-8´)f, 145.8 (C-8)f, 177.3 (C-1´)g, 180.0 (C-4´)g, 182.0 (C-1)g and 
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183.8 (C-4)g. (HRMS: Found M+  ; C, 77.1; H, 4.3. Calc. for C22H14O4: M 342.0892; C, 77.2; H, 
4.1%). 
 
1-Methoxy-3-methyl-1-trimethylsilyloxy-1,3-butadiene 3.15 
 
OCH3
OTMS
 
3.15 
 
Methyl-3-methyl-2-butenoate 3.17 (2.85 g, 25 mmol) in THF (10 ml) was added drop-wise over 
30 min to a solution of lithiumdiisopropylamide at -78˚C, prepared by addition of a hexane 
solution of n-butyllithium (18.3 ml, 1.5M, 27.5 mmol) to diisopropylamine (2.5 g, 25 mmol) in 
THF (60 ml). The mixture was stirred for 0.5h at the same temperature, after which trimethylsilyl 
chloride (4.07 g, 4.76 ml, 37.5 mmol) and triethylamine (1 ml) were added. The temperature was 
allowed to rise to 24˚C, and the reaction mixture was stirred for 2h after which hexane (100 ml) 
was added. The solution was filtered to remove the precipitated LiCl. The filtrate was 
concentrated to afford the product 3.15 (3.72 g, 80%) used immediately in the further reaction.                         
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2,5-Dibromo-1,4-benzoquinone 3.5 
 
O
O
Br
Br
 
3.5 
 
To a solution of 1,4-dimethoxybenzene 3.7 (10 g, 72.5 mmol) in acetic acid (20 ml) was added 
drop-wise a solution of bromine (23.15 g, 7.44 ml, 145 mmol) in acetic acid (7 ml) at 24˚C. The 
reaction mixture was stirred for 2h, then cooled down to 24˚C and filtered to afford 2,5-dibromo-
1,4-dimethoxybenzene 3.8 (15.69 g). The filtrate was diluted with water (15 ml) and extracted 
with DCM, which was washed with a 10% aqueous solution of NaHCO3, dried over MgSO4 and 
evaporated, yielding an additional amount (2.86 g) of the product 3.8. The combined fractions 
(18.55 g, 62.7 mmol) was dissolved in acetonitrile (150 ml) and heated. A solution of cerium (IV) 
ammonium nitrate (75 g, 136.8 mmol) in 300 ml of water was added drop-wise to the boiling 
solution of the 2,5-dibromo-1,4-dimethoxybenzene in acetonitrile. The reaction mixture was left 
to cool down at 24˚C while stirring for 30 min. The solid material was filtered and washed with 
water to afford quinone 3.5 (15.21g, 82%) as yellow solid, m.p. 159-160˚C (from 
EtOAc/hexane). (Lit.66 m.p. 160-161˚C). δH 7.48 (2H, s, H-3 and H-6). δC 137.2 (C-2 and C-5)a, 
137.9 (C-3 and C-6)a and 177.0 (C-1 and C-4).  
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2-Bromo-5-hydroxy-7-methyl-1,4-naphthoquinone 3.16 
 
O
O
Br
OH
 
3.16 
 
To a solution of 2,5-dibromo-1,4-benzoquinone 3.5  (3.99 g, 15.0 mmol) in dry THF (30 ml) at 
0°C under N2 was added a solution of 1-methoxy-3-methyl-1-trimethylsilyloxy-1,3-butadiene 
3.15 (2.58 g, 15.0 mmol) in dry THF (15 ml) drop-wise over 1h. The resulting solution was 
stirred at 25˚C for 8h. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:4) to afford the quinone 3.16 (2.31 g, 57%) as an orange red solid, m.p. 131-
133˚C (from EtOAc/hexane). (Lit.41 m.p. 132-133.5˚C). υmax 1672 (s, C=O), 1633 (m, C=O), 
1575 (m, Ar) and 1567 cm-1 (m, Ar). δH 2.43 (3H, s, CH3-7), 7.08 (1H, d, J 1.4, H-6), 7.44(1H, s, 
H-3), 7.52 (1H, d, J 1.4, H-8) and 11.70 (1H, s, 5-OH). δC 22.2 (CH3), 112.7 (C-2)a, 122.4 (C-3)b, 
124.8 (C-6)b, 130.5 (C-7)a, 140.4 (C-8)b, 140.5 (C-4a)c, 148.6 (C-8a)c, 162.0 (C-5), 177.5 (C-1)d 
and 186.9(C-4)d. 
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2-Bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 
 
 
Br
O
O
OCH3
 
3.13 
 
A mixture of 2-bromo-5-hydroxy-7-methyl-1,4-naphthoquinone 3.16 (2.31 g, 8.64 mmol), 
powdered Ag2O (13.91 g, 60.48 mmol) and methyl iodide (6.31 g, 2.68 ml, 43.2 mmol) in 
benzene (50 ml) was stirred and heated under reflux for 1h. After filtration, the residue obtained 
upon workup was chromatographed using EtOAc:hexane (1:4) to afford quinone 3.13 (1.36 g, 
56%) as yellow solid, m.p. 168-170˚C (form ethanol). (Lit.69 m.p. 168.5-170˚C). δH 2.48 (3H, s, 
CH3-7), 3.99 (3H, s, OMe), 7.12 (1H, d, J 1.2, H-6), 7.36 (1H, s, H-3) and 7.62 (1H, d, J 1.2, H-
8). δC 22.4 (CH3), 56.6 (OMe), 119.0 (C-3)a, 121.6 (C-6)a, 133.0 (C-2)b, 136.7 (C-4a)b, 142.5 (C-
8)a, 146.7 (C-7)b, 146.8 (C-8a)b, 160.3 (C-5), 178.6 (C-1)c and 181.3 (C-4)c.  
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2-Bromo-5- methoxy-7-methyl-1,4-naphthalenediol 3.18 
 
OH
OH
Br
OCH3
CH3
 
3.18 
 
A suspension of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 (1.1 g, 3.91 mmol) in 
dichloromethane (100 ml) was shaken in a separatory funnel with a freshly prepared solution of 
sodium dithionite (10.2 g, 58.65 mmol) in water (150 ml). After the mixture was shaken (3 x 50 
ml), the organic layer was separated, dried over MgSO4 and then concentrated in vacuo to afford 
the product 3.18 (0.86 g, 78%) as a white solid which is used in the next reaction without 
purification. δH 2.49 (3H, s, CH3-7), 4.04 (3H, s, OMe), 5.43 (1H, br s, 1-OH)a, 6.67 (1H, d, J 1.2, 
H-6), 6.84 (1H, s, H-3), 7.58 (1H, d, J 1.2, H-8) and 8.91 (1H, s, 4-OH)a. δC 21.8 (CH3), 55.8 
(OMe), 104.9 (C-2)a, 107.1 (C-3)b, 110.6 (C-6)b, 115.0 (C-8)b, 126.2 (C-7)a, 136.2 (C-4a)c, 140.4 
(C-8a)c, 142.3 (C-5)c, 147.9 (C-1)d and 155.5 (C-4)d. 
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2-Bromo-1,4,5-trimethoxy-7-methylnaphthalene 3.19 
 
OCH3
OCH3
Br
OCH3
CH3
 
3.19 
 
A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthalenediol 3.18 (1.0 g, 3.53 mmol) in dry 
acetone (50 ml), anhydrous potassium carbonate (5.85 g, 42.40 mmol) and dimethylsulphate 
(3.55 g, 28.24 mmol) was vigorously stirred and heated under reflux for 20h. The reaction 
mixture was then cooled to 25°C, filtered and the filtrate was concentrated under reduced 
pressure. The residue obtained was dissolved in 50 ml of ether and Et3 N (2.86 g, 3.92 ml, 28.24 
mmol) was added. After being stirred for 20 min at 24°C, the solution was washed with 1M HCl 
(2 x 20 ml) and water (1 x 25 ml). The residue obtained upon workup was chromatographed 
using EtOAc:hexane (1:4) to afford the product 3.19 (0.90 g, 82%) as colourless solid, m.p. 94-
96˚C (form EtOAc/hexane). (Lit. m.p. 95-96˚C). δH 2.50 (3H, s, CH3-7), 3.91 (3H, s, OMe), 3.93 
(3H, s, OMe), 3.95 (3H, s, OMe), 6.72 (1H, d, J 1.2, H-6), 6.83 (1H, s, H-3) and 7.46 (1H, d, J 
1.2, H-8). δC 22.0 (CH3), 56.3 (OMe), 56.6 (OMe), 60.9 (OMe), 108.9 (C-3)a, 109.0 (C-6)a, 112.5 
(C-2)b, 113.7 (C-8)a, 115.8 (C-7)b, 131.7 (C-4a)c, 137.6 (C-8a)c, 146.2 (C-5), 153.8 (C-1)d and 
157.3 (C-4)d. 
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1,4,5-Trimethoxy-7-methylnaphthalene-2-boronic acid 3.14 
 
OCH3
OCH3
B(OH)2
OCH3
CH3
 
3.14 
 
n-Butyllithium (2.90 ml, 1.32M, 3.88 mmol, 1.1 mol equiv) was added drop-wise to a stirred 
solution of 2-bromo-1,4,5-trimethoxy-7-methylnaphthalene 3.19 (1.1 g, 3.53 mmol) in dry THF 
(15 ml) at -78˚C. The reaction was stirred at this temperature under N2 atmosphere for 15 min 
during which time the colour of the mixture went from colourless to lime green. Trimethyl borate 
(2.0 ml, 1.83 g, 17.65 mmol, 5.0 mol equiv) was then added drop-wise causing the reaction 
mixture to become clear again. The reaction mixture was stirred at -78˚C for a further 30 min and 
then allowed to warm to 24˚C over 20h. The reaction mixture was the cooled to 0˚C and aqueous 
HCl (5% v/v) was added until the pH was approximately 6. The aqueous phase was extracted 
with DCM (3×30 ml) to afford the product 3.14 (0.73 g, 75%) that was immediately used without 
further purification. 
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2-(1′,4′,5′-Trimethoxy-7′-methylnaphthalen-2′-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 
3.20 
OCH3
OCH3
OCH3
CH3
OCH3
CH3
O
O
 
3.20 
A mixture of 2-bromo-5-methoxy-7-methylnaphthoquinone 3.13 (800 mg, 2.9 mmol) and 
Pd(PPh3)4 (340 mg, 0.30 mmol) in benzene (30 ml) was stirred for 0.5h at 24˚C under nitrogen. 
An aqueous solution of Na2CO3 (2M, 3.0 ml) and boronic acid 3.14 (780 mg, 2.80 mmol) in 
benzene (20 ml) were added successively. The mixture was heated under reflux for 16h with 
vigorous stirring. The residue obtained upon workup was chromatographed using EtOAc:hexane 
(1:1) to afford quinone 3.20 (510 mg, 41%) as reddish brown needles,  m. p. 84-86˚C (from 
EtOAc:hexane). υmax 1668 (m, C=O), 1651 (m, C=O) and 1599 cm-1 (m, Ar); δH 2.50 (6H, s, 
CH3-7´ and CH3-7), 3.68 (3H, s, OMe), 3.94 (3H, s, OMe), 3.97 (3H, s, OMe), 4.03 (3H, s, 
OMe), 6.61 (1H, s, H-3´), 6.76 (1H, d, J 1.2, H-6´), 7.07 (1H, s, H-3), 7.13 (1H, d, J 1.0, H-6), 
7.50 (1H, d, J 1.0, H-8) and 7.66 (1H, d, J 1.2, H-8´). δC 22.3 (CH3), 22.4 (CH3), 56.6 (OMe), 
56.8 (OMe), 57.0 (OMe), 62.1 (OMe), 106.6 (C-3´)a,  110.1 (C-6´)a, 114.6 (C-8´)a, 117.5 (C-2´)b, 
118.0 (C-2)b, 118.2 (C-3)a, 120.8 (C-6)a, 122.8 (C-7´)c, 131.4 (C-7)c, 134.7 (C-4a´)c, 137.2 (C-
8a´)c, 139.6 (C-8)a, 145.2 (C-4a)d, 146.4 (C-8a)d, 147.8 (C-5´)d, 153.4 (C-1´)e, 157.4 (C-4´)e, 
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159.8 (C-5)e, 184.3 (C-1)f and 184.5 (C-4)f. (HRMS: Found M+ 432.1546; C, 72.1; H, 5.4. Calc. 
for C26H24O6: M 432.1572; C, 72.2; H, 5.6%). 
 
2,2´-Bis(5-methoxy-7-methyl-1,4-naphthoquinone) 3.12 
 
OCH3
O
O
CH3
OCH3
CH3
O
O
 
3.12 
 
A suspension of 2-(1′,4′,5′-trimethoxy-7′-methylnaphthalen-2′-yl)-5-methoxy-7-methyl-1,4-
naphthoquinone 3.20 (250 mg, 0.58 mmol) in a mixture of acetonitrile (18ml) and water  (8 ml) 
was cooled to 0˚C. Over the course of 20 min a cooled solution of cerium (IV) ammonium nitrate 
(1.0 g, 1.80 mmol) in a mixture of acetonitrile (10 ml) and water (10 ml) was added to the 
suspension. The reaction mixture was stirred for 20 min and allowed to warm to 25˚C over 30 
min. The mixture was diluted with water and extracted with DCM. The residue obtained upon 
workup was chromatographed using EtOAc:hexane (1:1) to afford quinone 3.12 (80 mg, 34%) as 
yellow crystals, m. p. 219˚C (decomp.) (from EtOAc:hexane). υmax 1668 (m, C=O) and 1652 (m, 
C=O); δH 2.49 (6H, s, CH3-7´ and CH3-7), 4.02 (6H, s, 2 x OMe), 6.94 (2H, s, H-6´ and H-6), 
7.13 (2H, s, H-3´ and H-3), 7.58 (2H, s, H-8´ and H-8). δC 22.5 (CH3-7´ and CH3-7), 56.6 (2 x 
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OMe), 118.6 (C-6´ and C-6)a,  120.8 (C-3´ and C-3)a, 131.0 (C-2´ and C-2)b, 135.1 (C-7´ and C-
7)b, 139.8 (C-8´ and C-8), 141.1 (C-4a´ and 4a)c, 146.9 (C-8a´ and 8a)c, 160.0 (C-5´ and C-5), 
183.2 (C-1´ and C-1)d and 183.5 (C-4´ and C-4)d. (HRMS: Found M+ 402.1247; C, 71.4; H, 4.6. 
Calc. for C24H18O6: M 402.1103; C, 71.6; H, 4.5%). 
 
1,4-Dimethoxybenzene-2-boronic acid 3.22 
 
OCH3
OCH3
B(OH)2
  
                       3.22 
 
n-Butyllithium (3.84 ml, 1.32M, 5.06 mmol, 1.1 mol equiv) was added drop-wise to a stirring 
solution of 2-bromo-1,4-dimethoxybenzene 3.23 (1.0g, 4.60 mmol) in THF (10 ml) at -78˚C. The 
reaction was stirred at this temperature under N2 for 10 min, during which the colour of the 
mixture went from colourless to lime green. Trimethyl borate (2.58 ml, 2.39 g, 23.0 mmol, 5.0 
mol equiv) was then added drop-wise by syringe causing the reaction mixture to become clear 
again. The reaction mixture was stirred at -78˚C for a further 30 min and then allowed to warm to 
24˚C over 2h. The reaction mixture was then cooled to 0˚C and aqueous HCl (5% v/v) was added 
until the pH was approximately 6. The aqueous phase was extracted with DCM (3×30 ml) to 
afford the product 3.22 (671 mg, 80%) as white crystals, m.p. 86-87°C (from benzene). υmax 3227 
(s, -OH) and 1503 cm-1 (s, Ar); δH 3.81 (3H, s, OMe), 3.88 (3H, s, OMe), 6.38 (2H, br s, 
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B(OH)2), 6.85 (1H, d, J 8.6, H-6), 6.99 (1H, dd, J 8.6 and 2.8, H-5) and 7.39 (1H, d, J 2.8, H-3). 
δC 55.8 (OMe), 56.1 (OMe), 111.3, 118.7, 120.8 (C-2, C-3, C-5 and C-6), 153.9 (C-1)a and 158.9 
(C-4)a. (HRMS: Found M+ 182.0755; C, 52.6; H, 6.2. Calc. for C8H11BO4:  M 182.0752; C, 52.8; 
H, 6.1%). 
 
2-(1´,4´-Dimethoxybenzen-2´-yl)-7-methyl-1,4-naphthoquinone 3.24 
 
                                   
O
O
OCH3
OCH3
CH3 1
2
3
4
1´
2´
 
                                                                  3.24 
 
A mixture of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 (700 mg, 2.80 mmol) and Pd(PPh3)4 
(335 mg, 0.29 mmol) in benzene (30 ml) was stirred for 0.5h at 25˚C under Nitrogen. An aqueous 
solution of sodium carbonate (2M, 3.0ml) and 1,4-dimethoxybenzene-2-boronic acid 3.22 (500 
mg, 2.74 mmol) in benzene (20 ml) were added successively. The mixture was heated under 
reflux for 16h with vigorous stirring. The resulting cooled mixture was extracted with DCM. The 
residue obtained upon workup was chromatographed using EtOAc:hexane (1:5) to afford quinone 
3.24 (652 mg, 76%) as reddish brown crystals, m.p. 63-64˚C (from ethanol). υmax 1663 (s, C=O), 
1655 (m, C=O) and 1599 cm-1 (s, Ar); δH 2.51 (3H, s, CH3-7), 3.74 (3H, s, OMe), 3.79 (3H, s, 
OMe), 6.81 (1H, d, J 2.6, H-3´), 6.94 (1H, s, H-3)a, 6.94 (1H, m, H-6´)a, 6.97 (1H, m, H-5´)a, 
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7.56(1H, dd, J 8.2 and 2.0, H-6), 7.94 (1H, d, J 2.0, H-8) and 8.01 (1H, d, J 8.2, H-5). δC 21.8 
(CH3), 55.8 (OMe), 56.4 (OMe), 112.6 (C-3´)a, 115.9 (C-6´)a, 116.1 (C-5´)a, 124.4 (C-2´)b, 126.2 
(C-3)c, 127.3 (C-6)c, 130.0 (C-2)b, 132.5 (C-7)b, 134.3 (C-8)c, 136.8 (C-5)c, 144.8 (C-4a)d, 147.8 
(C-8a)d, 151.5 (C-1´)e, 153.5 (C-4´)e, 183.7 (C-1)f and 185.1 (C-4)f. (HRMS: Found M+ 
308.1049; C, 74.2; H, 5.3. Calc. for C19H16O4: M 308.1048; C, 74.0; H, 5.5%). 
 
2-(1´,4´-Benzoquinon-2´-yl)-7-methyl-1,4-naphthoquinone 3.21 
 
                                 
O
O
O
O
CH3 1
2
3
4
1´
2´
 
3.21 
 
A suspension of 2-(1´,4´-dimethoxybenzen-2´-yl)-7-methyl-1,4-naphthoquinone 3.24 (450 mg, 
1.45 mmol) in a mixture of acetonitrile (40 ml) and water (16 ml) was cooled to 0˚C. Over the 
course of 20 min, a cooled solution of cerium (IV) ammonium nitrate (2.4 g, 4.37 mmol) in a 
mixture of acetonitrile (25 ml) and water (25 ml) was added to the suspension. The reaction 
mixture was stirred for 20 min and allowed to warm to 25˚C over 30 min. The mixture was 
diluted with water and extracted with DCM (3×30 ml). The residue obtained upon workup was 
chromatographed using EtOAc:hexane (1:4) to afford quinone 3.21 (290 mg, 71%) as yellow 
crystals, m.p. 155-157°C (from ethanol).   υmax 1668 (s, C=O), 1658 (m, C=O), 1599 (s, Ar) and 
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1580 cm-1 (m, Ar); δH 2.52 (3H, s, CH3-7), 6.89 (3H, br s, H-3´, H-5´ and H-6´), 6.97 (1H, s, H-
3), 7.59 (1H, dd, J 8.0 and 2.0, H-6), 7.92 (1H, d, J 2.0, H-8) and 8.01(1H, d, J 8.0, H-5). δC 21.9 
(CH3), 126.6 (C-5´)a, 127.4 (C-6´)a, 129.8 (C-2´)b, 131.8 (C-2)b, 135.0 (C-3´)c, 135.5 (C-6)c, 
136.6 (C-8)c, 136.9 (C-5)c, 138.0 (C-3)c, 141.3 (C-4a)d, 142.2 (C-8a)d, 145.6 (C-7)d, 182.9 (C-
1´)e, 183.8 (C-4´)e, 184.6 (C-1)e and 186.4 (C-4)e. (HRMS: Found M+ 278.0570; C, 73.2; H, 3.4. 
Calc. for C17H10O4: M 278.0579; C, 73.3; H, 3.6%). 
 
2-(1´,4´-Dimethoxybenzen-2´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.26 
 
                              
O
O
OMe
CH3
OMe
OMe
1
4
1´
2´
 
      3.26 
 
A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 (760 mg, 2.70 mmol) and 
Pd(PPh3)4 (320 mg, 0.28 mmol) in benzene (30 ml) was stirred for 0.5h at 24˚C under Nitrogen. 
An aqueous solution of sodium carbonate (2M, 3.0 ml) and 1,4-dimethoxybenzene boronic acid 
3.22 (500 mg, 2.70 mmol) in benzene (20 ml) were added successively. The mixture was heated 
under reflux for 16h with vigorous stirring. The resulting cooled mixture was extracted with 
DCM. The residue obtained upon workup was chromatographed using EtOAc:hexane (3:7) to 
afford quinone 3.26 (290 mg, 32%) as reddish brown crystals, m.p. 147-149˚C (from ethanol). 
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υmax 1668 (m, C=O), 1649 (s, C=O) and 1603 cm-1 (m, Ar); δH 2.46 (3H, s, CH3), 3.71 (3H, s, 
OMe), 3.77 (3H, s, OMe), 3.98 (3H, s, OMe), 6.79 (1H, dd, J 2.4 and 0.6, H-3´), 6.86 (1H, s, H-
3), 6.90 (2H, m, H-5´ and H-6´), 7.08 (1H, d, J 2.0, H-6) and 7.58 (1H, d, J 2.0, H-8). δC 22.2 
(CH3), 55.7 (OMe), 56.3 (2 x OMe), 112.5 (C-3´)a, 115.7 (C-5´)a, 116.0 (C-6´)a, 117.7 (C-2´), 
117.9 (C-6)b, 120.4 (C-8)b, 123.9 (C-2)c, 134.6 (C-7)c, 138.8 (C-3)b, 145.3 (C-4a)d, 146.1 (C-8a)d, 
151.4 (C-1´)e, 153.4 (C-4´)e, 159.5 (C-5)e, 183.8 (C-1)f and 184.2 (C-4)f. (HRMS: Found M+ 
338.1143; C, 69.9; H, 5.6. Calc. for C20H18O5: M 338.1154; C, 71.0; H, 5.4%). 
 
2-(1´,4´-Benzoquinon-2´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.27 
 
                             
O
O
OMe
CH3
O
O
1
4
1´
2´
 
               3.27 
 
A suspension of 2-(1´,4´-dimethoxybenzene-2´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 
3.26 (290 mg, 0.86 mmol) in a mixture of acetonitrile (25 ml) and water (10 ml) was cooled to 
0˚C. Over the course of 10 min, a cooled solution of cerium (IV) ammonium nitrate (1.44 g, 2.62 
mmol) in a mixture of acetonitrile (15 ml) and water (15 ml) was added to the suspension. The 
reaction mixture was stirred for 20 min and allowed to warm to 25˚C over 30 min. The mixture 
was diluted with water and extracted with DCM. The residue obtained upon workup was 
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chromatographed using EtOAc:hexane (2:3) to afford quinone 3.27 (191mg, 72%) as orange 
crystals, m.p. >300°C (from ethanol). υmax 1667 (m, C=O), 1646 (w, C=O), 1597 (w, Ar) and 
1577 cm-1 (m, Ar); δH  [d6-DMSO] 2.42 (CH3), 3.90 (OMe), 7.03 (1H, dd, J 8.8 and 2.6, H-5´), 
7.34 (1H, d, J 2.0, H-6), 7.39 (1H, d, J 2.6, H-3´), 7.48 (1H, s, H-3), 7.66 (1H, d, J 8.8, H-6´) and 
9.91 (1H, d, J 2.0, H-8). δC [d6-DMSO] 21.7 (CH3), 56.3 (OMe), 106.3 (C-5´)a, 113.5 (C-6´)a, 
116.7 (C-2´)b, 118.3 (C-3´)a, 119.4 (C-2)b, 119.8 (C-3)c, 120.8 (C-7), 122.9 (C-6)c, 134.9 (C-8), 
146.9 (C-4a)d, 149.5 (C-8a)d, 154.7 (C-5), 155.8 (C-1´)e, 160.5 (C-4´)e, 173.4 (C-1)f and 180.8 
(C-4)f. (HRMS: Found M+ 308.0611; C, 70.0; H, 4.0. Calc. for C18H12O5: M 308.0684; C, 70.1; 
H, 3.9%). 
 
2-(1´,4´-Benzoquinon-2´-yl)-5-hydroxy-7-methyl-1,4-naphthoquinone 3.25 
 
 
                                 
O
O
OH
CH3
O
O
1
4
1´
2´
 
      3.25 
 
To a solution of 2-(1´,4´-benzoquinon-2´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.27  (150 
mg, 0.49 mmol) in dry CH2Cl2 (20 ml) at 25˚C under nitrogen was added aluminum trichloride 
(2.61 g, 19.6 mmol). The mixture was stirred at 25˚C for 24h, poured into water, then acidified 
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with dilute HCl, and extracted with DCM. The residue obtained upon workup was 
chromatographed using EtOAc:hexane (1:5) to afford quinone 3.25 (78mg, 55%) as red crystals, 
m.p. >300°C (from EtOAc:hexane). υmax 1650 (w, C=O), 1643 (m, C=O) and 1565 cm-1 (w, Ar); 
δH [d6-DMSO] 2.40 (3H, s, CH3), 7.09 (1H, dd, J 9.0 and 2.4, H-5´), 7.15 (1H, d, J 2.0, H-6), 
7.43 (2H, d, J 2.4, H-3´, overlaid by H-3), 7.72 (1H, d, J 9.0, H-6´), 9.97 (1H, d, J 2.0, H-8) and 
11.77 (1H, s, 5-OH). δH [d6-acetone] 2.48 (3H, s, CH3), 7.16 (1H, s, H-3), 7.22 (1H, dd, J 9.2 and 
2.4, H-5´), 7.56 (1H, d, J 2.2, H-6), 7.62 (1H, d, J 2.4, H-3´), 7.68 (1H, d, J 9.2, H-6´), 8.93 (1H, 
d, J 2.2, H-8) and 11.99 (1H, s, 5-OH). δC [d6-DMSO] 21.5 (CH3), 106.1 (C-5´)a, 113.0 (C-2´), 
113.7 (C-6´)a, 119.3 (C-3´)b, 120.4 (C-3)b, 123.0 (C-6)c, 123.3 (C-2), 124.0 (C-7)c, 133.0 (C-8), 
148.4 (C-4a)d, 150.1 (C-8a)d, 153.5 (C-5), 156.0 (C-1´)e, 161.4 (C-4´)e, 178.9 (C-1)f and 180.3 
(C-4)f. (HRMS: Found M+ 294.0571; C, 69.5; H, 3.6. Calc. for C17H10O5: M 294.0528; C, 69.4; 
H, 3.4%). 
 
2-(6′-Methoxynaphthalen-2′-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.29 
 
                             
O
O
OMe
CH3
OMe
1
4
1´
2´
6´
 
        3.29 
 
A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 (351 mg, 1.25 mmol) and 
Pd(PPh3)4 (130 mg, 0.11 mmol) in benzene (15 ml) was stirred for 0.5h at 24˚C under nitrogen. 
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An aqueous solution of Na2CO3 (2M, 1 ml) and 6-methoxynaphthalene-2-boronic acid 3.30 (238 
mg, 1.18 mmol) in benzene (10 ml) were added successively. The mixture was heated under 
reflux for 16h with vigorous stirring. The residue obtained upon workup was chromatographed 
using EtOAc:hexane (2:3) to afford quinone 3.29 (401 mg, 90%) as orange red needles, m. p. 
179-181°C (from ethanol). υmax 1663 (s, C=O), 1645 (m, C=O) and 1604 cm-1 (s, Ar); δH 2.51 
(3H, s, 7- CH3), 3.95 (3H, s, 6´-OMe)a, 4.03 (3H, s, 5-OMe)a, 7.07 (1H, s, H-3), 7.13 (1H, d, J 
1.2, H-6), 7.18 (2H, m, H-5´- and H-7´)b, 7.62 (1H, dd, J 8.4 and 1.8, H-3´), 7.67(1H, d, J  1.2, H-
8), 7.80 (2H, m, H-4´ and H-8´)b and 8.07 (1H, d, J 1.8, H-1´). δC 22.5 (7-CH3), 55.5 (6´-OMe)a, 
56.6 (5-OMe)a, 105.8 (C-2), 118.3 (C-3)b, 119.5 (C-6)b, 120.8 (C-1´)b, 121.9 (C-2´), 126.9 (C-
4´)c, 127.0 (C-5´)c, 128.4 (C-4a´)d, 128.6 (C-8a´)d, 129.5 (C-7´)c, 130.4 (C-8´)c, 135.0 (C-7), 
135.3 (C-3´)c, 137.2 (C-8)c, 145.6 (C-4a)e, 146.3 (C-8a)e, 158.9 (C-6´)f, 159.7 (C-5)f, 184.4 (C-1)g 
and 185.3 (C-4)g. (HRMS: Found M+ 358.1049; C, 77.2; H, 5.0. Calc. for C23H18O4: M 358.1204; 
C, 77.1; H, 5.1%). 
 
5-Hydroxy-2-(6-methoxynaphthalen-2′-yl)-7-methyl-1,4-naphthoquinone 3.31 
                             
O
O
OMe
CH3
OH
 
        3.31 
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To a solution of 2-(6´-methoxynaphthalen-2′-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.29 
(250 mg, 0.70 mmol) in dry DCM (20 ml) was added borontribromide (1M solution in CH2Cl2, 
0.9 ml, 0.9 mmol) drop-wise at -78ºC under nitrogen. The mixture was stirred for 3h at 25ºC, 
poured into ice water, acidified to litmus, extracted with DCM and the combined organic phase 
was washed with water. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:4) to afford quinone 3.31 (122 mg, 51%) as reddish brown needles, m. p. 262-
263°C (from ethanol). υmax 1665 (s, C=O), 1644 cm-1 (m, C=O); δH 2.48 (3H, s, 7-CH3), 4.07 
(3H, s, 6´-OMe), 7.12 (2H, m, H-3 and H-6), 7.26 (1H, d, J 1.0, H-5´), 7.33 (1H, dd, J 8.4 and 
1.0, H-7´), 7.55 (1H, d, J 1.2, H-1´), 7.71 (1H, dd, J 8.8 and 1.2, H-3´), 7.92 (1H, d, J 8.4, H-8´), 
8.10 (1H, d, J 1.0, H-8), 8.29 (1H, d, J 8.8, H-4´) and 12.00 (1H, s, 5-OH). δC 22.3 (7-CH3), 57.0 
(6´-OMe), 113.2 (C-2)a, 114.1 (C-3)b, 121.1 (C-1´)c, 124.0 (C-3´)c, 126.6 (C-4´)c, 127.9 (C-5´)c, 
128.9 (C-2´)a, 129.0 (C-4a´)d, 129.2 (C-8a´)d, 130.1 (C-7´)c, 130.2 (C-8´)c, 132.2 (C-7)b, 133.9 
(C-6)b, 135.1 (C-8)b, 148.3 (C-4a and C-8a)e, 155.1 (C-6´)f, 161.4 (C-5)f, 184.2 (C-1)g and 189.5 
(C-4)g. (HRMS: Found M+ 343.0867; C, 76.5; H, 4.7. Calc. for C22H16O4: M 344.1048; C, 76.7; 
H, 4.7%). 
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2-(6′-Hydroxynaphthalen-2′-yl)-5-hydroxy-7-methyl-1,4-naphthoquinone 3.28 
 
                                 
O
O
OH
CH3
OH
 
        3.28 
 
To a solution of 2-(6′-methoxynaphthalen-2′-yl)-5-hydroxy-7-methyl-1,4-naphthoquinone 3.31 
(400 mg, 1.11 mmol) in dry DCM (20 ml) was added borontribromide (1M solution in CH2Cl2, 
2.44 ml, 2.44 mmol) drop-wise at -78ºC under nitrogen. The mixture was stirred for 3h at 25ºC, 
poured into ice water, acidified to litmus, extracted with DCM and the combined organic phase 
was washed with water. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:4) to afford quinone 3.28 (178 mg, 46%) as reddish brown needles, m. p. 236-
238°C (form EtOAc/hexane). υmax 1664 (s, C=O), 1642 cm-1 (m, C=O); δH 2.47 (3H, s, 7-CH3), 
6.05 (1H, bs, 6´-OH), 7.12 (2H, m, H-3 and H-6), 7.32 (1H, dd, J 8.8 and 1.0, H-7´), 7.36 (1H, d, 
J 1.0, H-5´), 7.55 (1H, d, J 1.2, H-1´), 7.73 (1H, dd, J 9.2 and 1.2, H-3´), 7.83 (1H, d, J 8.8, H-
8´), 8.12 (2H, m, H-4´ and H-8) and 12.00 (1H, s, 5-OH). δC 22.3 (7-CH3), 117.2 (C-2)a, 118.0 
(C-3)b, 121.1 (C-1´)c, 124.0 (C-3´)c, 125.7 (C-4´)c, 128.1 (C-5´)c, 128.3 (C-2´)a, 129.0 (C-4a´)d, 
129.2 (C-8a´)d, 130.2 (C-7´)c, 130.3 (C-8´)c, 132.2 (C-7)b, 133.1 (C-6)b, 135.1 (C-8)b, 148.1 (C-
4a)e, 148.2 (C-8a)e, 152.1 (C-6´)f, 161.4 (C-5)f, 184.1 (C-1)g and 189.5 (C-4)g. (HRMS: Found 
M+ 330.0872; C, 76.5; H, 4.2. Calc. for C21H14O4: M 330.0892; C, 76.4; H, 4.3%). 
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7-Methyl-2-(thianthren-1´-yl)-1,4-naphthoquinone 3.34 
 
                                    
O
O S S
CH3
1
4
1´
 
3.34 
A mixture of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 (260 mg, 1.03 mmol) and Pd(PPh3)4 
(115 mg, 0.10 mmol) in benzene (10 ml) was stirred for 0.5h at 24˚C under nitrogen. An aqueous 
solution of Na2CO3 (2M, 1 ml) and thiantherene-1-boronic acid 3.33 (260 mg, 1.00 mmol) in 
benzene (15 ml) were added successively. The mixture was refluxed for 16h with vigorous 
stirring. The residue obtained upon workup was chromatographed using EtOAc:hexane (1:4) to 
afford  quinone 3.34 (330 mg, 82%) as a yellow solid, m.p. 208-209°C (from EtOAc/hexane). 
υmax 1671 (m, C=O), 1660 (s, C=O), 1599 (m, Ar); δH 2.55 (3H, s, CH3-7),  6.93 (1H, s, H-3), 
7.27 (5H, m, H-2´, H-3´, H-4´, H-7´ and H-8´), 7.51 (1H, dd, J 8.0 and 1.2, H-6) 7.61 (2H, m, H-
6´ and H-9´), 8.01 (1H, d, J 1.2, H-8) and 8.07 (1H, d, J 8.0, H-5 ). δC 21.9 (7-CH3), 126.4 (C-3)a, 
126.6 (C-2)b, 127.4 (C-2´)c, 127.6 (C-3´)c, 127.8 (C-4´)c, 127.9 (C-6´)c, 128.63 (C-7´)c, 128.64 
(C-8´)c, 128.9 (C-9´)c, 129.9 (C-5)a, 130.0 (C-1´)b, 132.1 (C-7), 134.1 (C-6)a, 134.8 (C-10a´)d, 
135.2 (C-4a´)d, 135.8 (C-5a´)d, 136.2 (C-9a´)d, 136.9 (C-8)a, 145.3 (C-4a)e, 148.8 (C-8a)e, 183.6 
(C-1)f and 184.8 (C-4)f. (HRMS: Found M+ 386.0487; C, 71.6; H, 3.5. Calc. for C23H14O2S2: M 
386.0435; C, 71.5; H, 3.7%). 
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2-(5´,10´-Dioxydithianthren-1´-yl)-7-methyl-1,4-naphthoquinone 3.32    
 
                                      
O
O
CH3
SS OO
1
4
7
1´
5´
 
3.32 
A mixture of 2-(thianthren-1´-yl)-7-methyl-1,4-naphthoquinone 3.34 (150 mg, 0.39 mmol) and 
m-chloroperbenzoic acid (2 mol equiv.,  135 mg ) in DCM (20 ml) was stirred for 2h at 25˚C and  
thereafter the organic acids were extracted into aqueous sodium hydrogen carbonate and the dried 
DCM yielded a residue upon workup which  was chromatographed using EtOAc:hexane (1:4) to 
afford sulphone 3.32 (94 mg,  58%) as orange needles, m.p. 115-117˚C (from EtOAc/hexane). 
υmax 1671 (m, C=O), 1658 (s, C=O), 1592 (m, Ar), 1164 (w, S=O) and 1328 (w, S=O); δH 2.50 
(3H, s, CH3-7), 6.84 (1H, s, H-3), 7.35 (7H, m, H-5, H-6, H-8, H-6´, H-7´, H-8´ and H-9´), 7.61 
(1H, dd, J 7.6 and 1.4, H-2´), 7.83 (1H, t, J 7.6, H-3´) and 8.19 (1H, dd, J 7.6 and 1.4, H-4´). δC 
21.1 (7-CH3), 123.5 (C-2)a, 125.8 (C-3)b, 127.4 (C-2´)c, 127.8 (C-3´)c, 128.0 (C-4´)c, 128.7 (C-6´ 
and C-7´)c, 129.0 (C-8´)c, 129.7 (C-9´)c, 130.1 (C-5)b, 134.0 (C-1´)a, 134.2 (C-7)a, 134.9 (C-6)b, 
135.1 (C-10a´)d, 135.8 (C-4a´)d, 136.2 (C-5a´)d, 137.2 (C-9a´)d, 138.0 (C-8)a, 147.7 (C-4a)e, 
149.4 (C-8a)e, 182.7 (C-1)f and 183.5 (C-4)f. (HRMS: Found M+ 418.1630; C, 66.2; H, 3.5. Calc. 
for C23H14O4S2: M 418.0334; C, 66.0; H, 3.4%). 
 
 
 
 
 105
5-Methoxy-7-methyl-2-(thianthren-1´-yl)- 1,4naphthoquinone 3.36  
 
O
O
OMe
S S
CH3
 
3.36 
A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 (351 mg, 1.25 mmol) and 
Pd(PPh3)4 (148 mg, 0.12 mmol) in benzene (10 ml) was stirred for 0.5h at 24˚C under nitrogen. 
An aqueous solution of Na2CO3 (2 M, 1 ml) and thiantherene-1-boronic acid 3.33 (306 mg, 1.18 
mmol) in benzene (15 ml) were added successively. The mixture was heated under reflux for 16h 
with vigorous stirring. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (2:3) to afford quinone 3.36 (420 mg, 86%) as a yellow solid, m. p. 203-204˚C 
(from EtOAc/hexane). υmax 1670 (m, C=O), 1658 (s, C=O); δH 2.52 (3H, s, CH3-7),  4.04 (3H, s, 
OMe), 6.83 (1H, d, J 1.4, H-6), 7.16 (1H, s, H-3), 7.27 (5H, m, H-2´, H-3´, H-4´, H-7´ and H-8´), 
7.49 (1H, dd, J 7.4 and 1.4, H-6´), 7.59 (1H, dd, J 7.6 and 1.8, H-9´), 7.67 (1H, d, J 1.4, H-8). δC 
22.3 (7-CH3), 56.5 (OMe), 118.4 (C-6)a, 120.8 (C-3)b, 127.4 (C-2´)c, 127.7 (C-3´)c, 127.9 (C-4´)c, 
128.3 (C-2)c, 128.6 (C-6´)c, 128.7 (C-7´)c, 128.9 (C-8´)c, 129.8 (C-9´)a, 131.5 (C-1´)b, 134.2 (C-
10a´)d, 134.6 (C-4a´)d, 135.3 (C-7)d, 136.2 (C-5a´)d, 136.9 (C-9a´)d, 139.0 (C-8)a, 146.4 (C-4a)e, 
146.6 (C-8a)e, 159.8 (C-5), 183.8 (C-1)f and 183.9 (C-4)f. (HRMS: Found M+ 416.0498; C, 69.4; 
H, 3.8. Calc. for C24H16O3S2: M 416.0541; C, 69.2; H, 3.9%). 
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2-(5´,10´-Dioxydithianthren-1´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.35 
 
O
O
CH3
SS
MeO
O O
 
3.35 
A mixture of 2-(thianthren-1´-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.36 (162 mg, 0.39 
mmol) and m-chloroperbenzoic acid (2 mol equiv.,  135 mg ) in DCM (20 ml) was stirred for 2h 
at 25˚C and  thereafter the organic acids were extracted into aqueous sodium hydrogen carbonate 
and the dried DCM yielded a residue upon workup which  was chromatographed using 
EtOAc:hexane (1:4) to afford sulphone 3.35 (112 mg,  64%) as orange needles, m.p. 112-114˚C 
(from EtOAc/hexane). υmax 1671 (m, C=O), 1660 (s, C=O), 1168 (w, S=O) and 1326 (w, S=O); 
δH 2.54 (3H, s, CH3-7), 4.04 (3H, s, OMe), 7.19 (1H, s, H-6), 7.61 (7H, m, H-3, H-8, H-2´, H-3´, 
H-7´, H-8´ and H-9´), 8.24 (1H, dd, J 7.6 and 1.4, H-6´), 8.32 (1H, dd, J 7.6 and 1.2, H-4´). δC 
22.4 (7-CH3), 56.5 (OMe), 119.0 (C-3)a, 120.9 (C-6)a, 126.0 (C-2´)b, 127.1 (C-3´)b, 128.8 (C-4´)b, 
130.3 (C-6´)b, 131.2 (C-7´)b, 131.8 (C-8´)b, 132.1 (C-9´)b, 132.2 (C-10a´)c, 133.1 (C-4a´)c, 133.4 
(C-5a´)c, 139.1 (C-9a´)c, 140.4 (C-8)d, 143.3 (C-4a)c, 147.0 (C-8a)c, 160.0 (C-5), 182.9 (C-1)e and 
185.0 (C-4)e. (HRMS: Found M+ 448.1156; C, 64.4; H, 3.5. Calc. for C24H16O5S2: M 448.0439; 
C, 64.3; H, 3.6%).  
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5-Methoxy-7-methyl-2-(4-methylnaphthalen-1′-yl)-1,4-naphthoquinone 3.39 
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1
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7
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3.39 
A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 (351 mg, 1.25 mmol) and 
Pd(PPh3)4 (148 mg, 0.12 mmol) in benzene (20 ml) was stirred for 0.5h at 24˚C under nitrogen. 
An aqueous solution of Na2CO3 (2M, 1 ml) and 4-methylnaphthalene-1- boronic acid 3.38 (220 
mg, 1.18 mmol) in benzene (10 ml) were added successively. The mixture was heated under 
reflux for 16h with vigorous stirring. The residue obtained upon workup was chromatographed 
using EtOAc:hexane (2:3) to afford quinone 3.39 (428 mg, 90%) as a yellow solid, m.p. 228-
230°C (from EtOAc/hexane). υmax 1659 (s, C=O), 1648 (m, C=O) and 1597 cm-1 (m, Ar); δH 2.51 
(3H, s, 7-CH3),  2.74 (3H, s, 4´-CH3), 4.04 (3H, s, OMe), 6.98 (1H, s, H-3), 7.15 (1H, d, J 1.0, H-
6), 7.44 (4H, m, H-2´, H-3´, H-6´ and H-7´), 7.65 (2H, m, H-5´ and H-8) and 8.06 (1H, dd, J 8.0 
and 1.0, H-8´). δC 19.7 (4´-CH3), 22.4 (7-CH3), 56.6 (OMe), 118.1 (C-2)a, 118.4 (C-3)b, 120.9 (C-
2´)c, 124.7 (C-3´)c, 126.01 (C-5´)c, 126.04 (C-6´)c, 126.1 (C-7´)c, 126.2 (C-8´)c, 127.2 (C-4´)c, 
130.2 (C-1´)a, 131.6 (C-4a´)d, 132.7 (C-8a´)d, 134.5 (C-7)d, 136.4 (C-6)b, 140.1 (C-8)b, 146.5 (C-
4a)e, 147.4 (C-8a)e, 159.8 (C-5), 184.3 (C-1)f and 185.0 (C-4)f. (HRMS: Found M+ 342.1272; C, 
80.8; H, 5.4. Calc. for C23H18O3: M 342.1255; C, 80.7; H, 5.3%). 
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5-Hydroxy-7-methyl-2-(4-methylnaphthalen-1′-yl)-1,4-naphthoquinone 3.37 
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OH
1
4
1´
4´
 
3.37 
To a solution of 2-(4-Methylnaphthalen-1′-yl)-5-methoxy-7-methyl-1,4-naphthoquinone 3.39 
(390 mg, 1.13 mmol) in dry CH2Cl2 (20 ml) was added BBr3 (1M solution in CH2Cl2, 1.3 ml, 1.3 
mmol) drop-wise at -78ºC under nitrogen. The mixture was then stirred for 3h at 25ºC, poured 
into ice water, acidified to litmus, extracted with CH2Cl2 and the combined organic phase was 
washed with water. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:4) to afford hydroxyquinone 3.37 (170 mg, 45%) as a red coloured solid, m.p. 
182-183°C (from EtOAc/hexane). υmax 3433 (bs, -OH), 1665 (m, C=O) and 1634 cm-1 (m, C=O); 
δH 2.58 (3H, s, 7-CH3),  2.76 (3H, s, 4´-CH3), 7.09 (2H, m, H-3 and H-6), 7.43 (4H, m, H-2´, H-
3´, H-6´ and H-7´), 7.63 (2H, m, H-5´ and H-8), 8.07 (1H, dd, J 7.6 and 0.8, H-8´) and 12.01 (1H, 
s, 5-OH). δC 19.7 (4´-CH3), 24.2 (7-CH3), 121.1 (C-2)a, 121.6 (C-3)b, 124.0 (C-1´)a, 124.6 (C-2´)c, 
125.9 (C-3´ and C-5´)c, 126.1 (C-6´)c, 126.3 (C-7´)c, 127.2 (C-8´)c, 129.7 (C-4´)c, 130.0 (C-4a´)d, 
131.3 (C-8a´)d, 132.7 (C-7)d, 137.0 (C-6)b, 137.3 (C-8)b, 148.1 (C-4a)e, 151.1 (C-8a)e, 161.6 (C-
5), 183.5 (C-1)f and 189.6 (C-4)f. (HRMS: Found M+ 328.0170; C, 80.3; H, 5.0. Calc. for 
C22H16O3: M 328.1099; C, 80.5; H, 4.9%). 
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2-(2´-Naphthyl)- 5-methoxy-7-methyl-1,4-naphthoquinone 3.42 
 
                            
O
O
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CH3
 
        3.42 
 
A mixture of 2-bromo-5-methoxy-7-methyl-1,4-naphthoquinone 3.13 (351 mg, 1.25 mmol) and 
Pd(PPh3)4 (148 mg, 0.12 mmol) in benzene (20 ml) was stirred for 0.5h at 25˚C under nitrogen. 
An aqueous solution of Na2CO3 (2M, 1 ml) and 2-naphthaleneboronic acid 3.41 (203 mg, 1.18 
mmol) in benzene (10 ml) were added successively. The mixture was heated under reflux for 16h 
with vigorous stirring. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (2:3) to afford quinone 3.42 (358 mg, 88%) as a yellow solid, m. p. 172-173°C 
(from ethanol). υmax 1658 (s, C=O) and 1651 cm-1 (m, C=O); δH 2.52 (3H, s, CH3-7), 4.03 (3H, s, 
OMe), 7.09 (1H, s, H-3), 7.13 (1H, d, J 1.4, H-6), 7.54 (2H, m, H-6´ and H-7´)a, 7.66 (2H, m, H-
5´ and H-8´)a, 7.89 (3H, m, H-1´, H-3´ and H-4´)a and 8.13 (1H, d, J 1.4, H-8). δC 22.5 (CH3), 
56.6 (OMe), 118.3 (C-6)a, 120.8 (C-3)a, 126.3 (C-1´)b, 126.6 (C-3´)b, 127.3 (C-4´)b, 127.8 (C-
6´)b, 128.1 (C-7´)b, 128.8 (C-5´)b, 129.6 (C-8´)b, 130.8, 133.2, 133.9, 134.8 (C-2´, C-2, C-4a´, C-
8a´ and C-7), 137.8 (C-8), 145.7 (C-4a)c, 146.5 (C-8a)c, 159.7 (C-5), 184.3 (C-1)d and 185.2 (C-
4)d. (HRMS: Found M+, 328.1181; C, 80.7; H, 4.8. Calc. M for C22H16O3: 328.1099; C, 80.5; H, 
4.9%).  
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2-(2´-Naphthyl)- 5-hydroxy-7-methyl-1,4-naphthoquinone 3.40 
 
                           
O
O
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        3.40 
 
To a solution of 2-(2´-naphthyl)- 5-methoxy-7-methyl-1,4-naphthoquinone 3.42 (310 mg, 0.94 
mmol) in dry DCM (20 ml) was added borontribromide (1M solution in CH2Cl2, 1 ml) drop-wise 
at -78ºC under nitrogen. The mixture was stirred for 4h at 25ºC, poured into ice water, acidified 
to litmus, extracted with DCM and the combined organic phase was washed with water. The 
residue obtained upon workup was chromatographed using EtOAc:hexane (3:7) to afford quinone 
3.40 (110 mg, 37%) as orange red needles, m. p. 216-218°C (form EtOAc/hexane). υmax 3340 (s, 
-OH), 1651 (s, C=O) and 1644 cm-1 (m, C=O); δH 2.58 (3H, s, CH3-7), 7.15 (1H, s, H-3), 7.26 
(1H, d, J 1.2, H-6), 7.59 (4H, m, H-1´, H-3´, H-6´ and H-7´)a, 7.91 (3H, m, H-4´, H-5´ and H-8´)b 
and 8.12 (1H, d, J 1.2, H-8). δC 24.4 (CH3), 121.1 (C-6)a, 121.6 (C-3)a, 126.1 (C-1´)b, 126.8 (C-
3´)b, 127.6 (C-2´)c, 127.7 (C-4´)b, 127.8 (C-6´)b, 128.3 (C-7´)b, 129.0 (C-5´)b, 130.2 (C-8´)b, 
130.3 (C-2)c, 130.4 (C-7)a, 133.0 (C-4a´)c, 134.1 (C-8a´)c, 134.9 (C-8), 148.1 (C-4a)c, 149.3 (C-
8a)c, 158.0 (C-5), 183.8 (C-1)d and 189.5 (C-4)d. (HRMS: Found M+ 314.0898; C 80.4; H 4.4. 
Calc. M for C21H14O3: 314.0943; C, 80.2; H, 4.5%).  
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2-(Naphthalen-2′-yl)-7-methyl-1,4-naphthoquinone 3.43 
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O
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        3.43 
 
A mixture of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 (314 mg, 1.25 mmol) and Pd(PPh3)4 
(148 mg, 0.11 mmol) in benzene (10 ml) was stirred for 0.5h at 24˚C under nitrogen. An aqueous 
solution of Na2CO3 (2M, 1 ml) and 2-naphthaleneboronic acid 3.41 (203 mg, 1.18 mmol) in 
benzene (5 ml) were added successively. The mixture was heated under reflux for 16h with 
vigorous stirring. The residue obtained upon workup was chromatographed using EtOAc:hexane 
(1:4) to afford quinone 3.43 (319 mg, 86%) as yellow needles, m.p. 169-170˚C (form 
EtOAc/hexane). υmax 1658 (s, C=O) and 1652 cm-1 (m, C=O); δH 2.53 (3H, s, CH3-7),  7.16 (1H, 
s, H-3), 7.59 (4H, m, H-1´, H-3´, H-6´ and H-7´), 7.99 (6H, m, H-4´, H-5´, H-8´, H-5, H-6 and H-
8). δC 22.0 (CH3-7), 126.3 (C-3)a, 126.4 (C-1´)a, 126.7 (C-3´)a, 127.4 (C-4´)a, 127.5 (C-5´)a, 127.8 
(C-6´)a, 128.2 (C-4a´)b, 128.9 (C-7´)a, 129.8 (C-8´)a, 130.1 (C-2´)b, 131.1 (C-8a´)b, 132.6 (C-2)b, 
133.1 (C-7)c, 134.0 (C-6)c, 134.7 (C-5)c, 135.6 (C-8)c, 145.1 (C-4a)d, 148.0 (C-8a)d, 185.0 (C-1)e 
and 185.1 (C-4)e. (HRMS: Found M+ 298.1030; C, 84.5; H, 4.8. Calc. for C21H14O2: M 298.0993; 
C, 84.5; H, 4.7%). 
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2-(4-Methylnaphthalen-1′-yl)-7-methyl-1,4-naphthoquinone 3.44 
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        3.44 
A mixture of 2-bromo-7-methyl-1,4-naphthoquinone 3.2 (314 mg, 1.25 mmol) and Pd(PPh3)4 
(148 mg, 0.11 mmol) in benzene (20 ml) was stirred for 0.5h at 24˚C under nitrogen. An aqueous 
solution of Na2CO3 (2M, 1 ml) and 4-methyl-1-naphthaleneboronic acid 3.38 (220 mg, 1.18 
mmol) in benzene (10 ml) were added successively. The mixture was heated under reflux for 16h 
with vigorous stirring. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:4) to afford  quinone 3.44 (352 mg, 90%) as red needles, m.p. 109-111°C (from 
EtOAc/hexane). υmax 1660 (s, C=O) and 1652 cm-1 (m, C=O); δH 2.53 (3H, s, CH3-7)a,  2.76 (3H, 
s, CH3-4´)a, 7.07 (1H, s, H-3), 7.49 (6H, m, H-2´, H-3´, H-5´, H-6´, H-7´ and H-8´), 7.97 (1H, d, J 
0.8, H-8) and 8.08 (2H, dd, J 8.2 and 0.8, H-5 and H-6). δC 19.7 (7-CH3), 21.9 (4´-CH3), 124.6 
(C-3)a, 125.9 (C-2´)b, 126.0 (C-3´)b, 126.1 (C-5´)b, 126.2 (C-6´)b, 126.4 (C-7´)b, 127.0 (C-8´)b, 
127.5 (C-4´)b, 130.1 (C-1´)c, 130.3 (C-2)c, 131.5 (C-4a´)d, 132.3 (C-8a´)d, 132.7 (C-7)d, 134.6 (C-
5)a, 136.5 (C-6)a, 137.9 (C-8)a, 145.1 (C-4a)e, 149.7 (C-8a)e, 184.8 (C-1)f and 185.0 (C-4)f. 
(HRMS: Found M+ 312.1139; C, 84.5; H, 5.0. Calc. for C22H16O2: M 312.1150; C, 84.6; H, 
5.2%). 
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1,5-Diacetoxynaphthalene 3.48 
 
                                                   
1
5
OAc
OAc   
3.48 
 
1,5-Naphthalenediol 3.47 (5.0 g, 31.2 mmol) was dissolved in pyridine (25 ml, 306 mmol) and 
acetic anhydride (25 ml, 265 mmol). The solution was stirred for 12h at 24˚C under nitrogen, and 
then the remaining acetic anhydride was quenched by addition of water. The solution was then 
filtered and the solid obtained was washed with ethyl alcohol:water (1:19) and dried in the air to 
afford the product 3.48 (7.39 g, 97%) as a light brown coloured solid, m.p. 158-160˚C (from 
benzene). (Lit.69 m.p. 161˚C); δH 2.47 (6H, s, 2 x -CH3), 7.29 (2H, dd, J 7.2 and 1.2, H-2 and H-
6), 7.51 (2H, dd, J 7.8 and 7.2, H-3 and H-7) and 7.79 (2H, dd, J 7.8 and 1.2, H-4 and H-8). δC 
21.0 (2 x -CH3), 118.8 (C-2 and C-6), 119.3 (C-3 and C-7), 126.0 (C-4 and C-8), 128.1 (C-4a and 
C-8a), 146.7 (C-1 and C-5) and 169.2 (2 x C=O). 
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5-Acetoxy-2-bromo-1,4-naphthoquinone 3.46 
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3.46 
 
A solution of 1,5-diacetoxynaphthalene 3.48 (2.4 g, 10.0 mmol) in warm acetic acid (100 ml) was 
added drop-wise to a solution of N-bromosuccinimide (7.2 g, 40.0 mmol) in acetic acid (200 ml) 
and water (100 ml) at 65°C. The solution was stirred for 1h at the same temperature and cold 
water (200 ml) was then added. The solution was extracted with DCM (4 x 50 ml) and the 
combined extracts were washed with water (4 x 200 ml). The residue obtained upon workup was 
chromatographed using EtOAc: hexane (1:4) to afford quinone 3.46 (2.7 g, 92%) as a yellow 
solid, m.p. 156-157°C (Lit.69 m.p. 158˚C); δH 2.44 (3H, s, -CH3), 7.39 (1H, s, H-3), 7.42 (1H, dd, 
J 8.2 and 1.6, H-6), 7.77 (1H, dd, J 8.2 and 8.0, H-7) and 8.14 (1H, dd, J 8.0 and 1.4, H-8). δC 
21.0          (-CH3), 123.2 (C-3), 126.3 (C-2)a, 130.3 (C-6)a, 132.6 (C-4a)b, 134.9 (C-7)a, 138.5 (C-
8a)b, 141.4 (C-8)a, 149.9 (C-5), 169.2 [C=O (ester)], 177.4 (C-1)c and 180.9 (C-4)c. 
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2-(Naphthalen-2′-yl)-5-acetoxy-1,4-naphthoquinone 3.45 
 
O
O
AcO
1
4
5
1´
2´
 
3.45      
         
A mixture of 2-bromo-5-acetoxy-1,4-naphthoquinone 3.46 ( 150 mg, 0.51 mmol) and Pd(PPh3)4 
(60 mg, 0.052 mmol) in benzene (15 ml) was stirred for 0.5h at 24˚C under nitrogen. An aqueous 
solution of Na2CO3 (2M, 0.5 ml) and 2-naphthaleneboronic acid 3.41 (86 mg, 0.50 mmol) in 
benzene (10 ml) were added successively. The mixture was heated under reflux for 16h with 
vigorous stirring. The residue obtained upon workup was chromatographed using EtOAc:hexane 
(1:4) to afford  quinone 3.45 (137 mg, 79%) as yellow needles, m.p. 182-183°C (from ethanol). 
υmax 1772 (m, C=O), 1668 (m, C=O), 1657 (s, C=O) and 1610 cm-1 (w, Ar); δH 2.49 [3H, s, -CH3 
(ester)], 7.07 (1H, s, H-3), 7.43 (1H, dd, J 8.2 and 1.0, H-6), 7.58 (3H, m, H-3´, H-6´ and H-7´)a, 
7.80 (1H, dd, J 8.2 and 9.2, H-7), 7.90 (3H, m, H-4´, H-5´ and H-8´)a, 8.11 (1H, d, J 1.0, H-1´) 
and 8.18 (1H, dd, J 9.2 and 1.2, H-8). δC 21.1 [ester,-CH3), 123.5 (C-2)a, 125.6 (C-3)b, 126.1 (C-
1´)c, 126.6 (C-3´)c, 127.4 (C-4´)c, 127.7 (C-5´)c, 128.1 (C-6´)c, 128.8 (C-7´)c, 129.5 (C-8´)c, 129.8 
(C-6)b, 130.3 (C-2´)d, 133.0 (C-4a´)d, 133.9 (C-8a´)d, 134.3 (C-4a)d, 134.7 (C-7)b, 136.5 (C-8)b, 
146.9 (C-8a)d, 149.2 (C-5), 169.4 (ester, C=O) and 183.7 (C-1)e and 183.8 (C-4)e. (HRMS: Found 
M+ 342.0890; C, 77.4; H, 4.0. Calc. for C22H14O4: M 342.0892; C, 77.2; H, 4.1%). 
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2-(4-Methylnaphthalen-1′-yl)-5-acetoxy-1,4-naphthoquinone 3.49 
 
                                
O
O
AcO
CH3
1
4
5
1´ 4´
 
3.49 
 A mixture of 2-bromo-5-acetoxy-1,4-naphthoquinone 3.46 (150 mg, 0.51 mmol) and Pd(PPh3)4 
(60 mg, 0.052 mmol) in benzene (15 ml) was stirred for 0.5h at 24˚C under nitrogen. An aqueous 
solution of Na2CO3 (2M, 0.5 ml) and 4-methyl-1-naphthaleneboronic acid 3.38 (93 mg, 0.50 
mmol) in benzene (10 ml) were added successively. The mixture was heated under reflux for 16h 
with vigorous stirring. The residue obtained upon workup was chromatographed using 
EtOAc:hexane (1:4) to afford  quinone 3.49 (140 mg, 77%) as reddish brown needles, m.p. 173-
174°C (from ethanol). υmax 1769 (m, C=O), 1667 (w, C=O), 1655 (s, C=O), 1613 (w, Ar) and 
1592 cm-1 (w, Ar); δH 2.49 [3H, s, -CH3 (ester)], 2.75 (3H, s, 4´-CH3), 6.98 (1H, s, H-3), 7.35 
(2H, m, H-2´ and H-3´)a, 7.45 (1H, dd, J 8.0 and 1.0, H-6), 7.54 (2H, m, H-6´ and H-7´)b, 7.65 
(1H, dd, J 7.4 and 1.4, H-5´)c, 7.80 (1H, dd, J 8.0 and 7.6, H-7), 8.07 (1H, dd, J 7.4 and 1.4, H-
8´)c and 8.15 (1H, dd, J 7.6 and 1.0, H-8). δC 19.6 (4´- CH3), 21.1 [ester,-CH3), 123.6 (C-2)a, 
124.6 (C-3)b, 125.7 (C-2´)c, 125.9 (C-3´)c, 126.0 (C-5´)c, 126.1 (C-6´)c, 126.3 (C-7´)c, 127.1 (C-
8´)c, 129.6 (C-6)b, 131.4 (C-1´)a, 132.7 (C-4a´)d, 134.1 (C-8a´)d, 134.8 (C-7)b, 136.7 (C-4´)d, 
138.9 (C-8)b, 147.2 (C-4a)e, 148.6 (C-8a)e, 149.4 (C-5)e, 169.5 (ester, C=O) and 183.7 (C-1 and 
C-4). (HRMS: Found M+ 356.1049; C, 77.5; H, 4.6. Calc. for C23H16O4: M 356.1048; C, 77.5; H, 
4.5%). 
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Chapter 5: Evaluation of the compounds as anti-mycobacterial agents 
 
This chapter describes details of the methods used to investigate the antimycobacterial activities 
of synthesized test compounds. Initially, two fast growing stains of mycobacterium viz., 
Mycobacterium smegmatis and Mycobacterium aurum were used to determine the activities using 
the broth micro-dilution method. Literature revealed that different strains of bacteria respond 
differently to the induced compounds. This insight led us to investigate the activities of the 
synthesized compounds on a clinical strain of M. tuberculosis using the radiometric BACTEC 
method and an exploratory analysis is thus presented. 
 
Section 5.1:  Materials and Methods 
Broth micro-dilution methodology was performed in 96-well plates using 7H9 Middlebrook 
broth.  Each sample was tested in duplicate in two separate assays, including a third, organism-
free, replicate in each plate to allow for background colour arising from each compound.  The test 
compounds were prepared in concentrations of 1mg/ml in 18% DMSO/82% sterile distilled 
water.  Normally compounds would be dissolved in 10% DMSO, but these compounds 
precipitated out of solution at this concentration.  A solvent control was prepared in the same 
manner.  The concentration of compounds used in the assay ranged from 2µg/ml – 250µg/ml (8 
half dilutions tested in total).  Ciprofloxacin 1.8 was used as a positive control.  MICs were 
determined as the lowest concentration at which 100% inhibition of organism growth occurred. 
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Section 5.1.1:  Media composition 
Middlebrook 7H10 agar: Add 3.8g of Middlebrook 7H10 (DIFCO TM) and 1mg of glycerol to 
180ml distilled water. Sterilize by autoclaving at 121°C for 15 minutes.  Once cooled, added 10% 
OADC (Becton Dickinson; oleic acid, albumin, dextrose, catalase).  
1x Middlebrook 7H9:  Add 0.94g Middlebrook 7H9 (DIFCOTM) and 0.4ml glycerol (Merck) to 
180ml distilled water.  Sterilize by autoclaving at 121°C for 15 minutes.  Once cooled, added 
10% OADC (Becton Dickinson; oleic acid, albumin, dextrose, catalase). 
 
Section 5.1.2:  Organism preparation for experimentation 
A single glycerol stock of M.aurum A+ (Pasteur Institute) and M. smegmatis (clinical strain) was 
used to inoculate two supplemented Middlebrook 7H10 agar (7H10 + 10% OADC) plates.  The 
plates were incubated at 37°C for 4 days and loosely sealed in a plastic packet to avoid 
dehydration.  A single colony was used to inoculate 5ml supplemented 1x 7H9 broth, which was 
grown at 37°C for 72 h. Section 5.1.3:  Broth micro-dilution method    
To flat-bottomed 96-well plates, 100µl of 2x 7H9 broth (double the recommended strength) 
supplemented with 20% OADC was added to each well using a multi-channel pipette, except for 
the medium control well to which 200µl of 1x7H9 supplemented with 10% OADC was added.  
For the drug and solvent controls, as well as the test samples, 100µl of the respective sample was 
added to the first well of the column.  A multi-channel pipette was used to perform serial 
doubling dilutions from the top to the bottom of the plate by transferring 100µl aliquots and 
mixing thoroughly at each step.  The final 100µl was discarded. A stock concentration of 62.5µg/ 
ml of ciprofloxacin 1.8 was used as the drug control. The optical density (OD) of the 72 h liquid 
culture was adjusted to 0.125 at 550nm,76 using the supplemented 1x 7H9 broth as a ‘blank’.  
100µl of the diluted culture was added to every well of the microtitre plate excluding the wells of 
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the first column that serve as the medium control. The plates were loosely sealed in plastic bags 
to prevent dehydration and incubated at 37°C for 48 h for M. smegmatis and 72 h for M. aurum.   
The plates were then removed from the incubator and 40µl of a 0.4 mg/ml solution of p-
iodonitrotetrazolium salt (INT; Fluka) was added to each well of the plate.77 The tetrazolium salt 
turns red in the presence of metabolizing organism.  The plates were left sealed in plastic packets 
and were checked after 6 and 18 h to avoid dehydration and contamination.  The lowest 
concentration containing no indication of red as a result of INT was deemed to be the MIC. IC50 
values can be determined with the use of a micro-plate reader set at a wavelength of 620 nm 
(nanometer).  Strongly coloured extracts/compounds affect these readings and therefore an 
organism-free column should be included for each concentration of each sample.   
 
Section 5.1.4:  Results   
Seven synthetic analogues of diospyrin 1.22 were tested for activity against two strains of 
mycobacterium. Ciprofloxacin 1.8 was used as the positive control. The positive control should 
have an MIC less than 2µg/ml. The negative control demonstrated that the highest concentration 
of DMSO tested (4.5%) did not affect bacterial growth.  The antibiotic, medium and organism 
controls were acceptable throughout experimentation. The MIC values obtained from duplicate 
experiments were used to generate a measure of the final average activity of the compounds. The 
results of the analysis are presented in Table 5.1. 
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Table 5.1 The MIC’s of the test compounds against M. smegmatis and M. aurum.  All 
concentrations are expressed in µg/ml. 
Compound M. smegmatis M. aurum 
3.34 >250 >250 
3.21 125 125 
3.25 >250 >250 
3.40 250 >250 
3.45 >250 >250 
3.32 >250 >250 
3.43 >250 >250 
 
Section 5.1.5: Discussion 
All the tested compounds did not appear to have very good activity against the two mycobacteria.  
Compound 3.21 had the best activity, with an MIC of 125µg/ml.  Promising anti-mycobacterials 
should have activity under 10µg/ml, so this activity would not justify further investigation with 
regard to anti-mycobacterials.  Due to the high concentrations at which activity was noted, if at 
all, IC50 values (the concentration at which 50% of organism is killed) were not determined. 
The ability of mycobacteria to develop multi-drug resistance in some strains shows that different 
strains of mycobacteria respond selectively towards different drugs. It is thus possible that the 
above two strains of mycobacteria were not responsive to the compounds administered and that 
perhaps these compounds might act against other strains of mycobacteria. To test this hypothesis, 
the test compounds were further tested on another clinical strain of mycobacterium by employing 
radiometric BACTEC method. 
Section 5.2: The radiometric BACTEC method: 
All work was carried out in the Biosafety Level 3 laboratory of the Division of Molecular 
Biology and Human Genetics of the University of Stellenbosch. A clinical isolate of M. 
tuberculosis was also selected from a bank of genetically well-characterized (according to their 
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IS6110 fingerprint profile) strains located in the Division of Molecular Biology and Human 
Genetics of the University of Stellenbosch for the evaluations.78 The strain was drug sensitive to 
Isoniazid 1.1 and Rifampicin 1.2.  
The 7H9 middlebrook mycobacterial growth medium, which contains the 14C-labeled substrate 
(palmitic acid) as a source of carbon, was used for the testing. Growth of the organism leads to 
the consumption of the substrate, with subsequent release of 14CO2 into the atmosphere above the 
medium in the sealed vial; the BACTEC TB-460 instrument (Becton Dickinson and Company, 
USA) detects the amount of 14CO2 and records it as a growth index (GI) on a scale of 0-999. 
Compounds to be tested for antimycobacterial activity were filter sterilized through 0.22 micron 
syringe filters (millex LG) The M. tuberculosis clinical strain 1432 was grown on Lowenstein-
Jensen culture medium for 4 weeks.79 After incubation at 37°C, bacteria were collected, 
suspended in 7H9 mycobacterial growth medium and the bacterial suspension added to a 
BACTEC vial containing BACTEC 12B growth medium (Becton Dickinson, USA). Growth was 
monitored every 24 h until a GI value of 400-500 was reached. A volume of 0.1ml of this culture 
was added to a new BACTEC vial and the growth monitored every 24 h until a GI value of 500 
was reached.80     This culture was the primary culture and was used for testing bacterial viability 
against a variety of inhibitors. 0.1ml of inhibitor was added to a BACTEC vial to give a final 
concentration of 125 µg/ml. A 1:11 dilution with DMSO was made of the compounds to give a 
final concentration of 12 µg/ml and 0.1ml of this was added to a BACTEC vial. BACRWC vials 
were incubated at 37°C and the GI was monitored every 24 h. A GI below 10 was considered as 
negative growth and above 10 as positive growth. The GI of the treated samples was compared to 
a control containing sterile DMSO. The control experiments have shown that the final amount of 
DMSO (1%) in the media had no effect on the growth of M. tuberculosis. 
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Section 5.2.1: Results  
The GI of the bacteria was measured over a period of 5 days, with a skip of the fourth day. Fig 
5.1 represents the effect of compounds on the growth of mycobacterium.  
Fig 5.1 Effect of test compounds in concentration of 5 mg/ml on the growth of the clinical 
strain of mycobacterium measured over a period of 5 days 
 
0
100
200
300
400
500
Compounds tested
G
I
1 Day 32 7 10 11 9 6 17 11
2 Day 64 2 3 7 3 3 22 5
3 Day 127 0 1 3 1 0 37 1
5 Day 481 1 1 1 2 0 156 0
control 3.24 3.21 3.25 3.32 3.28 3.29 3.49
 
 
The control has a normal doubling rate every 24 h. The graph in Fig 5.1 reveals that all the 
compounds except 3.29 have the ability to inhibit the growth of mycobacterium (clinical strain 
1432) tested. This is not a true indicator of inhibitory activity since the compounds were added in 
very high concentration. To observe the true activity of the test compounds, dilutions were made 
 
 
 
 
 123
up to a factor of eleven i.e. 12 µg/ml. The activity of the diluted compounds in BACTEC vials 
was measured for the same period of time as that of the undiluted ones. 
 
Fig 5.2 Effect of the test compounds with a 1:11 dilution on the growth of the clinical strain 
1432 of mycobacterium measured over a period of 5 days 
 
0
100
200
300
400
500
Compounds tested
G
I
1 Day 32 21 32 23 9 11 26 22
2 Day 64 33 48 19 4 4 35 19
3 Day 127 68 73 16 5 1 55 16
5 Day 481 260 203 18 13 1 152 16
control 3.24 3.21 3.25 3.32 3.28 3.29 3.49
 
 
It is clear from Fig 5.2 that compounds 3.32 and 3.28 demonstrate the most promising activity. 
These are bactericidal even at 1:11 dilution. Most of the samples show inhibition of growth at a 
concentration of 5 mg/ml but at 1:11 dilution, although reduced considerably, growth of cells 
continues. Even if the diluted versions of the test compounds other than 3.32 and 3.28 show some 
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growth inhibition they only appear to be bacteristatic at 12 µg/ml, a concentration much to high 
to even consider developing it as a drug.  
 
The results of the analysis Fig 5.1 and Fig 5.2 reveal that the different strains of bacteria respond 
differently to the treatment regimes. Some of the compounds were common in two methods viz., 
3.21, 3.25, and 3.32 and others were unique to each methodology, viz., 3.24, 3.28, 3.29 and 3.49 
were tested using BACTEC method and 3.34, 3.40, 3.43 and 3.45 were tested using micro-
dilution method. Since the two methods used to evaluate the anti-mycobacterial activities of the 
test compounds are entirely different in terms of their underlying principle, the results of these 
methods cannot be compared directly. However, a conclusion can be made based upon activities 
measured in the various strains of mycobacterium. It is observed here that the test compound 3.28 
has enhanced activity against the clinical strain 1432 of mycobacterium as compared to all other 
compounds. It was further observed that binaphthoquinone types of compounds generally show 
good activity. This is the first time to our knowledge that biaryl compounds having as one half a 
naphthoquinone unit and as the other half, a naphthalene unit that also shows good activity. It is 
also the first time to our knowledge that sulphone 3.32 has been tested for its anti-mycobacterial 
activity and is now reported to show promising activity. Compounds 3.24, 3.21 and 3.29 did not 
demostrate potent inhibition of the strains of mycobacterium tested. However, these are 
preliminary results and further indepth testing is required to unfold the true effects of compounds 
3.32 and 3.28 to confirm that the observed effects are not due to cytotoxicity. As far as the 
different methods that were used are concerned, both are well standardized and routinely used in 
mycobacterium testing. The advantage of using a liquid medium is that there is more cell-to-drug 
contact. 
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Section 5.3: Discussion 
Quinonoid compounds, by virtue of their facile redox cycle capacity, are known to possess wide-
ranging anti-mycobacterial activities, however, the underlying mechanism of action is still 
unknown. More than 2000 naturally occurring quinones, for example - anthraquinones, 
naphthoquinones, and benzoquinones are now known and widely distributed in nature as 
pigments and as intermediates in cellular respiration and photosynthesis.81, 82 Some quinones 
have important roles in the biochemistry of energy production and serve as vital links during 
electron transport. Most quinones, which are aromatic compounds present in bacteria and 
eukaryotes,83 are often involved in electron transport and include, ubiquinones and 
menaquinones.84They provide a defense role as a result of their effectiveness at inhibiting the 
growth of bacteria, fungi, or parasites .85- 88 Therefore, a number of them have been shown to 
possess physiological activities as antimicrobial and anticancer compounds.89 The mechanism of 
toxicity is still under investigation, but two theories viz., redox cycling and reductive alkylation 
dominate the literature,90 with some quinones proposed to exhibit one or both mechanisms.  
Redox cycling is the concept in which compounds catalytically cycle and generate oxidative 
radicals or reactive oxygen species (ROS), such as hydrogen peroxide and superoxide, which 
then damage the cell. NADPH oxidases, also known as NOX proteins, produce ROS in response 
to exogenous stimuli. NADPH oxidases catalyze the univalent reduction of O2 to produce O2-, 
which is rapidly converted to H2O2.91 
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Fig 5.3 Redox cycling of NADH or NAD(P)H and quinone. 
 
 
Lin92 introduced the term “bioreductive alkylation” and this hypothesis was formalized by Moore 
to explain the biological activity of several natural products.93 Moore’s emphasis lay in the use of 
naturally occurring and synthetic quinones as potential bioreductive alkylating agents. The 
cytotoxic effect of these quinones can be viewed as occurring over three steps as shown in 
Scheme 5.1. 
1. The quinone undergoes an in vivo bioreduction to the hydroquinone. 
2. Mesomerically assisted cleavage of a benzylic substituent by formal loss of HX results in the 
formation of a quinone methide. 
3. Michael addition of the biological nucleophiles such as DNA, proteins or carbohydrates to the 
reactive enone system of the quinone methide results in the formation of covalent adducts. 
Finally, after the cytotoxic effect of the quinone has been carried out, oxidation of the resulting 
adduct results in its biologically inactive quinone form, which is now covalently bonded to the 
biological target i.e. bacteria. Because of this, the cell is no longer able to carry out its normal 
function or to replicate, thus leading to cell death. 
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     Scheme 5.1 
Conclusion:  
Quinone compounds are intermediates in many pathways of gene regulation, enzyme protein 
induction, feedback control, and waste product elimination in addition to the role as substrates 
and products in metabolism. Quinones play a pivotal role in energy metabolism, many other key 
processes, and even in chemotherapy where redox cycling drugs are utilized. However, the 
molecular mechanisms involved in quinone cytotoxicity and pharmaceutical activity are still 
mostly unknown. Their widespread use as antibiotics, antiparasitic agents, antitumor agents, and 
a variety of other agents makes it imperative to understand their effects on cellular function. Until 
this is clarified, it is not possible to use a rational approach to search for or design more effective 
quinone agents with less side-effects, and the current approach of random screening and analog 
development will continue to dominate current research. 
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Chapter 6: Introduction to Apoptosis 
 
Apoptosis, or programmed cell death, is a normal component of the development and health of 
multicellular organisms. Cells die in response to a variety of stimuli and during apoptosis they do 
so in a controlled, regulated fashion including membrane blebbing, cell shrinkage, protein 
fragmentation, chromatin condensation and DNA degradation followed by rapid engulfment of 
corpses by neighbouring cells. This makes apoptosis distinct from another form of cell death 
called necrosis in which uncontrolled cell death leads to lysis of cells, inflammatory responses 
and, potentially, to serious health problems. Apoptosis, by contrast, is a process in which cells 
play an active role in their own death (which is why apoptosis is often referred to as cell suicide).  
Section 6.1: The development of the term apoptosis  
In 1964, term programmed cell death was introduced, proposing that cell death during 
development follows a sequence of controlled steps leading to locally and temporally defined 
self-destruction and is not of an accidental nature.94 Kerr, Wyllie and Currie in 1972 coined the 
term apoptosis in order to describe the morphological processes leading to controlled cellular 
self-destruction .95 The apoptotic mode of cell death is an active and defined process, which plays 
an important role in the development of multicellular organisms and in the regulation and 
maintenance of the cell populations in tissues under physiological and pathological conditions.96 
Section 6.2: The importance of apoptosis  
A complex and sophisticated interplay of cells forms multicellular organisms and during 
maintenance of the biological systems cells die in routine and the way in which most cells die is 
conserved from worm to mammal. During maintenance of body about 10 billion of our cells die 
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on a normal day to balance the number of new cells that arise through mitosis.  During 
development, many cells are produced in excess, which eventually undergo programmed cell 
death and thereby contribute to sculpturing many organs and tissues.97 
Apoptosis represents a process of great biological importance, being involved also in 
differentiation, development, proliferation, homoeostasis, regulation and function of the immune 
system. Thus, failures in apoptosis may result in autoimmune diseases, neoplasia and spreading 
of viral infections. Conversely, excessive apoptosis has been associated with other sorts of 
diseases, such as AIDS, neurodegenerative disorders and ischaemic diseases.98  
Section 6.3: Characteristic morphological features of apoptosis  
Apoptotic cells are characterized by morphological changes viz., the cell shrinks, shows 
deformation and looses contact with its neighboring cells. The cell chromatin condenses and 
marginates at the nuclear membrane, the plasma membrane is blebbing or budding, and finally 
the cell is fragmented into compact membrane-enclosed structures, called 'apoptotic bodies' 
which contain cytosol, the condensed chromatin, and organelles (Fig 6.1). The macrophages 
engulf the apoptotic bodies and are removed from the tissue without causing an inflammatory 
response. The sequential morphological changes are result of molecular and biochemical events 
within the cell undergoing apoptosis leading to activation of proteolytic enzymes, which 
eventually mediate the cleavage of DNA into small fragments.99 The other mode of cell death is 
necrosis and in this type of cell death the cells suffer a major insult, resulting in a loss of 
membrane integrity, swelling and disrupture of the cells. During necrosis, the cellular contents 
are released uncontrolled into the cell's environment which results in damage of surrounding cells 
and a strong inflammatory response in the corresponding tissue.96 
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Fig 6.1 Hallmarks of the apoptotic and necrotic cell death process.100 
 
Apoptosis can be triggered by various stimuli from outside or inside the cell, e.g. by ligation of 
cell surface receptors, by DNA damage as a cause of defects in DNA repair mechanisms, 
treatment with cytotoxic drugs or irradiation, by a lack of survival signals, contradictory cell 
cycle signalling or by developmental death signals. There are four main groups of stimuli (Fig 
6.2) for apoptosis.101-109 
Fig 6.2 Possible mechanisms through which apoptosis can be induced (Apoptosis, Phil 
Dash, http://www.sgul.ac.uk/depts/immunology/~dash/apoptosis/)
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The first group of stimuli includes ionizing radiations and anticancer drugs, which are alkylating 
in action and cause DNA damage. The second group of stimuli induces apoptosis via receptor 
mechanisms, either by receptor activation mediated by glucocorticoids (acting on the thymus).104 
tumor necrosis factor-a (TNF-a), or by withdrawal of growth factors (nerve growth factor and 
interleukin (IL)-3).105, 106 The third group of stimuli includes biochemical agents that include 
phosphatases and kinase inhibitors (e.g. calphostin C, staurosporine) and act via enhancing the 
downstream components of the apoptotic pathway 102. The heat, ultraviolet light and oxidizing 
agents (super oxide anion, hydrogen peroxide) are classified as the fourth group of stimuli and 
have property to cause direct cell membrane damage. Excessive production of reactive oxygen 
species (ROS), such as superoxide, hydrogen peroxide and the hydroxyl radicals, produces free 
radicals that damage lipid membranes, proteins and nucleic acids. Many of these stimuli cause 
necrosis in larger doses.107, 108 
Following an appropriate stimulus, the first stage or `decision phase' of apoptosis is the genetic 
control point of cell death. The cells, which do not recover during first stage after getting 
stimulus, enter the second stage or `execution' phase, which is responsible for the morphological 
changes of apoptosis. Although several pathways have been suggested to be involved in the 
process of apoptosis, two pathways have been the targets of extensive studies i.e signalling via 
mitochondria, and signaling via 'death-receptors' such as CD95 or Fas and these pathways trigger 
the cell to enter the first stage of apoptosis. The pathways are both further discussed below; 
however, it would firstly be prudent to introduce the major players in apoptosis, the caspases. 
Actually, cell death only can be strictly defined to follow a classical apoptotic mode if execution 
of cell death is dependent on caspase activity.96  
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Section 6.4: Caspases are key players of apoptosis 
The term caspases is derived from Cysteine-dependent aspartate-specific proteases i.e. they 
cleave proteins, and their catalytical activity depends on a critical cysteine-residue within a 
highly conserved active-site pentapeptide QACRG, and the caspases have a property to 
specifically cleave their substrates after Aspartate residues. In mammals 14 different members of 
the caspase-family have been identified so far, whereas this number is limited to seven in 
Drosophila.110, 111 According to a unified nomenclature, the caspases are referred to in the order 
of their publication: caspase-1 is ICE (Interleukin-1ß-Converting Enzyme), the first mammalian 
caspase identified.112, 113 
The caspases are synthesized as inactive zymogens, so called procaspases, and carry a pro-
domain followed by a large and a small subunit separated by a linker peptide. The procaspases 
are proteolytically cleaved between the large and small subunit, which result in separate small 
and large subunits. A heterotetramer consisting of two small and two large subunits then forms an 
active caspase. 
The pro-domain is also frequently but not necessarily removed during the activation process. The 
pro-apoptotic caspases can be divided into the group of initiator caspases including procaspases-
2, -8, -9 and –10, and into the group of executioner caspases including procaspases-3, -6, and –7. 
Whereas the executioner caspases possess only short pro-domains, the initiator caspases possess 
long pro-domains, containing death effector domains (DED) in the case of procaspases-8 and –10 
or caspase activated recruitment domains (CARD) as in the case of procaspase-9 and procaspase-
2.114 
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Fig 6.3 Hypothetical hierarchy of caspases114 
 
 
After receiving the death inducing signal the death inducing signaling complexes are activated 
and recruit the initiator caspases via their pro-domains either in response to the ligation of cell 
surface death receptors (extrinsic apoptosis pathways) or in response to signals originating from 
inside the cell (intrinsic apoptosis pathways).  
Section 6.5: Pathways of apoptosis 
Section 6.5.1: The extrinsic (receptor) pathway 
The cell surface has death receptors that are activated in response to a stimulus and transmit 
apoptotic signals after binding   to   specific ligands. The extrinsic apoptosis pathway mediates 
this process. The   extrinsic apoptosis    pathway   involves procaspase-8 which is recruited by its 
death effector domains (DEDs) to the death inducing signaling complex (DISC), a membrane 
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receptor complex formed to the ligation of a member of the tumor necrosis factor receptor 
(TNFR) family. This superfamily has several death receptors including TNFR-1, Fas/CD95 and 
the TRAIL receptors DR-4 and DR-5. Several procaspase-8 molecules bound to DISC are joined 
in close proximity and then activate each other by autoproteolysis. The signal is then transmitted 
through conserved death domain (DD), which is the cytoplasmic part of the death receptor. The 
DDs harboured by adapter molecules like FADD (Fas-activated Death Domain) or TRADD (Toll 
receptor activated death domain) are recruited to the DDs of the activated death receptor, and 
form the DISC and the local concentration of several procaspase-8 molecules at the DISC leads 
to their autocatalytic activation and release of active caspase-8. The caspase-8 is now ready for 
acting on downstream effector caspases, which subsequently cleave specific substrates resulting 
in apoptosis (Fig 6.4). The cells possessing the ability to induce apoptosis via direct caspase-
dependent pathway are classified as type I cells. In type II cells, the signal coming from the 
activated receptor does not directly mediate a caspase signaling cascade and the signal is 
processed via mitochondria-dependent apoptotic pathway. The Bcl-2 gene family member Bid 
links the caspase signaling cascade and the mitochondrial pathway. Bid is cleaved by caspase-8 
into the truncated form (t-BID), which translocates to the mitochondria where it acts in concert 
with the pro-apoptotic Bcl-2 family members Bax and Bak to induce the release of cytochrome c 
and other mitochondrial pro-apoptotic factors into the cytosol.110 
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Fig 6.4 Receptor-mediated caspase activation at the DISC (ApoReview, Introduction to 
Apoptosis, Andreas Gewies, 2003, http://www.celldeath.de/encyclo/aporev/aporev.htm) 
 
 
Section 6.5.2: The intrinsic (mitochondrial) pathway 
The main initiator caspase in the intrinsic apoptosis pathways is procaspase-9, which is activated 
downstream of mitochondrial pro-apoptotic events at the apoptosome. The apoptosome is a 
cytosolic death signalling protein complex that is formed upon release of cytochrome C from the 
mitochondria.115 In cancer, DNA damage caused by chemotherapy and irradiation activates the 
intrinsic pathway. Other stimuli for intrinsic pathway mediated apoptosis include hypoxia, 
defective cell cycle events, and deprivation of growth factors.  
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Fig 6.5 Mitochondria-mediated caspase activation at the apoptosome (Apoptosis, Phil 
Dash, http://www.sgul.ac.uk/depts/immunology/~dash/apoptosis/) 
 
 
In response to an apoptotic stimulus, Bax (the prototypic pro-apoptotic protein), undergoes 
homodimerization and oligodimerization and inserts into the mitochondrial membrane and the 
increased permeabilization results in loss of membrane potential, which consequently lead to 
release of apoptogenic factors including cytochrome c, ATP, and SMAC/DIABLO (second 
mitochondria-derived activator of caspase/direct IAP binding protein with low pI).  The binding 
of nucleotide-binding domain of apoptotic protease-activating factor 1 (APAF1) to ATP result in 
the formation of large oligomers (heptamers). Cytochrome c binds to APAF1 and through a 
CARD in APAF1, binds to a complementary CARD on procaspase-9 leading to activation of 
caspase 9 (Fig 6.5) and of the downstream “executioner” caspases 3, 6, and 7.110 These activated 
caspases auto-induce activation of themselves as well as downstream caspases and the proteolytic 
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cascade, that ultimately cleaves substrates essential for cell viability, results in the characteristic 
biochemical and morphological changes of apoptosis. 
Section 6.6: Regulation of apoptosis signaling  
As described in the previous sections, the process of apoptosis is activated after encountering a 
specific death-inducing signal. This suggests that the apoptosis signaling pathways in viable cells 
are kept in an inactive state and are only turned on in response to a death stimulus. This further 
suggests that there must be some regulatory signals, which promote survival of cell and suppress 
the cell death in normal circumstances. Various growth factors, hormones and nutrients help to 
maintain homeostasis in organisms. It has been shown that the survival signals enhance the 
expression and/or activity of anti-apoptotic regulatory molecules thereby keeping in check the 
activation of pro-apoptotic factors.116, 117 Follows the description of some of the anti-apoptotic 
molecules and mechanisms. 
Section 6.6.1: The Bcl-2 family 
This is the family of oncogenes that inhibits cell death rather than promoting proliferation. The 
discovery of this gene family demonstrated for the first time that the pathway toward 
tumorigenesis depends not only on the ability to escape growth control but also depends on the 
ability to prevent apoptosis.118 The Bcl-2 family of proteins can be characterized by the presence 
of conserved sequence motifs known as Bcl-2 homology domains (BH1 to BH4). In mammals, 
up to 30 members have been identified under this family of which some belong to a group of pro-
survival members and others to a group of pro-apoptotic members.119 The pro-apoptotic group of 
Bcl-2 members is comprised of two subgroups: first, the Bax-subfamily, which consists of Bax, 
Bak, and Bok all possessing the domains BH1, BH2, and BH3, and the second known as the 
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BH3-only proteins (Bid, Bim, Bik, Bad, Bmf, Hrk, Noxa, Puma, Blk, BNIP3, and Spike) all of 
which have only the short BH3 motif, an interaction domain that is both necessary and sufficient 
for their killing action.120, 121 The central function of mammalian Bcl-2 family members is to 
prevent mitochondrial membrane loss and to control the release of mitochondrial proteins into the 
cytoplasm.120
In summary, a current model of how Bcl-2 family members regulate apoptosis can be described 
as follows (Fig 6.6): specific apoptotic stress signals trigger the activation of particular BH3-only 
proteins which then interact with anti-apoptotic members on the outer mitochondrial membrane 
resulting in the release of Bax-like pro-apoptotic factors. Bax-like factors undergo a 
conformational change (possibly assisted by some BH3-only proteins), and then insert 
themselves into the outer mitochondrial membrane to provoke the release of apoptogenic 
factors.119 
Fig 6.6 Role of various apoptosis related genes (ApoReview, Introduction to Apoptosis, 
Andreas Gewies, 2003, http://www.celldeath.de/encyclo/aporev/aporev.htm) 
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Section 6.6.2: Regulation of apoptosis by IAPs  
IAPs (inhibitors of apoptosis proteins) are a family of anti-apoptotic proteins transactivated by 
transcription factor NF-κB, which is also a regulator of anti-apoptotic proteins such as Bcl-2, Bcl-
XL, and A1. 122, 123  In humans, eight IAPs have been identified so far, including among others 
NAIP, c-IAP1, c-IAP2, XIAP and survivin. The anti-apoptotic properties of IAPs are conferred 
by the interaction between the baculovirus IAP repeat (BIR) domains and caspases. BIR domain 
is a conserved 70 amino acids motif and through binding of this domain the XIAP, c-IAP1 and c-
IAP2 are thought to directly inhibit caspases-3, -7, and –9.124  
Section 6.6.3: Mitochondria as central regulator of intrinsic apoptosis pathways 
Mitochondria has been demonstrated to have a key role in the integration and propagation of 
death signals originating from inside the cell such as DNA damage, oxidative stress, starvation, 
as well as those induced by chemotherapeutic drugs.125, 126 One of the common events in 
mitochorial mediated apoptosis is the disruption of the mitochondrial inner transmembrane 
potential (∆ψ) as well as the so called permeability transition (PT) (defined as a sudden increase 
of the inner mitochondrial membrane permeability to solutes with a molecular mass below 
approximately 1.5 kDa). The influx of water into the mitochondrial matrix leads to osmotic 
mitochondrial swelling causing rupturing of the outer mitochondrial membrane and result in the 
release of pro-apoptotic proteins from the mitochondrial intermembrane space into the 
cytoplasm.127 Released proteins include cytochrome c, which activates the apoptosome and 
therefore the caspase cascade. In addition to the release of mitochondrial factors these changes in 
membrane potential also affect the biochemical homeostasis of the cell: ATP synthesis is 
stopped, redox molecules such as NADH, NADPH, and glutathione are oxidized, and reactive 
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oxygen species (ROS) are increasingly generated.128 Increased levels of ROS directly cause the 
oxidation of lipids, proteins, and nucleic acids, thereby enhancing the disruption of ∆ψ as part of 
a positive feedback.129 Since PT, loss of ∆ψ, and release of mitochondrial proteins are of central 
importance in mediating and enhancing apoptotic pathways, those mitochondrial events must be 
kept under strict control of regulatory mechanisms which are in many ways dependent on 
members of the Bcl-2 family. 
Section 6.7: Disease as a consequence of dysregulated apoptosis  
Dysregulation of apoptotic signaling has been linked to several diseases. The insufficient 
apoptosis leads to cancer (cell accumulation, resistance to therapy, defective tumor surveillance 
by the immune system), autoimmunity (failure to eliminate autoreactive lymphocytes), persistent 
infections (failure to eradicate infected cells), whereas excessive apoptosis contributes to 
neurodegeneration (Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic 
lateral sclerosis), autoimmunity (uncontrolled apoptosis induction in specific organs), AIDS 
(depletion of T lymphocytes), and ischaemia (stroke, myocardial infarction).130 Mutations in the 
genes have been linked with the malfunctioning of the death machinery and several mutations in 
apoptosis genes have been identified as a causing or contributing factor in human diseases.131 
Defective apoptosis pathways contribute to formation, progression, and metastasis of tumors as 
well as the as well as contribute to multi-drug resistance during cancer therapy. The impairment 
of apoptosis checkpoints also contribute to tumorigenesis.132, 133 
As an example and as already mentioned, Bcl-2 was the first apoptosis-related gene that was 
recognized to play a role in tumorigenesis, and indeed, Bcl-2 is over expressed in a variety of 
cancers, contributing to cancer cell survival through direct inhibition of apoptosis.134, 135 
Conversely, mutated or down regulated Bax and Bak are observed in certain cancers136, 137 and 
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disruption of those genes promotes tumorigenesis in mice.138 During the past few years of 
research, p53 has emerged as a central checkpoint for apoptosis and is inactivated in more than 
50% of all human cancers.139 The tumor suppressor protein  p53 is activated as a transcription 
factor in response to e.g. oncogene activation, hypoxia and especially DNA damage, resulting in 
growth arrest and/or apoptosis by stimulating the expression of various p53 target genes such as 
p21, Bax, Puma, Noxa, Apaf-1, Fas, and DR5140 or by repressing the expression of anti-apoptotic 
proteins, e.g. Bcl-2, Bcl-XL or surviving.141, 142 Recent evidence suggests transcription-
independent p53 apoptosis pathways in which p53 translocates to the mitochondria, interacts with 
Bcl-XL, induces PT and the release of cytochrome c.143 
In non-stressed and undamaged cells, p53 is present at low cellular concentrations and it is 
retained in the cytosol.144 In response to cellular stress (such as DNA damage), p53 is 
phosphorylated at specific serine/threonine residues, and thus p53 is stabilized and activated.145 
Moreover, p53 is central to oncogene-induced cell death because it is induced by oncogenes such 
as c-myc, adenovirus E1A, and ras as well as by loss of the retinoblastoma tumor suppressor 
pRb.146 All those oncogenes activate the transcription factor E2F-1, which not only can promote 
cell cycle progression and proliferation but at the same time directly triggers expression of the 
tumor suppressor ARF which leads to stabilization and activation of p53.147 This explains in part 
why oncogene activation not always leads to uncontrolled cell proliferation but under certain 
circumstances to the stabilization of p53 and activation of cell death..148  
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Section 6.8: Cell cycle regulation 
 
The homeostasis is not only important at physiological and biochemical level, also the 
maintenance of genome stability is essential for normal cell proliferation. Genome stability is 
compromised by genotoxic agents that damage DNA, resulting in the direct or indirect induction 
of DNA breaks. Somatic cells are continually dividing via a highly ordered and regulated process 
called the cell cycle. The cell cycle comprises of four phases namely; G1 (cell grows), S (DNA 
replication), G2 (cell prepares to divide) and the M phase (cell division) (illustrated in figure 6.7). 
Cell cycle progression through these replication events is stalled at the G1/S checkpoint, the 
intra-S-phase checkpoint or the G2/M checkpoint if DNA damage induced by the drugs and other 
sources activates the DNA repair mechanism.  
 
The G1/S checkpoint prevents cells from entering the S phase in the presence of stress, thus 
inhibiting replication. The exact pathway of cell cycle arrest depends on the kind of stress 
induced. The intra-S-phase checkpoint prevents cells from entering the G2 phase in the presence 
of stress encountered during replication or stress that escaped the G1/S checkpoint. The G2/M 
checkpoint prevents cells from entering the M phase in the presence of stress. 
DNA damage can activate checkpoint pathways that lead to cell cycle arrest in the G1, S or G2 
phases of the cell cycle.149-152 DNA breaks can occur after an interference with the DNA 
replication machinery.153, 154 Inhibition of the elongation stage of DNA replication activates the 
replication checkpoint which is closely related to the S phase DNA damage checkpoint, and leads 
to cell cycle arrest.151, 155 The mechanisms proposed to generate DNA breaks during the 
elongation phase of DNA replication rely on  events arising from the inhibition of replication fork 
progression.156,157 At present, it is unclear what kind of DNA structure is detected at the 
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replication checkpoint; inhibition of replication elongation has been shown to result in the 
accumulation of single stranded stretches of DNA in yeast,158 and can also lead to the formation 
of double-strand breaks (DSBs) in bacteria,159 yeast158 and higher eukaryotes.154 
 
Fig 6.7 Cell cycle phases (Blue stars represent checkpoints) 
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Gaining insight into the mechanisms and alterations by which components of the apoptotic 
machinery contribute to pathogenic processes, should allow the development of more effective, 
higher specificity and therefore better-tolerable therapeutic approaches. Those may include the 
targeted activation of pro-apoptotic tumour suppressors or alternatively the blockade of 
antiapoptotic oncogenes in the case of cancer, whereas for the treatment of premature cell death 
during e.g. neurodegeneration the inhibition of pro-apoptotic key components such as the 
caspases might be promising.130 The universality of the genetic programme controlling apoptosis 
has helped to rapidly analyse the regulation of apoptosis in different tissues and diseases. While 
there are high expectations about possible therapeutics that might be targeted against apoptosis 
regulating factors, the ubiquitous nature of the event also sets limitations to the possible 
measures. 
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Section 6.9: Plant-derived anti-cancer drugs 
For centuries, medicinal plants have been the biggest source of relief from several ailments. 
During recent years the extraction of active compounds from the plant extracts has been an area 
of active research and several currently used drugs for cancer are either directly extracted 
compounds or are derivatives of these compounds. The web page 
(http://biotech.icmb.utexas.edu/botany/chemtab.html) provides very succinct information about 
the plant-derived compounds. Some of the currently used plant-derived compounds in cancer 
treatment are summarized below: 
Section 6.9.1: Paclitaxel (6.1) and Docetaxel (6.2)  
These drugs were originally extracted from the bark of the Taxus brevifolius . Docetaxel (6.2) is a 
derivative of Paclitaxel 6.1 and is twice as effective in causing G2-M arrest during cell cycle as 
compared to the parent compound. Paclitaxel 6.1 is used to treat breast, ovarian, lung and 
oesophageal cancers. 161  
 
         
                         6.1                                                                         6.2 
Docetaxel 6.2, is also an intravenous drug that is being tested on carcinomas of the bladder, 
cervix, lung, and ovaries, on malignant melanoma; and on non-Hodgkin's lymphoma.  
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Section 6.9.2: Camptothecin 6.3 and Topotecan 6.4 
Camptothecin 6.3 is a quinoline-based alkaloid isolated from the bark of the Camptotheca 
acuminata (Nyssaceae). Camptothecin 6.3 and its derivatives aminocamptothecin, CPT-11 
[irinotecan], DX-8951f, and topotecan 6.4 act as DNA topoisomerase-I inhibitors and target the 
cell during S–phase of cell cycle.162 
Topotecan 6.4 is approved to use for the treatment of advanced ovarian cancers, and irinotecan 
HCl as a treatment for metastatic cancer of the colon or rectum.  
       
 
 
  6.3      6.4 
Section 6.9.3: Colchicine 6.5, a water-soluble alkaloid and mitosis inhibitor, was isolated from 
the Colchicum autumnale.  
6.5 
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Cancer cells divide more rapidly than normal cells and thus are more susceptible to being 
poisoned by mitotic inhibitors such as colchicines 6.5, paclitaxel 6.1, and the Vinca alkaloids.163 
However, colchicines 6.5 has proven to have a fairly narrow range of effectiveness as a 
chemotherapy agent, so its only FDA-approved for use in the treatment of gout.  
Section 6.9.4: Podophyllotoxin 6.6 and etoposide 6.7 
Podophyllotoxin 6.6 was extracted from the Podophyllum peltatum (Berberidaceae). Etoposide 
6.7is a derivative of podophyllotoxin 6.6 and both block the cell cycle in G1 phase and the S 
phase and induce breaks in DNA via an interaction with DNA topoisomerase II.164 
Podophyllotoxin 6.6 has been found effective against genital infection caused by the human 
papillomavirus (HPV). Etoposide 6.7 is used mainly to treat testicular cancer. It is also used to 
treat chorionic carcinomas, lymphomas and malignant melanomas.165 
     
                              6.6                                                           6.7         
Section 6.9.5: Tetrahydrocannabinol 6.8 
Tetrahydrocannabinol (THC) 6.8 was first extracted from Cannabis sativa (Cannabaceae). THC's 
derivative Delta-trans-tetrahydrocannabinol commonly known as Dronabinol is recognized as an 
appetite stimulant and anti-nausea/vomiting (antiemetic) agent.166 
  
  
 
 
 
 
148  
 
      6.8 
It inhibits nerve impulse that causes nausea and is used to treat chemotherapy related nausea and 
glaucoma.  
Section 6.9.6: Vinblastine 6.9, vincristine 6.10 and vindesine 6.11  
Vinblastine 6.9 and vincristine 6.10 are alkaloids found in the Catharanthus roseus. Vindesine 
6.11 is a semi-synthetic derivative of vinblastine 6.9 and all of these alkaloids works by inhibiting 
mitosis in metaphase.  
     
    6.9     6.10 
 
Vinblastine 6.9 is useful for treating Hodgkin's disease, lymphocytic lymphoma, histiocytic 
lymphoma, advanced testicular cancer and advanced breast cancer. Vincristine 6.10 is used 
mainly to treat acute leukemia, neuroblastoma, Hodgkin's disease and other lymphomas.  
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      6.11      
Vindesine 6.11 is used to treat melanoma and lung cancers. It is also effective in treating uterine 
squamous cell carcinomas.   
Current plant derived anti-cancer drugs primarily target cell cycle phases and thus their toxicity is 
not restricted to cancer cells. Clinical application of these drugs has been partially successful, as 
they have been administered in phases and in combination with other anti-cancer agents. The 
research community thus endeavors to identify site specific, non-toxic novel anti-cancer drugs 
that target the underlying genetic components of malignancy in an effort to overcome the 
cytotoxic effects of conventional drugs.  
In recent years, apoptosis has become an important issue in biomedical research. The rate of 
apoptosis significantly affects the life span of normal as well as cancer cells within a living 
system. Because apoptosis is a discrete manner of cell death that differs from necrotic cell death 
and is regarded as an ideal way to eliminate damaged cells, agents that can modulate apoptosis 
may be used for the management and therapy of cancer by modulating the steady-state cell 
population. 
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Chapter 7: Evaluation of the compounds for Apoptosis 
 
The objective of this section is for the purposes of undertaking preliminary screening for anti-
cancer activity of the synthesized analogues of diospyrin 1.22, which has demonstrated 
encouraging anti-tumor activity. The literature indicates that with a few modifications to the basic 
structure, the anti-tumor activity of diospyrin 1.22 can be enhanced.167 In the present study, a few 
novel analogues of diospyrin 1.22 viz., 3.20, 3.21, 3.25, 3.32 were synthesized and subjected to 
anti-tumor evaluation. The Biotechnology department of University of the Western Cape, Cape 
Town has in house facilities available to undertake apoptosis analysis. The choice of the cell lines 
was restricted to the routinely used cell lines in the department. Thus, this chapter reports on the 
cytotoxicity (via the neutral red colorimetric assay) of test compounds on the 'normal' non-
transformed mammalian cell line; the CHO (Chinese Hamster Ovaries) cell line and apoptosis 
activity (via APOpercentageTM assay, Biocolor Ltd) on three cancer cell lines namely; MCF-7 
(human breast adenocarcinoma), HeLa (human cervical carcinoma), MG-63 (human bone 
osteosarcoma). The cytotoxic and apoptotic activity was used to identify the synthetic analogue 
having the most significant anti-cancer activity. This pro-apoptotic activity was conclusively 
demonstrated with more specific markers of apoptosis namely; the externalisation of 
phosphatidylserine, DNA fragmentation and cell cycle apoptosis.  
 
Section 7.1: Material Used 
Section 7.1.1: General chemicals and assay kits 
Active Caspase – 3 FITC Mab Apoptosis Kit   BD Biosciences 
APOpercetageTM apoptosis assay    Biocolor Ltd 
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Crystal Violet       Sigma 
DMSO (Dimethyl sulphoxide)    Sigma 
Ampicillin        Roche 
APO-DIRECT™ Kit      Roche 
Propidium Iodide (1 mg/ml in 3.8 mM sodium citrate) Sigma 
RNase        Roche 
Phosphate Buffer Saline (PBS) (Ca++, Mg++ free)  Sigma 
Camptothecin       Sigma 
  
Section 7.1.2 Tissue culture media components and cell lines 
Invitrogen supplied tissue culture media: 
Dulbecco’s modified eagle medium (DMEM)       with 4500mg/l glucose and GlutamaxTM  
Nutrient mix Ham’s F12    with L-glutamine 
RPMI 1640 medium     with L-glutamine 
100x penicillin streptomycin 
Foetal calf serum (FCS) 
Media composition: 
Complete Ham’s F12 = Ham’s F12 + 0.2 % penicillin streptomycin + 5 % FCS 
Complete DMEM = DMEM + 0.2 % penicillin streptomycin + 10 % FCS 
Complete RPMI = RPMI + 0.2 % penicillin streptomycin + 10 % FCS 
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Table 7.1 The cell lines used during apoptosis analysis  
Species Cell lines Medium Serum 
Hamster CHO 22 Hams F12 5 % FCS 
Human HeLa DMEM 10 % FCS 
Human MCF7 RPMI 1640 10 % FCS 
Human MG-63 DMEM 10 % FCS 
 
 
Section 7.2: General Methods for cell culturing and various apoptosis assays 
Section 7.2.1: Thawing of cells 
The frozen cell filled cryovials were removed from storage at -150oC and immediately thawed in 
a 37oC water bath. The contents of the vials were then transferred into a 15 ml tube containing 5 
ml Hams F12 media. The 15 ml tube was centrifuge for 2min. @ 2000rpm. The supernatant was 
discarded whilst the pellet was re-dissolved in 5 ml relevant media (specific for different cell 
lines) that was transferred to a 25cm2 tissue culture flask for incubation. All the cell lines used 
were adherent and were incubated at 37oC in a humidifier atmosphere of 5 % CO2. 
 
Section 7.2.2: Trypsinization of cells 
Once cells reach confluency, cells need to be trypsinized (or potentially die of overcrowding). 
The media in the flask was then discarded. Cells were washed with trypsin, then allowed to 
trypsinized with 3 ml of 0.0625 % trypsin in hood. After 3 min., 12 ml of media was added to the 
trypsin (to stop trypsinization). The cells were split into three 25cm2 tissue culture flasks for 
incubation (media in flasks are topped up to a minimum of five milliliters). 
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Section 7.2.3: Freezing of cells 
To ensure continuity of cell lines, cells were grown to confluency and then stored at -150oC. To 
store cells they were trypsinized after which the pellet was re-dissolved in a 10 % DMSO and 90 
% media mixture. The suspensions were aliquoted into 2 ml cryovials, then stored at -150oC. 
 
Section 7.2.4: Seeding of cells  
Once cells have been thawed and incubated in a 25cm2 tissue culture flask, they will be left for 48 
h to 72 h to grow to confluency. The cells can then be used for various experiments and are ready 
to be seeded in the appropriate well plates for testing. That is, cells are trypsinized, and are then 
counted using a Hausser Scientific Fuchs Rosenthal Ultra Plane Hemocytometer using crystal 
violet dye and seeded at a concentration of 2.5x104 cells per well. When 6, 24 or 96 well plates 
were used 2 ml, 500 μl or 100 μl of cells were seeded respectively. Cells were incubated 
overnight at 37oC for 24 h. 
Section 7.2.5: Dissolving compounds 
The compounds were dissolved in DMSO to obtain a final concentration of 100μl. This was the 
stock solution and further required dilutions were made from this stock. The stock was stored at -
20 oC and the dissolved compounds were stable during storage. 
 
Section 7.3: Tests authenticating the induction of apoptosis 
Section 7.3.1: Cytotoxicity assay 
CHO cells were seeded in 96 well tissue culture plates and treated with compounds of 
concentrations ranging from 0.625μM  to 10μM for 24 h with in triplicate. The supernatants were 
removed from the well, cells were washed with PBS and 100 µl of neutral red solution (100 µg/ 
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ml, in serum free media) was added to each well. The plates were incubated for 2 h at 37°C. 
Wells were washed rapidly with 100 μl, 1 % paraformaldehyde. Nutrient red (NR) dye from the 
cells was extracted by adding 100 μl of NR desorb to each well. The plates were incubated for 
15min. and then placed on a shaker for an additional 30 min. before determining the optical 
density at 540 nm (OD540) on a multi-well spectrophotometer.  Cytotoxicity is calculated as 
follows: 
 
 
Where Abs = Absorbance measured using spectrophotometer 
 
Section 7.3.2: APOpercentageTM assay 
The APOpercentage dye was prepared by adding 15.9 ml media to 0.1 ml APOpercentage dye. 
Cells were seeded in 24 well tissue culture plates and tested for 24 h with concentrations ranging 
from 0.625μM to 10μM in triplicate. After the cells were treated with the test compound, the 
supernatant was removed and placed in 15 ml tubes. Cells were washed with 1 ml PBS and 
trypsinized with 300 μl trypsin. Cells were centrifuged @ 3000 rpm for 5 min. Cells were re-
suspended in 200 μl of the prepared APOpercentage dye, followed by incubation for 30 min. at 
37°C. The cells were washed with 2 ml PBS to remove excess dye. The cells were analyzed 
within one hour on a (Fluorescent Activated Cell Sorting) FACScan instrument using 
CELLQuest PRO software (BD Biosciences). The cell fluorescence was measured by flow 
cytometry using the FL2 channel and a minimum of 10 000 events was acquired per sample. 
 
 
% cytotoxicity = Abs of negative control – Abs of treated cellsAbs of negative control 
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Section 7.3.3: APO-DIRECT™ Kit (DNA fragmentation)   
The cells were seeded in 6 well tissue culture plates and cells were exposed to the required 
concentration of the compounds (3.20, 3.21, 3.25, 3.32) for 48 h and 72h. After the cells were 
treated with the compound, cells were trypsinized and re-suspended in 5 ml of 1 % (w/v) 
paraformaldehyde in PBS and placed on ice for 15 min. The cells were centrifuged @ 3000 rpm 
for 5 min. and the supernatant was discarded. The cells were washed twice in 5 ml of PBS 
followed by centrifugation @ 3000 rpm for 5 min. The cells were re-suspended in 0.5 ml of PBS 
and 5 ml of ice-cold 70 % (v/v) ethanol was added drop by drop and cells were stored in 70 % 
(v/v) ethanol at –20oC for 48 h. The cells were removed from storage and centrifuged at 3000 
rpm for 5 min. at room temperature and supernatant was discarded and cells were re-suspended in 
1 ml of wash buffer supplied with the kit. The cells were centrifuged as before and the 
supernatant agsin discarded and the washing with wash buffer was repeated. The cell pellet was 
resuspended in 50 ml of the staining solution (prepared as described in table 7.2). The cells were 
incubated in the staining solution for 60 min at 37oC. At the end of the incubation, 1 ml of rinse 
buffer was added to each tube and the cells centrifuged as before. The supernatant was removed 
by aspiration. The treatment with rinse buffer was repeated and the cells were re-suspended in 0.5 
ml of the Propidium Iodide (PI)/RNase A solution. The cells were incubated in the dark for 30 
min. at room temperature. The cells were analysed in Propidium Iodide/RNase solution within 3 
h on FACScan instrument using CELLQuest PRO software after time intervals 48 and 72 h. 
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Table 7.2 APO-DIRECTTM kit staining solution 
Staining Solution 1 Assay (µl) 4 Assay (µl) 
TdT reaction 10 40 
TdT enzyme 0.75 3 
Fluorescein-dUTP 8 32 
dH2O 32 128 
Total volume 50.75 203 
 
 
Section 7.3.4: Cell Cycle analysis with Propidium Iodide (PI):  
The cells were seeded in 6 well tissue culture plates and cells were induced with 10 μM 
concentration of the compound for 24 h, 48 h and 72h. After completion of incubation, the cells 
were gently trypsinized using 500 μl trypsin. The trypsinized cells were then harvested and were 
washed with 5 ml of PBS using centrifugation. The cell pellet was re-suspended in 200 μl PBS 
and 4 ml ice-cold 70% ethanol was added drop-wise to prevent aggregation of cells and was 
mixed well. The cells were fixed at -20o C for at least 48 h. After the fixation, the cells were 
washed with 5 ml 1x PBS by centrifuging at 3000 rpm for 5 minutes. The cells were re-
suspended in PI master mix and were incubated at 37o C for 30 minutes. The cells were stored on 
ice until analysed by FACScan instrument using CELLQuest PRO software (BD Biosciences). 
The cell fluorescence was measured by flow cytometry using the FL2 channel and a minimum of 
10 000 events was acquired per sample. 
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PI Master Mix (10 ml): 
PBS 9.5 ml 
RNase 100 μl 
PI 400 μl 
 
Section 7.4: Results 
Section 7.4.1: Screening cytotoxic effects of compounds using the neutral red (NR) assay 
The cytotoxicity of a compound is believed to be an indicator of its apoptotic potential. The 
cytotoxicity test is routinely used in the preliminary screening of the compounds extracted from 
plants and their anti-cancer activities. The neutral red (NR) cytotoxicity assay is a cell viability 
assay based on the ability of viable cells to incorporate and bind the NR dye. NR is a weak 
cationic dye that penetrates cell membranes by non-ionic diffusion and accumulates 
intracellularly at the anionic sites in the lysosomal matrix. Alterations in the cell membrane or the 
sensitive lysosomal membrane lead to lysosomal fragility.168, 169 As a consequence, only cells that 
are intact  (viable) will bind NR dye i.e. the viable cells with an intact lysosomal membrane will 
be stained with the dye while the dead cells with lysosomal membrane damage will not be 
labelled. It thus follows that the dye trapped within live cells can be released, quantified and 
expressed as a function of cell death.  
Fig 7.1 shows the percentage of apoptotic cells in CHO cell line observed in response to various 
concentrations of compounds. The compound 3.32 showed the maximum killing (60%) at a 5 μM 
concentration followed by a sharp increase in cytotoxicity by 3.20 at 10 μM. Two other 
compounds 3.21 and 3.25 had no cytotoxic effects on the CHO cells under similar conditions.  
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Fig 7.1 Test compounds screened for cytotoxicity on CHO cell line 
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The cytotoxicity test is considered a preliminary test for screening compounds as potential 
apoptosis inducers. However, a recent study by M Essack, Masters thesis, UWC, submitted in 
2007, demonstrated that cytotoxicity is not such a good indicator of apoptotic potential of a 
compound. Keeping this in mind, it was decided to perform apoptosis analysis on all four 
compounds as shown in Fig 7.1. 
Section 7.4.2: TheAPOpercentageTM assay 
Apoptosis may be defined as programmed cell death characterized by certain morphological 
features such as membrane asymmetry and attachment, condensation of the chromatin, and 
internucleosomal cleavage of DNA. In cells at early stage of apoptosis, the membrane 
phospholipid phosphatidylserine (PS) is externalized to the outer-leaflet of the plasma membrane. 
The APOpercentageTM assay is a dye uptake assay, which stains apoptotic cells with a red dye 
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(Biocolor Ltd). This exposure of the PS allows the unidirectional uptake of the APOpercentageTM 
dye.170 As a consequence, only cells that have undergone apoptosis i.e. externalization of 
phosphatidylserine; will be dye labeled, whereas the normal and necrotic cells that are present 
remain unlabelled. The experiments were performed in triplicates and the average was used to 
represent killing.  
Fig 7.2 indicates that all four test compounds have different apoptotic abilities in CHO cells. The 
compounds 3.32 and 3.20 showed maximum induction of apoptosis in CHO cells at 5 μM, with 
not much change at 10 μM. Compound 3.25 was also active with 90% of apoptotic cells at 10 
μM. An initial increase was observed followed by a decrease in case of compound 3.21. 
Fig 7.2 Test compounds screened for apoptosis activity on the CHO cell line  
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Compound 3.25 showed negligible cytotoxicity, but when observing the percentage of cells 
undergoing apoptosis measured using the APOpercentage assay (Fig 7.2) it is clear that 
compound 3.25 do have apoptotic potential.  
In Fig 7.3 it can be clearly seen that compound 3.32 induced apoptosis in MCF-7 cells (65%) in 
relation to the other two compounds that caused a less than 20% of cells to undergo apoptosis 
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even at a concentration of 10 μM. The important observation here is the selective killing induced 
by compound 3.32 against MCF-7, which is a breast cancer cell line and is deficient in caspase-
3.171 This selectivity could be contributed to in part, the underlying mechanisms of apoptosis.  
 
Fig 7.3 Test compounds screened for apoptosis activity on MCF-7 cell line   
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Fig 7.4 indicates that compound 3.25 displayed the highest apoptosis activity (67%) at 10 μM. In 
this case compounds 3.20, 3.21 and 3.32 all displayed negligible apoptosis activity. 
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Fig 7.4 Test compounds screened for apoptosis activity on the HeLa cell line 
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In culture, 3.25 have been shown to selectively kill HeLa cells (70%) at a concentration of 10 
μM. This selective killing could be due to different signalling pathways used by the various 
compounds in the  different cancer cells. 
 
Fig 7.5 Test compounds screened for apoptosis activity on the MG-63 cell line 
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In Fig 7.5 it is obvious that compounds 3.25 and 3.32 displayed apoptosis activity (above 35%) in 
relation to the other two compounds in MG-63 cell line that only caused 10% of the cells to 
become apoptotic.  
The results for the CHO cell line proved that the cytotoxicity test (Fig 7.1) is not that reliable 
since 3.25 displays significant apoptosis activity but negligible cytotoxicity, indicating that this 
compound would have been mistakenly eliminated during the initial screening process. Test 
compounds 3.32, 3.20 and 3.21 induced the highest degree of apoptosis activity for the CHO cell 
line as opposed to MCF-7 and HeLa cells which displayed the maximum apoptosis with test 
compounds 3.32 and 3.25 respectively. This is to be expected, as the CHO cell line is a 'normal' 
animal cell line that should not have any mutations affecting its ability to undergo apoptosis, that 
is; it should have a larger array of apoptosis inducers. Also, MCF-7 in particular has been 
characterized with caspase-3 gene mutation.171 From the extensive coverage of the most common 
extrinsic and intrinsic pathways in section 6.5 it can be inferred that these pathways commonly 
converge at caspase-3. This highlights the reason why the presence of caspase-3 is recognized as 
a hallmark of apoptosis and accounts for the high resistance to apoptosis inducers displayed by 
the MCF-7 cell line. It can thus be deduced that test compound 3.32 can induce an apoptotic 
pathway independent of caspase-3. Test compound 3.25 was found to be most active apoptosis 
inducer for the HeLa cell line.  Additionally, 3.32 and 3.25 are both active in MG-63 cell line at a 
10 μM concentration, indicating that 3.32 might have both a caspase-3-dependent and a caspase-
3-independent mode of action, since 3.32 is also active in the caspase-3 deficient cancer cell line 
MCF-7. An analysis of the above graphs reveals that the compounds have selective killing 
properties in different cell lines. The purpose of the above analyses was to identify a lead 
compound, which could be subjected to further testing for identifying downstream apoptotic 
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signals. Since 3.25 has shown outstanding results in three of the cell lines, it was therefore 
decided to perform further analyses for testing the specific hallmarks of apoptosis, using this 
compound at a 10 μM concentration. Since test compound 3.25 was most active in HeLa cell 
line, it is logical to use this cell line for performing downstream apoptosis analyses. 
 
Section 7.5: Screening 3.25 for specific markers of apoptosis 
Section 7.5.1: DNA fragmentation   
The fragmentation of the genomic DNA is a late event during apoptosis. DNA fragmentation is a 
result of active caspase-3 mediated cleavage of ICAD (Inhibitor of CAD) to activate CAD 
(caspase-activated deoxyribonuclease), which is responsible for the fragmentation of the 
DNA.172, 173 The APO-DIRECT™ Kit allows for the detection and quantification of DNA breaks 
by FACS analysis. DNA fragmentation during apoptosis exposes 3’ -hydroxyl groups in terminal 
positions. This characteristic can be used to differentiate apoptotic cells from viable cells by 
labelling the DNA breaks with fluorescein-tagged deoxyuridine triphosphate nucleotides (F-
dUTP). The enzyme, terminal deoxynucleotidyl transferase (TdT), catalyzes a template-
independent addition of deoxyribonucleoside triphosphates to the 3' -hydroxyl terminal groups of 
double- or single-stranded DNA.174Consequently, the apoptotic cells that contain DNA breaks 
will fluoresce. Results can be acquired and analysed in the form of a histogram or dot plot. For 
the results obtained in histogram form, normal cells will fluoresce in the first decade (101), whilst 
a horizontal fluorescent shift along the X-axis from the first decade (101) to the second decade 
(102) or third decade (103) is expected for apoptotic cells. In the case of results obtained as a dot 
plot, the normal convention of this display is to put DNA (Linear Red Fluorescence) on the X-
axis and the F-dUTP (Log Green Fluorescence) on the Y-axis, apoptotic cells will display an 
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increase in fluorescence of fluorescein by shifting vertically up along the Y-axis. The graph is 
divided into two regions R3 and R2 corresponding to the percentage of apoptotic and normal 
cells respectively.  
HeLa cells were plated in 6 well tissue culture plates. The cells were induced with test compound 
3.25 and the standard positive control camptothecin 6.3. The results for DNA fragmentation were 
obtained after treating the cells with test compound for 48 h and 72 h. The reason for choosing 
these time points was that DNA fragmentation is a late event during the process of apoptosis and 
it was observed that most cells were in early stage of apoptosis after 24 h (as demonstrated by 
APOpercentage assay).  
Fig 7.6 DNA fragmentations in untreated control HeLa cells after 48 h    
 
R3 = apoptotic cells (3.85%) 
 
Fig 7.6 suggests that the cells in the normal state do undergo apoptosis but only a small 
percentage of cells (3.85%) dies during normal growth cycles. This is the control index for us to 
compare all apoptosis percentage levels obtained after induction of apoptosis by 3.25 compound. 
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Fig 7.7 DNA fragmentations in positive control (treated for 48 h with 10 µM camptothecin 
6.3) 
 
R3 = apoptotic cells (51.68%) 
In Fig 7.7 it can be seen that the positive control shows a significant increase in F-dUTP staining. 
This is denoted by an increase in the fluorescence of fluorescein. Camptothecin 6.3 is a DNA 
topoisomerase-I inhibitor and induces apoptosis at very low concentration. In the present study, a 
killing of about 51.68% was observed in the HeLa cell line after treatment for 48 h. This is 
visible from the histogram shift from first decade (101) to the second decade (102). Another 
indicator is the spreading of cells towards the Y-axis in the dot plot. The more the DNA 
fragments, the higher will be the percentage of cells shown in region R3. 
 
Fig 7.8 demonstrates the DNA strand breaks in HeLa cells treated for 48 hr with 10 μM of test 
compound 3.25, which in turn induced DNA fragmentation in 93.51% of the HeLa cells, 
compared to the 3.85% for the untreated cells.  
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Fig 7.8 DNA fragmentations in HeLa cells treated for 48 h with 10 µM 3.25 
  
R3 = apoptotic cells (93.51%) 
The above graphs in Fig 7.8 show that the compound 3.25 has the potential to kill about 94% 
HeLa cells via apoptosis within 48 h of treatment. This shows that with treatment of compound 
3.25 at a concentration of 10 µM, about 94% of HeLa cell population under investigation was in 
a late apoptosis phase, as represented by DNA fragmentation, which is a late apoptosis event. 
Since all the cells in a population do not undergo similar cell cycle phases at the same time 
(meaning that the cells in a population divide at different time intervals), it is appropriate to 
analyze the cells at different time intervals. Thus, the DNA fragmentation analyses were 
performed on HeLa cells after treatment with compound 3.25 for 72 h and also after treatment 
with standard compound viz., camptothecin 6.3. 
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The untreated control after 72 h showed a minimal increase in the percentage of apoptotic cells 
(7.74%) as presented in Fig 7.9.  
Fig 7.9 DNA fragmentation in untreated HeLa cells after 72 h  
 
R3 = apoptotic cells (7.74%) 
Fig 7.10 DNA fragmentation in HeLa cells treated for 72 h with 10 µM camptothecin 6.3 
  
R3 = apoptotic cells (66.32%) 
Fig 7.10 demonstrates DNA strand breaks in cells treated for 72 h with 10 μM of camptothecin 
6.3, which induced DNA fragmentation in 66.32% of the cells, compared to the 7.74% for the 
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untreated cells. This is visible from both the histogram and dot plot. 
Fig 7.11 demonstrates DNA strand breaks in cells treated for 72 h with 10 μM 3.25, which 
induced DNA fragmentation in 98.94% of the cells, compared to the 7.74% for the untreated 
cells. 
Fig 7.11 DNA fragmentation in HeLa cells treated for 72hr with 10 µM 3.25 
  
R3 = apoptotic cells (98.94%) 
About 99% of HeLa cells were found to be in the late apoptosis stage after 3.25 induction for 
72h. This shows that the test compound 3.25 has the potential to kill 99% of HeLa cells in the 
culture after 72 hr of induction. The histogram has shifted to the second decade (102) and the 
corresponding dot plot representation has most of the cells shifted towards the Y-axis in region 
R3. This is a clear proof of apoptotic potential of 3.25. 
Section 7.5.2: Cell cycle analysis:  
Cell cycle checkpoints are the pathways which regulate the completion of specific events in one 
phase of cell cycle before entering the next phase during the eukaryotic cell cycle progression.. 
These checkpoints also serve as sites where cells can arrest to repair any damage, responding to 
an exogenous cellular stress signal and making use of essential growth factors, hormones or 
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nutrients. If the cells fails to repair the damage during arrest at checkpoints, it could activate the 
pathways leading to apoptosis and the defects in cell cycle checkpoints have been reported to 
result in gene mutations, chromosome damage and ultimately contribute to tumorigenesis. 175 
DNA damaging agents trigger checkpoints that produce arrest in G1, and G2, stages of the cell 
cycle. The G1, and G2, phases of the cycle represented the “gaps” in the cell cycle that occur 
between the two obvious landmarks, DNA synthesis and mitosis. In the first gap, G1, phase, the 
cell is preparing for DNA synthesis. S phase cells are synthesizing DNA and therefore have 
double DNA content. Cells can also arrest in S phase, which leads to a prolonged S phase with 
slowed DNA synthesis. The G2, phase is the second gap in the cell cycle during which the cell 
prepares for mitosis or M phase. Arrest in G1, allows repair before DNA replication, whereas 
arrest in G2, allows repair before chromosome separation in mitosis.176 
The cell cycle assay is performed by tagging the DNA with the PI dye as explained in the section 
7.3.4. The underlying mechanism used to label the DNA fragments during apoptosis is explained 
in DNA fragmentation assay in section 7.5.1 above. Results can be acquired and analysed in the 
form of a histogram or dot plot. The graph is divided into four regions M1, M2, M3 and M4 
corresponding to sub-G1, G1, S and G2 phases respectively. The sub-G1 represents the apoptotic 
cells whereas the G1 represents the first phase of cell cycle in which cell prepares itself for DNA 
synthesis. The second phase in cell cycle is the S phase i.e. synthesis phase during which the 
DNA is synthesized. The third phase of cell cycle is the G2 phase, when cell prepares for entering 
the mitosis and divides into two. For the results obtained in histogram form, normal cells will 
fluoresce in the M2, M3 and M4 regions whilst a horizontal backward fluorescent shift along the 
X-axis is expected for apoptotic cells. The normal convention of this display is to put DNA 
vertically (Linear Red Fluorescence) on the Y-axis and the FL2-H (PI Fluorescence) horizontally 
 
 
 
 
 170
on the X-axis, apoptotic cells will display an increase in fluorescence of fluorescein by shifting 
vertically up along the Y-axis as a peak before the G1 peak. 
To elucidate the mechanism behind the anti-tumor activity of 3.25, the effect of 3.25 on the 
viability and cell-cycle progression of HeLa cells was investigated. HeLa cells were plated in 6 
well tissue culture plates. The cells were exposed to test compound 3.25 at a concentration of 10 
µM and the standard camptothecin 6.3 at a concentration of 10µM. The cells were analysed on a 
FACScan instrument using CELLQuest PRO software after time intervals 24, 48 and 72 h. 
Fig 7.12 Cell cycle analysis of untreated HeLa cells after 24 h 
 
Where FL2-H = PI fluorescence 
It is shown in Fig 7.12 that M1 has 19.81% cells, which is the percentage of apoptotic cells in 
normal untreated control. This will be an index for measuring apoptosis in treated samples. If the 
percentage of cells in M1 region in treated cells is increased, this will be an indicator of the 
apoptosis during cell cycle. In untreated control most of the cells were found to be in G1 phase of 
cell cycle. 
Fig 7.13 represents the distribution of cells in various phases of cell cycle after treatment with   
10 µM camptothecin 6.3 for 24 h. It is visible that in positive control more cells are present in M1 
 
 
 
 
 171
region representing the percentage of apoptotic cells. The observed increase in percentage of cells 
in M3 region reveals that after treatment with camptothecin 6.3, the cells were possibly arrested 
in the S phase of cell cycle, as in line with the previous report.177  
Fig 7.13 Cell cycle analysis of HeLa cells treated with 10 µM camptothecin 6.3 for 24 h 
 
The effect of compound 3.25 on cell cycle of HeLa cells is presented in Fig 7.14. As is visible 
from graph that after treatment with compound 3.25, about 47% cells are present in M2 region as 
compared to the 50.50% in untreated control and 30.64% in camptothecin 6.3 treated positive 
control.  
Fig 7.14 Cell cycle analysis of HeLa cells treated with 10 µM 3.25 for 24 h 
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There is approximately same percentage of cells in G1 phase as observed in Fig 7.14 as compared 
to the untreated cells (Fig 7.12). To observe the long-term effects of the test compound 3.25, the 
cell cycle analysis was extended to 48 and 72 h.  
Fig 7.15 Cell cycle analysis of untreated HeLa cells after 48 h 
 
Fig 7.15 represents the percentages of cells in various phases of cell cycle in untreated control 
after 48 h. The Fig 7.15 shows that percentages of the cells in various regions of the graph are not 
much changed as compared to untreated control after 24 h (Fig 7.12). The percentages of cells in 
various phases of cell cycle and cells undergoing apoptosis after treatment with camptothecin 6.3 
are represented in Fig 7.16. This graph also doesn’t show much change in percentages of cells as 
compared to the cells treated with camptothecin 6.3 for 24 h Fig 7.13. 
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Fig 7.16 Cell cycle analysis of HeLa cells treated with 10 µM camptothecin 6.3 for 48 h 
 
The cells after treatment with camptothecin 6.3 for 48 h could possibly be in S and G2 phases of 
cell cycle as revealed by the increase in percentage of cells in regions M3 and M4 respectively as 
compared to the untreated control after 48 h.  
The percentages of cells in various phases of cell cycle after treatment with test compound 3.25 
for 48 h are shown in Fig 7.17. 
Fig 7.17 Cell cycle analysis of HeLa cells treated with 10 µM 3.25 for 48 h 
 
Fig 7.17 explains that after treatment of test compound for 48 h, a greater percentage (72.75%) of 
HeLa cells undergo apoptosis. This is represented as a peak in M1 region of the graph. It is 
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visible that about 28% (percentage of cells in M2, M3 and M4 regions) cells are present in the 
sample after treatment with compound 3.25 for 48 h. 
The analysis was extended to 72 h and Fig 7.18 shows the results obtained after leaving the 
untreated cells in the media for 72 h.  
Fig 7.18 Cell cycle analysis of untreated HeLa cells after 72 h 
 
As is clear from Fig 7.18 that the normal untreated cells have approximately the same number of 
cells in various phases of cell cycle even after 72 h. The number of apoptotic cells (as represented 
in M1 region of graph) has increased as compared to shown in Fig 7.12. In comparison to this, 
the percentages of cells in various phases of cell cycle are changed in cells treated with 
camptothecin 6.3 for 72 h. 
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Fig 7.19 Cell cycle analysis of HeLa cells treated with 10 µM camptothecin 6.3 for 72 h 
 
The Fig 7.19 shows that about 40% of the HeLa cells have undergone apoptosis after induction 
with camptothecin 6.3 for 72 h. Similar effects are observed in cells treated with test compound 
3.25 for 72 h. 
Fig 7.20 shows that after 72 h of treatment with test compound 3.25, approximately 80% cells 
were apoptotic. This is clear from the sharp peak observed in M1 region corresponding to sub-G0 
or apoptotic phase. The percentages of the cells in G1, S and G2 phases of cell cycle are 
markedly decreased as observed in M2, M3 and M4 regions of the graph respectively. 
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Fig 7.20 Cell cycle analysis o HeLa cells treated with 10 µM 3.25 for 72 h 
 
The results of the cell cycle analysis reveal that the test compound 3.25 has the ability to induce 
apoptosis when induced for longer periods, as well as limiting the population of cells in G1 phase 
of the cell cycle when treated for shorter time periods. Another highlight of the analysis is that 
the compound 3.25 has enhanced apoptotic potential as compared to the camptothecin 6.3, which 
is a known inducer of apoptosis. 
Section 7.6: Discussion  
Quinones occur widely in animals, plants and microorganisms, and often carry out indispensable 
roles in the biochemistry of energy production by providing vital links in the respiratory chain of 
living cells. These compounds act as inhibitors of electron transport, uncouplers of oxidative 
phosphorylation, and give rise to a wide range of antiproliferative activies.178 
Quinones comprise the second largest class of anti-tumor agents currently in use. Studies have 
demonstrated that these drugs kill the tumor cells through apoptosis.167 In the present study, 3.25, 
an analogue of diospyrin 1.22 has been shown to have potential apoptotic activity against two 
human cancer cell lines derived from human cervical carcinoma and human bone osteosarcoma at 
a concentration of 10 μM. This compound is more active compared to diospyrin 1.22, as the latter 
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has been shown to have anti-tumor activity (IC50) at 100 μM after 48 h of treatment.52 The 
compound 3.25 is also much more active than the other derivatives of diospyrin 1.22 tested so 
far. The derivatives of diospyrin 1.22 were shown to have IC50 values in the acute myeloblastic 
leukemia (HL-60) cell line at concentrations of 64 µM for diospyrin dimethyl ether, 54 µM for 
hydroquinonoid derivative and 30 µM for diospyrin diethyl ether derivative after 48h of 
treatment respectively. In a recently published study,55 the aminoquinonoid derivative 1.29 of 
diospyrin 1.22 exhibited IC50 values of 0.06μM, i.e. thus inhibited growth of 50% of Ehrlich 
ascites carcinoma (EAC) after 16 hr in vitro. This shows that the amino group enhances the anti-
tumor activity immensely. Since the analogues of diospyrin 1.22 have never been synthesized and 
tested for the anti-tumor activity, the present study we have undertaken is considered to be 
unique.  
Several mechanisms have been proposed for the action of quinones. One of the operating 
mechanisms for quinones has been associated with oxidative stress.179-182 Quinonoid compounds 
can act as prodrugs through ‘bioreductive alkylation’ which involves two-electron reductions to 
the hydroquinones which in turn would react with biological nucleophiles like DNA and proteins. 
Since the 3.25 compound structurally differs from the 3.21 compound involving the OH group 
only, this may explain the higher activity associated with 3.25, compared to 3.21. The present 
study also supports the hypothesis that the OH group enhances the anti-tumor activities 
associated with quinonoids. Another possible mechanism could be the one-electron reduction of a 
quinonoid compound, to produce a semiquinone radical which in turn would generate reactive 
oxygen species causing dramatic changes in mitochondrial transmembrane potential and other 
associated events signaling cell death.52 
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The diospyrin 1.22 is a specific inhibitor of DNA topoisomerase49 as camptothecin 6.3. DNA 
topoisomerase enzymes have been recognized as potential chemotherapeutic targets and several 
naphthoquinonoid natural products have been found to be topoisomerase active.41, 52, 182, 183 
Topoisomerase I is primarily known as a DNA nicking/closing enzyme capable of resolving 
topological constraints in DNA. Its ability to relax supercoiled DNA and its implication in 
chromatin (de)condensation have already been  discussed.184  In addition to DNA,     
topoisomerase I interacts with different protein partners, among which are p53, nucleolin, and 
various other nuclear proteins.185 One key feature of this enzyme is its capacity to perform 
reactions via two distinct activity domains on both DNA and a class of proteins called SR proteins 
implicated in RNA splicing, such as the SF2/ASF splicing factor.186-189 With DNA, topoisomerase 
I functions as a phosphodiesterase, introducing simple strand breaks and then as a ligase to reseal 
the break after the DNA has been conformationally manipulated.190 With SR proteins, 
topoisomerase I acts as a kinase to phosphorylate their arginine-serine-rich domain, as has been 
shown for the SF2/ASF splicing factor.186, 191 
For a long time, the DNA cutting activity of topoisomerase I has attracted the attention of 
chemists and pharmacologists because the characterization in the early 1980s of the plant alkaloid 
camptothecin 6.3 which acts as a potent and specific inhibitor of topoisomerase I. Camptothecin 
6.3 promotes DNA cleavage by topoisomerase I through the stabilization of topoisomerase I 
phosphotyrosine-DNA intermediates. The accumulation of DNA breaks activates specific 
molecular circuits through the nucleus, cytoplasm, and mitochondria, leading to apoptotic cell 
death, mostly in rapidly proliferating tumor cells. The majority of the topoisomerase I inhibitors 
reported thus far intervene at the level of DNA-topoisomerase I complex, through stabilization of 
the covalent intermediate whereby the enzyme is covalently attached to the DNA via a 
phosphotyrosyl linkage. This intermediate complex is selectively trapped by camptothecin 6.3 or 
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other drugs referred to as poisons, such as certain indolocarbazoles and indenoisoquinolines. 
Diospyrin does not belong to this group of poisons. Its action certainly results from a direct 
interaction with the enzyme, as suggested for isodiospyrin.192 
Selective inhibition of topoisomerase I from L. donovani has been reported with diospyrin,57 and, 
the related compound isodiospyrin, extracted from Diospyros morrisiana, was shown to inhibit 
human topoisomerase I.192 These two studies suggested that the diospyrin-type biaryl molecule 
interacts directly with topoisomerase I but not with its DNA partner as is frequently the case with 
other inhibitors like camptothecin 6.3. Most interestingly, it was reported that isodiospyrin 
antagonizes camptothecin-induced DNA cleavage mediated by topoisomerase I and strongly 
inhibits the kinase activity of the enzyme toward SF2/ASF.192 Since the synthesized compounds 
in the present study are analogues of diospyrin 1.22 and are diospyrin-like compounds, it is 
possible that they might also act as inhibitors of topoisomerase I activity. 
Another possible mechanism of action of quinines involves glutathione. Glutathione transferases 
(GSTs) are multifunctional enzymes that catalyse conjugation of a wide variety of electrophilic 
endogenous and exogenous compounds with the tripeptide glutathione (GSH).193 The GSH 
conjugates are more hydrophilic and can therefore be excreted easily, thus facilitating the cells to 
get rid of exogenous chemicals. Thus, the cancer cells become less responsive to the drugs 
administered. GSTs also protect cells by sequestering compounds through high affinity 
binding.194 In human liver, GSTs make up between 4%-10% of the total cytosolic protein. Due to 
their abundance in the cell, GSTs are likely to interact with novel compounds presented to them 
as evidenced by their broad substrate specificity. The overexpression of GSTs has been 
implicated in resistance to alkylating anticancer type drugs.195 Diospyrin 1.22 has been found to 
inhibit the human GSTs in vitro196and it also possess anti-tumor activity, which makes it an ideal 
candidate for a comprehensive testing regime as a potential anti-tumor drug. It could be thus 
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inferred from previous studies that co-administration of diospyrin 1.22 with an alkylating anti-
cancer drug could inhibit tumor growth and at the same time prevent resistance to the co-drug by 
inhibiting GST-mediated detoxication of the latter.  
In the present investigation, the effect of the test compounds on expression of apoptosis 
regulating genes (p53, Bax, bcl-2 etc.) is unknown and thus a more detailed study at expression 
level could shed some light on the underlying mechanism of action of these compounds. Since 
the induction of apoptosis following chemotherapy is associated with the activation of pro-
apoptotic genes and the suppression of anti-apoptotic genes, attenuation of pro-apoptotic genes 
and increases in anti-apoptotic genes causes resistance to apoptosis. Thus, to increase the 
therapeutic effect of cancer chemotherapy, the assessment of molecular mechanisms and 
targeting apoptosis-related genes may lead to new strategies for the enhancement of the anti-
tumor effect. 
 
Section 7.7: Summary 
The aim of this study was to test the pro-apoptotic activity and therefore also the anti-cancer 
activity of synthetic analogues of diospyrin 1.22. The results demonstrated that not all of the 
compounds were active in all the cell lines available for the study. The selective killings represent 
the different apoptotic pathways initiated after induction with each of the test compounds. 
Furthermore, it was also observed that compounds that are cytotoxic are not necessarily pro-
apoptotic, that is, cell death induced by these compounds may be a consequence of necrotic rather 
than apoptotic cell death.  For example, compound 3.20 has been found to be cytotoxic in CHO 
cells, whereas it was unable to induce apoptosis in the cancer cell lines tested. Also, the non-
cancerous CHO cells were more sensitive to the effects of compound 3.20 than the cancer cell 
lines themselves. Test compounds 3.25 and 3.32 demonstrated much higher apoptotic activity 
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than the other two compounds 3.20 and 3.21. Compound 3.25 has displayed the ability to induce 
specific markers of apoptosis in HeLa cells such as phosphatidylserine externalization, DNA 
fragmentation and apoptosis at the level of cell cycle. Test compound 3.32 is the only one that 
induced apoptosis in the MCF-7 cell line that is characterized by caspase-3 gene mutation. This 
ability of 3.32 to induce apoptosis in the MCF-7 cell line indicates that it compound has the 
ability to induce apoptosis via caspase-3 independent pathways respectively. It is known that 
compounds that act on the basic apoptosis machinery do not induce apoptosis in all cells and this 
may be due to the differential expression of various pro- and anti-apoptosis factors in normal 
versus cancer cells and may thus provide a strategy for selectively targeting cancer cells. 
 
Conclusion: Above analyses has revealed that the synthesized analogues of diospyrin 1.22 in the 
present study have the potential to induce apoptosis in various cancer cell lines in vitro. The 
activity of test compound 3.25 is dose and time dependent and at 10 µM concentration, the 
compound induced apoptosis in 67% HeLa cells in 24h, which is more enhanced than diospyrin 
(100 µM for 48h induction). After 72h of treatment with test compound 3.25, about 99% of HeLa 
cells were found to be in late apoptosis stages as revealed by DNA fragmentation. Additionally 
test compound 3.25 might have chemotherapeutic potential, which needs a more detailed and 
comprehensive investigation. Other compounds 3.20, 3.21 and 3.32 were also found to be 
apoptotic and the subsequent detailed analysis of these compounds was beyond the scope of this 
thesis. We believe that a complete analysis at the mechanism level could unravel the 
chemotherapeutic potential of these compounds. 
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